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Inflammatory rheumatic diseases
Inflammatory rheumatic diseases are characterised by chronic inflammation predominantly 
affecting the joints. They might differ in other clinical manifestations, pathological features 
and response to treatment. Three examples of common inflammatory rheumatic diseases are 
listed below:
Rheumatoid arthritis (RA) is typically characterised by symmetric joint pain and swelling in 
the hands and feet. Approximately 80% of RA patients have autoantibodies in their blood 
(rheumatoid factor (RF) and/or anti-citrullinated peptide antibodies (ACPA)). The prevalence 
of RA is between 0.5% and 1.0% of the adult population.1 The onset of the disease is mostly 
between the fourth and sixth decade of life and the female:male ratio is 2:1 to 3:1. 
Psoriatic arthritis (PsA) is an inflammatory joint disease associated with cutaneous psoriasis. 
Not only the joints but also the surrounding structures can be involved and be manifested 
clinically as dactylitis (“sausage digit”, complete swelling of a single digit in the hand or foot) 
and enthesitis (inflammation at sites of bony insertion of tendons and ligaments). Prevalence 
estimates of PsA vary from 0.3% to 1.0%.2 In most people the age of onset is between thirty and 
fifty years and it occurs just as frequently in both sexes.2 
Axial spondyloarthritis (axSpA) is characterised by chronic back pain and pronounced 
stiffness which improve with exercise. In approximately 85% of axSpA patients the HLA-B27 
gene is present3 and many patients have radiographic sacroiliitis. Other common clinical 
manifestations are peripheral arthritis (usually asymmetric oligoarthritis in the lower 
extremities) and enthesitis. The prevalence of axSpA is between 0.1% and 1.4%.4,5 In general, 
first symptoms start before the age of forty and the female:male ratio is 1:2.6
Pharmacological treatment of Inflammatory rheumatic diseases
The main goal of treatment is to reduce pain and swelling, maintain physical functioning 
and prevent joint destruction. In the past, a limited number of drugs was available to treat 
inflammatory rheumatic diseases including non-steroidal anti-inflammatory drugs (NSAIDs), 
glucocorticoids and some disease-modifying anti-rheumatic drugs (DMARDs). DMARDs can 
be divided into 2 major classes: synthetic chemical compounds (sDMARDs) and biological 
agents (bDMARDs, biologics).7 
Until the late 1990s, the group of sDMARDs comprised solely of conventional synthetic DMARDs 
(csDMARDs) including methotrexate, leflunomide, sulfasalazine, hydroxychloroquine and 
gold salts. A common feature of csDMARDs is that they have been developed in a conventional 
way, meaning that they were first synthesised and subsequently a target was searched.8 In 
2017, tofacitinib and baricitinib were approved by the European Medicines Agency.9,10 Since 
these sDMARDs were specifically developed to target a molecular structure (i.e. janus kinases 
(JAKs)), they were classified as targeted synthetic DMARDs (tsDMARDs).8
Since the late 1990s, several bDMARDs have been introduced for the treatment of 
inflammatory rheumatic diseases. Biological DMARDs specifically target different cells (B- 
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and T cells) and cytokines (tumour necrosis factor alpha (TNFα), interleukin 6 (IL-6)) involved 
in the inflammatory cascade. Most widely used bDMARDs are TNF-inhibitors (TNFi’s: e.g. 
adalimumab, certolizumab pegol, etanercept, golimumab, infliximab). Examples of bDMARDs 
with other modes of action are abatacept (CTLA4-Ig fusion protein), anakinra (IL-1 inhibitor), 
rituximab (anti-CD20 monoclonal antibody) and tocilizumab (anti-IL-6 receptor antibody). 
Meta-analyses have shown that anakinra is less effective. All other currently approved 
bDMARDs are similarly effective and generally safe for use as initial bDMARD therapy.7
Starting treatment
According to the European League Against Rheumatism (EULAR) recommendations, DMARD 
treatment should be started as early as possible (ideally within 3 months) in patients at risk 
of persistent arthritis, even if they do not fulfil the classification criteria for an inflammatory 
rheumatologic disease (yet).11 Risk factors for persistent disease include number of swollen 
joints, acute-phase reactants, RF, ACPA and imaging findings (i.e. erosions (radiological 
term for breaks in the cortical bone surface) and/or synovitis (inflammation of the synovial 
membrane which lines the joints)). The timeframe of 3 months constitutes a “window of 
opportunity” that should be considered to provide an optimal outcome in the patients at 
risk.7 Furthermore, the EULAR recommendations state that treatment should be based on 
a “treat-to-target” principle.12-14 This consists of assessing disease activity regularly with 
appropriate instruments, defining treatment targets (e.g. sustained remission in RA) and 
changing treatment until the treatment target is reached. The proposed sequence of drugs 
varies slightly between inflammatory rheumatic diseases:12-14 
In RA patients, methotrexate should be part of the first treatment strategy. If the treatment 
target is not achieved with a csDMARD, addition of a bDMARD should be considered.12
In PsA patients with peripheral arthritis (particularly in those with many swollen joints and 
raised inflammatory markers), a csDMARD should be considered at an early stage. In patients 
with an inadequate response, treatment with a bDMARD should be commenced.13
In axSpA patients, a NSAID should be first-line drug treatment for axial inflammatory 
complaints. CsDMARDs should normally not be used in patients with solely axial disease. A 
bDMARD (usually a TNFi) should be considered in patients with persistently high disease 
activity despite at least 2 NSAIDs over 4 weeks.14
 
Tapering treatment
A disadvantage of the “hit-hard-and-hit-early” strategy is that it does not allow individual 
titration of the minimal efficacious dose of bDMARDs.15 This leads to overtreatment in a 
considerable number of patients, which is associated with an increased risk of adverse 
effects like dose-dependent serious infections and higher medication costs.16 Therefore, the 
EULAR recommendations state to taper treatment if a patient is in sustained remission.12,14 
Disease activity guided tapering of a bDMARD (dose reduction until either the disease activity 
increases or the bDMARD can be stopped) has proven to be feasible, safe and effective in RA 
patients with low disease activity or remission.17
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Prediction of treatment response
For all current available bDMARDs applies that they are not effective in the majority of 
patients. As a result, many patients have to undergo a “trial-and-error” process of trying 
different bDMARDs consecutively. Non-responding to the start of a bDMARD or flaring after 
tapering of a bDMARD are both undesirable, since a (short) period of high disease activity 
might cause worsening of physical functioning and radiographic joint damage.18,19
Prediction of individual response to treatment with a bDMARD probably improves treatment 
outcomes compared to the current “trial-and-error” treatment. In patients who are unlikely to 
respond to a (certain) bDMARD, starting another bDMARD might potentially be more effective. 
In addition, when it can be predicted that tapering will be unsuccessful in a patient, tapering 
would not be attempted thereby preventing disease flares, minimising physician efforts and 
easing uncertainty in patients. And when successful discontinuation can be predicted, the 
dose tapering phase could be skipped and the bDMARD could be stopped directly, saving time 
and medication.
To be able to predict which patients are likely to fail on treatment with a bDMARD, a 
biomarker should be identified that accurately predicts treatment response. A biomarker 
is defined as a characteristic objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes or pharmacological responses to a therapeutic 
intervention.20 Patient characteristics, biochemical tests and imaging measurements can 
all serve as biomarkers. So far, studies have failed to consistently identify a biomarker that 
can predict individual treatment response to a bDMARD.21 Also, several tapering studies 
have shown conflicting results on various biomarkers for predicting successful tapering of a 
bDMARD. 
Introduction of biosimilars
A recent development in the treatment of inflammatory rheumatic diseases is the introduction 
of biosimilars. In 2015 biosimilar infliximab (CT-P13) became the world’s first biosimilar to be 
launched for the treatment of inflammatory rheumatic diseases in 12 European countries 
including the Netherlands. A biosimilar is defined as a ‘biological medicine highly similar to 
another already approved biological medicine (the “reference medicine” or “originator”)’ that 
shows ‘no clinically meaningful differences with the reference medicine in terms of safety, 
quality and efficacy’.22 Biosimilars can be launched when the marketing exclusivity rights of 
the reference medicine have expired and may provide a reduction of healthcare costs due to 
price competition.
Aim and outline of this thesis
Despite all available bDMARDs and recommended therapeutic strategies, it must be considered 
that many patients still can not attain the therapeutic targets without cumbersome “trial-
and-error”. Moreover, the high costs of bDMARDs are an expanding financial burden on public 
health-care systems. Therefore, the aim of this thesis is to explore possibilities to optimise 
bDMARD treatment of inflammatory rheumatic diseases in daily practice by focussing 
on prediction of response after respectively starting and tapering of bDMARDs and on 
transitioning treatment from bDMARDs to biosimilars.  
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Firstly, since the predictive value of biomarkers for tapering of bDMARDs had not been 
summarised yet, we started with systematically reviewing all prospective studies with a 
predefined tapering protocol to provide an overview of the investigated biomarkers for 
predicting successful dose reduction or discontinuation of bDMARDs in RA. Chapter 2 presents 
the results of this systematic review. 
As data on tapering of non-TNFi bDMARDs in daily practice were scarce, we conducted a 
retrospective controlled cohort study (Study ON Abatacept and Tocilizumab Attenuation 
[SONATA]) to evaluate the feasibility, effectiveness and safety of tapering of abatacept and 
tocilizumab in RA patients. Chapter 3 describes the results of this study.
Based on previous studies, serum calprotectin (a heterodimer of S100A8/S100A9) seemed 
to be a promising biomarker for predicting clinical response to anti-TNF treatment.23,24 In 2 
longitudinal RA studies (Biologic Individual Optimized Treatment Outcome Prediction [BIO-
TOP] study; Dose REduction Strategies of Subcutaneous TNF inhibitors [DRESS] study), we 
assessed the added predictive value of serum baseline calprotectin for clinical response after 
starting a TNFi and investigated its predictive value for clinical response after tapering a TNFi 
(chapter 4). 
According to the EULAR recommendations, no preference of one over another bDMARD should 
be expressed, because evidence does not suggest any one bDMARD to be better than another 
one when active disease prevails despite treatment with the initial bDMARD.7 However, new 
data on sequential bDMARD treatment suggested that RA patients who are non-responsive 
to adalimumab also have a high risk for non-response to golimumab.25 To elucidate this, we 
decided to compare the ex-vivo effects of adalimumab, etanercept and golimumab on multi-
cytokine profiles of RA patients who started a bDMARD in the BIO-TOP study. In chapter 5 
the ex-vivo inhibition of cytokine production by respectively adalimumab, etanercept and 
golimumab are compared. 
Next, we were interested if ex-vivo inhibition of cytokine production might predict individual 
treatment response to different bDMARDs (i.e. abatacept, adalimumab, etanercept, rituximab 
and tocilizumab). We hypothesised that determining the ex-vivo effect of a bDMARD on 
cytokine production (“drug-inhibited cytokine production”) in blood samples taken before the 
start of a next bDMARD might be promising, since it might resemble the actual drug effect 
in RA patients and this had not been investigated before. Chapter 6 presents the predictive 
value of ex-vivo drug-inhibited cytokine production for clinical response to treatment with a 
bDMARD in the BIO-TOP study.
Secondly, the introduction of biosimilars in daily practice could reduce the expenditure of 
healthcare on costly bDMARD treatment without any differences in health outcomes, which is 
important from socioeconomic perspective. While prescribing a biosimilar for patients naive 
to bDMARD treatment is a well-accepted treatment option, transitioning clinically stable 
patients from an originator to a biosimilar is still a concern.26 Regulatory guidelines in the 
Netherlands state that transitioning between an originator and a biosimilar is permitted if 
patients are properly informed and adequate clinical monitoring is performed.27-29 
In July 2015, 4 departments of rheumatology in the Netherlands (Sint Maartenskliniek 
Nijmegen, Maartenskliniek Woerden, Radboud University Medical Center Nijmegen and 
Rijnstate Arnhem) open-label transitioned treatment from originator infliximab to biosimilar 
infliximab (CT-P13). The clinical outcomes were collected in a multicentre prospective cohort 
study (Biosimilar of Infliximab Options, Strengths and Weaknesses of Infliximab Treatment 
CHange [BIO-SWITCH]). In chapter 7 we describe the 6-month results of this study.
Taking lessons from this first transition into account, the Sint Maartenskliniek Nijmegen 
implemented a structured communication strategy when the hospital initiated its second 
transition project from originator etanercept to biosimilar etanercept (SB4) in June 2016. The 
effects of this strategy were analysed in a prospective controlled cohort study (BIOsimilar 
switch, Study on Persistence and role of Attribution and Nocebo [BIO-SPAN]) in which drug 
survival and effectiveness over 6 months were compared with a historical cohort of patients 
who continued originator etanercept. In chapter 8 we present the 6-month results of this 
study.
Finally, chapter 9 gives a summary of all our results. Gained insights are discussed and clinical 
recommendations and propositions for future research are suggested. 
11
General introductionChapter 1
1514
References
1. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the 
rheumatic diseases. Arthritis Res Ther 2009;11(3):229. 
2. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, 
course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14-7.
3. Bakland G, Nossent HC. Epidemiology of spondyloarthritis: a review. Curr Rheumatol Rep 2013;15(9):351.
4. Van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in 
HLA-B27 positive individuals: a comparison of relatives of spondylitis patients with the general population. 
Arthritis Rheum 1984;27:241-9.
5. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-
aged population of Tromsø, northern Norway. Ann Rheum Dis 1985;44:359-67.
6. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 
2002;61 Suppl 3:iii8-18.
7. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M et al. EULAR recommendations for 
the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic 
drugs: 2013 update. Ann Rheum Dis 2014;73(3):492-509.
8. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of 
disease-modifying antirheumatic drugs. Ann Rheum Dis 2014;73(1):3-5. 
9. European Medicines Agency. 
 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004085/human_
med_002074.jsp (accessed 1 November 2017).
10. European Medicines Agency. 
 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004214/human_
med_001662.jsp (accessed 1 November 2017).
11. Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM et al. 2016 update of the EULAR 
recommendations for the management of early arthritis. Ann Rheum Dis 2017;76(6):948-959. 
12. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al. EULAR 
recommendations for the management of rheumatoid arthritis with synthetic and biological disease-
modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76(6):960-977. 
13. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M et al. European League Against 
Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological 
therapies: 2015 update. Ann Rheum Dis 2016;75(3):499-510. 
14. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, van den Bosch F, Sepriano A et al. 2016 update of the 
ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76(6):978-
991.
15. den Broeder AA, van der Maas A, van den Bemt BJ. Dose de-escalation strategies and role of therapeutic 
drug monitoring of biologics in RA. Rheumatology (Oxford) 2010;49(10):1801-3.
16. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R et al. Risk of serious infection in 
biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 
2015;386(9990):258-65.
17. van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF et al. Down-
titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis 
in patients with low disease activity. Cochrane Database Syst Rev 2014;9:CD010455.
18. Nair SC, Bijlsma JWJ, van de Werf JH, van der Veen MJ, Linn-Rasker SP, Vreugdenhil S et al. Do radiographic 
joint damage and disease activity influence functional disability through different mechanisms? Direct 
and indirect effects of disease activity in established rheumatoid arthritis. J Rheumatol 2013;40(9):1505-
1512.
19. Welsing PMJ, Landewé RBM, van Riel PLCM, Boers M, van Gestel AM, van der Linden S et al. The relationship 
between disease activity and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 
2004;50(7):2082-2093.
20. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and 
conceptual framework. Clin Pharmacol Ther 2001;69(3):89-95.
21. Cuppen BV, Welsing PM, Sprengers JJ, Bijlsma JW, Marijnissen AC, van Laar JM et al. Personalized 
biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. 
Rheumatology (Oxford) 2016;55(5):826-39.
22. European Medicines Agency.
 http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000168.
jsp&mid=WC0b01ac0580533e0b (accessed 1 November 2017).
23. Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D et al. MRP8/14 serum levels as a 
strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum 
Dis 2015;74(3):499-505.
24. Nordal HH, Brokstad KA, Solheim M, Halse AK, Kvien TK, Hammer HB. Calprotectin (S100A8/A9) has the 
strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: 
results from a longitudinal study of patients with established rheumatoid arthritis. Arthritis Res Ther 
2017;19(1):3.
25. Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S et al. Insights into the efficacy of golimumab plus 
methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis 
factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis 2014;73(10):1811-8.
26. Inotai A, Prins CP, Csanádi M, Vitezic D, Codreanu C, Kaló Z. Is there a reason for concern or is it just hype? 
- A systematic literature review of the clinical consequences of switching from originator biologics to 
biosimilars. Expert Opin Biol Ther 2017;17(8):915-926.
27. Dutch Society for Rheumatology.
 https://www.nvr.nl/wp-content/uploads/2015/10/Standpunt-NVR-vergelijkbaarheid-en-plaatsbepaling-
biosimilar-TNF-remmers-2015.pdf (accessed 1 November 2017). 
28. Dutch Medicines Evaluation Board. 
 https://www.cbg-meb.nl/actueel/nieuws/2015/03/31/standpunt-cbg-over-voorschrijven-van-biosimilars 
(accessed 1 November 2017).
29. Dutch Federation of Medical Specialists. 
 https://www.demedischspecialist.nl/sites/default/files/Standpunt%20Biosimilars%20Federatie%20
Medisch%20Specialisten.PDF (accessed 1 November 2017)
11
General introductionChapter 1
1716
Chapter 2
Little evidence for usefulness of 
biomarkers for predicting successful 
dose reduction or discontinuation 
of a biologic agent in rheumatoid 
arthritis: a systematic review
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Abstract
Objective
To systematically review studies addressing prediction of successful dose reduction or 
discontinuation of a bDMARD in rheumatoid arthritis (RA).
Methods
PubMed, Embase and Cochrane Library databases were searched for studies that examined the 
predictive value of biomarkers for successful dose reduction or discontinuation of a bDMARD 
in RA. Two reviewers independently selected studies, extracted data and assessed risk of bias. 
A biomarker was classified as a “potential predictor” if the univariate association was either 
strong (odds ratio or hazard ratio >2.0 or <0.5) or statistically signiﬁcant. For biomarkers that 
were studied multiple times, qualitative best-evidence synthesis was performed separately 
for the prediction of successful dose reduction and discontinuation. Biomarkers that were 
defined in ≥75% of the studies as potential predictors were regarded as “predictor” for the 
purposes of our study.
Results
Of 3,029 non-duplicate articles initially searched, 16 articles regarding 15 cohorts were 
included in the present study. Overall, 17 biomarkers were studied multiple times for the 
prediction of successful dose reduction, and 33 for the prediction of successful discontinuation 
of a bDMARD. Three predictors were identified: higher adalimumab trough level for successful 
dose reduction and lower Sharp/van der Heijde erosion score and shorter symptom duration 
at the start of a bDMARD for successful discontinuation. 
Conclusion
The predictive value of a wide variety of biomarkers for successful dose reduction or 
discontinuation of bDMARD treatment in RA has been investigated. We identified only 3 
biomarkers as predictors in just 2 studies. The strength of the evidence is limited by the low 
quality of included studies and the likelihood of reporting bias and multiple testing. 
Introduction
Treatment of rheumatoid arthritis (RA) is based on the “hit-hard-and-hit-early” strategy. 
Starting treatment early and achieving low disease activity as soon as possible by using a 
combination of disease-modifying anti-rheumatic drugs (DMARDs) (including glucocorticoids) 
and rapid escalation to biological DMARDs (bDMARDs), if necessary, are pivotal in this strategy.1 
However, a disadvantage of such a strategy is that it leads to overtreatment with bDMARDs 
in a considerable number of patients.2 Overtreatment is associated with an increased risk of 
adverse effects such as dose-dependent serious infections, as well as higher medication costs.3 
In order to reduce overtreatment, the start of intensive treatment should be followed by 
attempts to find the lowest individual efficacious dose. This can be done in patients with low 
disease activity by discontinuing the bDMARD all at once, or tapering the dosage. In general, 
discontinuation all at once of a bDMARD has proven to be inferior to continuing bDMARD 
treatment with respect to disease activity, radiologic outcomes and function.4 Alternatively, 
tapering of a bDMARD guided by disease activity (dose reduction until either disease activity 
increases or the bDMARD can be stopped) appears to be feasible, safe and effective in RA 
patients with low disease activity or whose disease is in remission.4  
The ability to accurately predict the success of dose reduction or discontinuation of a bDMARD 
is likely to constitute a major improvement over the current “trial-and-error” disease activity 
guided tapering. When it can be predicted that dose reduction will be unsuccessful, dose 
reduction should not even be attempted. Such predictions would prevent disease flares, 
minimise physician efforts, and ease uncertainty in patients. Additionally, when it can be 
predicted that discontinuation will be successful, the dose tapering phase can be skipped and 
the bDMARD can be stopped directly, saving time and medication cost. 
A biomarker is defined as a characteristic objectively measured and evaluated as an indicator of 
normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention.5 Patient characteristics, biochemical tests, and imaging measurements can all 
serve as biomarkers. If there is a biomarker that can accurately predict the success of dose 
reduction or discontinuation prior to the tapering of a bDMARD, it could be used for optimising 
treatment in daily clinical care.
As previous narrative reviews have demonstrated, it remains challenging to identify 
those patients whose treatment with bDMARDs can be tapered without risk of a flare.6-9 
In the past few years, several studies have investigated various biomarkers for predicting 
successful tapering of different bDMARDs. To our knowledge, these results have not yet been 
systematically summarised. Therefore, we conducted analysis of all prospective studies with 
a predefined tapering protocol, in order to provide an overview of the investigated biomarkers 
for predicting successful dose reduction or discontinuation of bDMARD treatment in RA.
 
Systematic review of prediction of biologic tapering in RA
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Methods
Search strategy
In November 2015, a search was conducted using PubMed, Embase, and Cochrane Library 
databases for studies that examined the predictive value of biomarkers for the success of 
dose reduction or discontinuation of bDMARD treatment in patients with RA. The search 
strategy (Supplementary file 1) consisted of the Haynes broad filter (recommended for finding 
predictive research)10, keywords regarding the patient group, as well as the outcome of interest 
(successful dose reduction or discontinuation). The patient group consisted of those who 
were treated with any registered bDMARD for RA (i.e. abatacept, adalimumab, certolizumab 
pegol, etanercept, golimumab, infliximab, rituximab, or tocilizumab) at a standard dosing 
regimen for >24 weeks, who had low disease activity, and in whom the dosage of a bDMARD 
was subsequently reduced or discontinued. Anakinra was excluded because it is now rarely 
used due to lack of efficacy. The search was not limited by language, nor by year or type of 
publication. Included articles and excluded reviews were used for cross checking of references.
Study selection
This review was conducted and reported according to the procedures outlined in the PRISMA 
Statement.11 Two reviewers (EB, FB) independently selected articles, primarily by title and 
abstract and subsequently by review of the full text (when necessary). Any disagreement was 
resolved by consensus meetings with another reviewer (LT). During full-text analyses, studies 
were excluded if 1) biomarkers were not determined or data on them were not collected 
prior to tapering of bDMARDs, 2) follow-up periods were <3 months or >24 months, 3) <20 
participants were included in the cohort or a retrospective design was utilised, or 4) they were 
only reviews or abstracts from a conference. Additionally, studies that analysed the data in 
a way that could not provide answers to our primary question (e.g. pooling the outcomes of 
conventional synthetic DMARD (csDMARD) and bDMARD tapering or the outcomes of the 
continuing arm and tapering arm) were also excluded.
Data extraction 
Data on study designs, patient characteristics, tapering strategies, biomarkers, outcomes 
(clinical response criteria), and analysis (association measure between biomarker and 
outcome) were independently extracted from each article by 2 reviewers (FB, LT) using a data 
extraction form. The form was pilot tested on 3 randomly selected articles (which were not 
included in the review) and was refined accordingly. Any doubts were resolved by consultation 
with a third reviewer (CvdE or AdB).
Quality assessment
Two reviewers (FB, LT) independently assessed the methodologic quality of the included 
studies using the Quality In Prognosis Studies (QUIPS) tool.12 The tool was operationalised 
a-priori and pilot tested on 3 randomly selected articles that were not included in the review.
One of the 6 domains of the tool, study confounding, was excluded because all of the studies 
included in our review investigated multiple biomarkers in an exploratory manner, making it
impossible to summarise all potential confounding factors. Each of the remaining domains 
was judged as having low, moderate, or high risk of bias. Disagreements were resolved by 
discussion and, when necessary, a third reviewer (CvdE) made final decisions. Since the 
use of a summed score for overall study quality is not recommended, we decided a-priori 
to consider a study of high quality if the 2 domains that we consider to be most important 
(study participation and statistical analysis) were either both assessed as having a low risk of 
bias, or one as low risk and the other as moderate.13 Studies not meeting these criteria were 
considered of low quality.
Statistical analysis 
The heterogeneity of the biomarkers, outcome measures, and statistics precluded a 
quantitative meta-analysis. Therefore, results regarding the predictive value of biomarkers for 
the success of dose reduction and discontinuation of bDMARD treatment were qualitatively 
synthesised in 3 steps.
In step 1, we assessed whether each investigated biomarker was a potential predictor. A 
biomarker was defined as a “potential predictor” if the univariate association between the 
biomarker and the success of dose reduction or discontinuation was either strong (odds ratio 
[OR] or hazard ratio [HR] >2.0 or <0.5) or statistically significant (p<0.05).14 If no univariate OR 
or HR was provided, results of other univariate association measures, multivariate results or 
textual conclusions on the statistical significance of findings were used. 
In step 2, biomarkers were divided into 5 different categories (patient, treatment, disease 
activity, laboratory, and imaging measurements) and an overview of biomarkers that were 
studied multiple times (i.e. in >1 separate study) and those that were studied only once was 
completed.15 
In step 3, qualitative best-evidence synthesis of biomarkers (studied multiple times) was 
performed separately for predicting the success of dose reduction and discontinuation of 
bDMARDs. A biomarker was regarded as a “predictor” if it was defined as a potential predictor 
in ≥75% of the studies in which the biomarker was investigated. Subsequently, we defined 4 
levels of evidence as used in previous systematic reviews:16,17 
1) strong evidence: consistent findings (≥75% of findings in same direction) in at least 2 high-
quality studies, 
2) moderate evidence: consistent findings in 1 high-quality study and at least 2 low-quality 
studies, 
3) limited evidence: findings in 1 high-quality study or consistent findings in at least 2 low-
quality studies,
4) conflicting evidence: inconsistent findings irrespective of study quality (<75% of findings in 
same direction).
Of note, the level of conflicting evidence was checked first before assigning a strong, moderate 
or limited evidence level to a biomarker.
 
Results
Study selection
Through the database search in November 2015, we retrieved 3,029 non-duplicate articles.
The cross-checking of references yielded no relevant articles. In total, 21 articles met our 
selection criteria. However, 5 articles were publications of the BeSt study (Behandel Strategieën 
voor Reumatoïde Artritis)18-21,23 and 2 of the HONOR study (Humira Discontinuation Without 
Functional and Radiographic Damage Progression Following Sustained Remission)22,24. Of the 
BeSt study publications, we only analysed the article that explicitly answered our primary 
question23, as the other articles contained no additional information. Of the 2 HONOR study 
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publications, we selected the article reporting the study with the longest follow-up time24, 
since the outcome measures between these publications were similar. Eventually 16 articles 
regarding 15 cohorts were included in this review. A flow diagram of the study selection is 
depicted in Figure 1.
Figure 1. Flow diagram of study selection 
Study characteristics
The characteristics of the included studies are listed in Supplementary file 2. In 7 studies, 
the dosage of the bDMARD was reduced25-31 and in 9 studies the bDMARD was discontinued 
all at once23,24;32–38. There were 4 randomised controlled trials23,27,28,30 and 12 observational 
cohort studies24–26,29,31–38. Overall, 1,093 participants were included in these studies. They were 
all in remission or had low disease activity prior to dose reduction or discontinuation of the 
bDMARD, according to different disease activity criteria. In 11 of the 16 studies23–27,30,34–38, a 
minimum duration of 6 months of low disease activity was part of the inclusion criteria. Studies 
varied with respect to sample size (range 21–187), type of bDMARD (abatacept, adalimumab, 
certolizumab pegol, etanercept, golimumab, infliximab, or tocilizumab), follow-up period 
(range 24 weeks-24 months) and outcome measure (meeting criteria for low disease activity, 
remission, or flare). The included studies examined a wide variety of biomarkers. Fifty-two 
biomarkers were studied for their predictive value for the success of dose reduction (17 of 
which were studied multiple times), and 64 biomarkers for the success of discontinuation of a 
bDMARD (33 of which were studied multiple times). 
The predictive value of biomarkers for the prediction of the success of dose reduction and 
discontinuation of a bDMARD were analysed separately. The Dose REduction Strategy of 
Subcutaneous TNF inhibitors (DRESS) study examined the predictive value of biomarkers for 
both the success of dose reduction and the success of discontinuation of bDMARD treatment; 
data on these biomarkers were therefore included in both analyses.27 For the Spacing of 
TNF-blocker injections in Rheumatoid Arthritis Study (STRASS)30, only those biomarkers that 
were investigated in the multivariate analysis and that included the strategy of spacing TNF 
blockers could be analysed in our review, since the univariate analysis with maintenance and 
spacing arms combined was not suitable. 
The results for the biomarkers that were studied multiple times for prediction of the success 
of dose reduction and the success of discontinuation are depicted in Supplementary file 3. In 
summary, 3 predictors were identified: higher adalimumab trough level for the success of dose 
reduction, and lower Sharp/van der Heijde erosion score and shorter symptom duration at the 
start of bDMARD treatment for the success of discontinuation. 
The results for biomarkers that were studied once for the prediction of the success of dose 
reduction and the success of treatment discontinuation are depicted in Supplementary file 4. 
Ten of 34 biomarkers were classified as potential predictors for the success of dose reduction 
and 8 of 31 for discontinuation.
Quality assessment and best-evidence synthesis
A total of 80 domains (5 domains in 16 studies) were judged by 2 reviewers (FB and LT) who 
agreed on 65 of 80 domains, representing good interrater agreement (κ=0.71).39 Disagreements 
were caused by different interpretation of missing data and different judgment of the overall 
risk of bias of the domain study attrition. According to our predefined criteria, 5 studies were 
classified as high-quality study and 11 studies as low-quality study (Supplementary file 5). 
Limitations of the studies mostly concerned insufficient data presentation and selective 
reporting of results. 
Qualitative best-evidence synthesis for the prediction of the success of dose reduction and the 
success of discontinuation of a bDMARD is depicted in Tables 1 and 2, respectively.
 
22
Systematic review of prediction of biologic tapering in RAChapter 2
2524
Table 1. Best-evidence synthesis for prediction of successful dose reduction of a bDMARD
Biomarker N Potential predictor* Quality# Predictor† Level of 
evidence‡
Yes No High Low 
Age 5 0 5 25-27,29,31 1 25 4 26,27,29,31 No Moderate 
Gender 5 0 5 25-27,29,31 1 25 4 26,27,29,31 No Moderate 
Disease duration 4 1 31 3 25,27,29 1 25 3 27,29,31 No Moderate 
Smoking 4 1 25 3 26,27,31 1 25 3 26,27,31 No Limited 
Number previous  
csDMARDs
3 1 31 2 26,27 0 3 26,27,31 No Conflicting 
Number previous 
bDMARDs
2 0 2 27,31 0 2 27,31 No Limited 
Time from symptom 
onset to bDMARD 
2 0 2 26,31 0 2 26,31 No Limited 
Duration current 
bDMARD treatment 
before tapering
3 1 29 2 25,27 1 25 2 27,29 No Conflicting 
Concomitant 
csDMARD 
4 0 4 25-27,31 1 25 3 26,27,31 No Moderate 
Methotrexate 3 0 3 25,27,29 1 25 2 27,29 No Moderate
Glucocorticoids 3 0 3 27,29,31 0 3 27,29,31 No Limited 
DAS28-ESR at 
tapering
4 2 29,31 2 25,27 1 25 3 27,29,31 No Conflicting 
Rheumatoid factor 6 2 26,30 4 25,27,29,31 1 25 5 26,27,29-31 No Conflicting 
ACPA 5 0 5 25,27-29,31 1 25 4 27-29,31 No Moderate 
ESR 2 0 2 27,29 0 2 27,29 No Limited 
CRP 2 1 29 1 27 0 2 27,29 No Conflicting 
Adalimumab trough 
level 
2 2 28,29 0 0 2 28,29 Yes Limited 
*Potential predictor: number of studies with a strong and/or significant association between biomarker and successful dose 
reduction. #Quality: number of studies with a high / low quality according to the QUIPS tool. †Predictor: biomarker defined as 
potential predictor in ≥75% of the studies in which the biomarker was investigated. ‡Level of evidence: composite outcome 
of predictive value and study quality.
ACPA, Anti-Citrullinated Peptide Antibodies; bDMARD, biological Disease-Modifying Anti-Rheumatic Drug; CRP, C-Reactive 
Protein; csDMARD, conventional synthetic DMARD; DAS, Disease Activity Score; ESR, Erythrocyte Sedimentation Rate.
 
 
Table 2. Best-evidence synthesis for prediction of successful discontinuation of a bDMARD
Biomarker N Potential predictor* Quality# Predictor† Level of 
evidence‡Yes No High Low 
Age 7 1 37 6 23,24,27,32,33,38 3 23,24,37 4 27,32,33,38 No Strong 
Gender 7 0 7 23,27,32-34,37,38 3 23,34,37 4 27,32,33,38 No Strong 
Disease duration 9 4 23,24,35,37 5 27,32-34,38 4 23,24,34,37 5 27,32,33,35,38 No Conflicting 
Remission duration 3 1 38 2 33,35 0 3 33,35,38 No Conflicting 
Smoking 2 1 23 1 27 1 23 1 27 No Conflicting
BMI 2 0 2 23,27 1 23 1 27 No Limited 
Number previous   
csDMARDs
2 0 2 27,38 0 2 27,38 No Limited 
Number previous 
bDMARDs
2 0 2 27,38 0 2 27,38 No Limited 
Time from symptom   
onset to bDMARD 
2 2 23,35 0 1 23 1 35 Yes Limited 
Duration current 
bDMARD treatment   
before tapering
4 3 23,24,38 1 27 2 23,24 2 27,38 No Conflicting
Concomitant   
csDMARD 
2 0 2 27,38 0 2 27,38 No Limited 
Methotrexate 4 0 4 24,27,33,37 2 24,37 2 27,33 No Strong 
Glucocorticoids 4 1 34 3 27,33,37 2 34,37 2 27,33 No Moderate 
HAQ 8 3 34-36 5 23,24,33,37,38 4 23,24,34,37 4 32,33,35,38 No Conflicting 
DAS28-ESR at 
discontinuation
5 3 24,34,37 2 27,33 3 24,34,37 2 27,33 No Conflicting 
DAS28-CRP at 
discontinuation
3 1 37 2 27,33 1 37 2 27,33 No Conflicting 
DAS28-ESR at start 
bDMARD
2 0 2 37,38 1 37 1 38 No Limited 
TJC 3 0 3 23,27,37 2 23,37 1 27 No Strong 
SJC 3 0 3 23,27,37 2 23,37 1 27 No Strong 
VAS disease activity 2 0 2 23,37 2 23,37 0 No Strong
SDAI 2 0 2 24,33 1 24 1 33 No Limited
CDAI 2 0 2 24,33 1 24 1 33 No Limited
Rheumatoid factor 7 1 34 6 23,24,27,33,37,38 4 23,24,34,37 3 27,33,38 No Strong
ACPA 4 0 4 23,27,33,38 1 23 3 27,33,38 No Moderate 
ESR 4 1 24 3 23,27,37 3 23,24,37 1 27 No Strong 
CRP 5 1 36 4 23,24,27,37 3 23,24,37 2 27,36 No Strong 
MMP-3 
concentration
2 1 34 1 24 2 24,34 0 No Conflicting 
SvdH total score 4 1 37 3 23,24,27 3 23,24,37 1 27 No Strong 
SvdH erosion score 2 2 23,37 0 2 23,37 0 Yes Strong 
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SvdH joint space 
narrowing score
2 0 2 23,37 2 23,37 0 No Strong 
Yearly SvdH 
progression at   
discontinuation
2 1 23 1 37 2 23,37 0 No Conflicting 
Gray scale 
ultrasound 
2 1 33 1 35 0 2 33,35 No Conflicting
Power Doppler 
ultrasound 
2 1 33 1 35 0 2 33,35 No Conflicting 
*Potential predictor: number of studies with a strong and/or significant association between biomarker and successful 
discontinuation. #Quality: number of studies with a high / low quality according to the QUIPS tool. †Predictor: biomarker 
defined as potential predictor in ≥75% of the studies in which the biomarker was investigated. ‡Level of evidence: composite 
outcome of predictive value and study quality.
ACPA, Anti-Citrullinated Peptide Antibodies; bDMARD, biological Disease-Modifying Anti-Rheumatic Drug; BMI, Body Mass 
Index; CDAI, Clinical Disease Activity Index; CRP, C-Reactive Protein; csDMARD, conventional synthetic DMARD; DAS, Disease 
Activity Score; ESR, Erythrocyte Sedimentation Rate; HAQ, Health Assessment Questionnaire; MMP, Matrix MetalloProteinase; 
N, Number of studies; SDAI, Simplified Disease Activity Index; SJC, Swollen Joint Count; SvdH, Sharp van der Heijde; TJC, Tender 
Joint Count; VAS, Visual Analogue Scale. 
Discussion
To our knowledge, this is the first systematic review summarising the predictive value of 
biomarkers for the success of dose reduction or discontinuation of a bDMARD in RA. Of all the 
studied biomarkers, we identified 3 as predictors. Of note, each of these 3 biomarkers was only 
investigated in 2 studies, meaning that more frequent investigation of specific biomarkers 
yielded no consistent predictors. Moreover, 2 of the biomarkers (Sharp/van der Heijde erosion 
score and shorter symptom duration at the start of bDMARD treatment) showed a statistically 
significant but weak association. Therefore, the clinical relevance of these identified predictors 
could be questioned. Also, our findings regarding the predictive value of the third biomarker 
(adalimumab trough level) could be questioned considering extensive multiple testing in one 
study28 and disputed results in another29,40.
In addition, of those biomarkers that were studied only once, we found 10 of 35 biomarkers and 
8 of 31 biomarkers that were classified as potential predictors for the success of dose reduction 
and discontinuation of a bDMARD, respectively. Most of them were serum markers and 
imaging measurements. This may indicate that the assessment of subclinical inflammation 
by laboratory or imaging testing provides a useful tool to determine a patient’s risk of 
flare.8 However, results with these biomarkers need to be replicated in other cohorts, with a 
predefined tapering protocol, before they can be considered predictors.
A strength of this review is that we executed a broad literature search to identify all biomarkers 
that have ever been investigated for their ability to predict the success of dose reduction 
or that of discontinuation of a bDMARD. Furthermore, we have performed a best-evidence 
synthesis to provide an overview of the results, making the review process transparent and 
reproducible. For the identification of potential predictors we chose criteria that can be easily 
met, taking into account the fact that univariate analyses could lead to an overestimation of 
the strength of associations. However, even with these non-strict criteria, only 3 biomarkers 
could be defined as predictors.
The studies we included show substantial heterogeneity in study design and outcome 
definition. Several studies included more than 1 bDMARD precluding investigation of the 
potential different effect for bDMARDs. Regarding outcome definition, all studies used a 
disease activity measure but the threshold for failure and the time point of assessment 
differed. To collect comparable information, the use of a standardised outcome definition 
is essential.41 An increase in the 28-joint Disease Activity Score (DAS28) of >1.2 (or >0.6 if the 
initial score is ≥3.2) appeared most discriminating and valid, although the Outcome Measures 
in Rheumatology RA flare group is developing a patient-reported flare questionnaire that 
could also be used in the future.42,43
Another important limitation is the low quality of 11 of the 16 included studies, according 
to the operationalised QUIPS tool. Most of the studies were defined as low quality based 
on incomplete reporting. This classification may have been caused by the fact that finding 
predictive markers for successful tapering was rarely the main research question of the 
included studies. Also, there is no specific guideline for predictive research. In our opinion, 
the use of the Standards for Reporting Diagnostic Accuracy (STARD) guideline44 should be 
encouraged to ensure that sufficient information for editors, peer reviewers, and readers is 
provided to facilitate understanding of how the research was performed and to judge the 
credibility of the findings. Furthermore, data analysis was complicated by the statistical 
methods used in the studies. For example, in some studies data were assessed in a way that 
could not answer our primary question (e.g. pooling the outcomes of csDMARD and bDMARD 
tapering or the outcomes of the continuing arm and tapering arm). In addition, appropriate 
association measures (e.g. OR or HR) were rarely reported. However, if more studies had been 
of high quality, we would not have found more potential predictors, since the mean frequency 
of potential predictors in high-quality studies was slightly lower (31.6%) in comparison to low-
quality studies (38.6%). This effect of higher-quality studies being associated with lower effect 
estimates has been well recognised.45 Finally, positive findings should be interpreted with 
caution due to reporting bias and multiple testing. It is very likely that negative results found 
for potential biomarkers were not mentioned by all studies. This means that there would have 
been stronger evidence for non-predictive biomarkers if all data were reported. Also, there is 
a chance of false-positive results due to multiple tests, because some studies simultaneously 
investigated more than 20 biomarkers without correction for multiple testing by lowering the 
required p-value.
 
There are currently several studies investigating predictive markers for successful tapering 
of bDMARDs in RA (e.g. STARA [Stopping Anti–Tumor Necrosis Factor Agents in Rheumatoid 
Arthritis], RABioStop [Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid 
Arthritis], BioRRA [Biomarkers of Remission in Rheumatoid Arthritis]).46 We would recommend 
that the various research groups replicate the prognostic value of potential predictors 
and report the predictive value of all their investigated biomarkers with the appropriate 
association measures.
Conclusion
We investigated the predictive value of a wide variety of biomarkers for the success of dose 
reduction or discontinuation of a bDMARD in RA. We identified only 3 biomarkers as predictors 
in just 2 studies. The strength of the evidence is limited by the low quality of included studies 
and the likelihood of reporting bias and multiple testing.
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Supplementary file 1. Search strategy
PUBMED
search strategy
RA AND bDMARD 1. Arthritis, Rheumatoid[Mesh:NoExp])
2. "rheumatoid arthritis"[Text Word]
3. 1 or 2 
4. Antirheumatic Agents/administration and dosage[Mesh:NoExp] OR Antirheumatic 
Agents/therapeutic use[Mesh:NoExp] 
5. abatacept[Title/Abstract]) OR adalimumab[Title/Abstract]) OR certolizumab 
[Title/Abstract]) OR etanercept[Title/Abstract]) OR golimumab[Title/Abstract]) 
OR infliximab[Title/Abstract]) OR rituximab[Title/Abstract]) OR tocilizumab[Title/
Abstract])
6. Tumor Necrosis Factor-alpha/antagonists and inhibitors[Mesh:NoExp]
7. Antibodies, Monoclonal/therapeutic use[Mesh:NoExp]
8. Antibodies, Monoclonal, Humanized/therapeutic use[Mesh:NoExp]
9. Antibodies, Monoclonal, Murine-Derived/therapeutic use[Mesh:NoExp]
10. “anti-tnf"[Title/Abstract]) OR "anti-tumor necrosis factor alpha"[Title/Abstract]) 
OR "anti-tumour necrosis factor alpha"[Title/Abstract]) OR "tnf inhibition"[Title/
Abstract]
11. biologic*[Title/Abstract]
12. or / 4-11
13. 3 and 12
Prediction 14. Biological Markers[Mesh:NoExp]
15. (biomarker*[Title/Abstract] OR marker*[Title/Abstract]) 
16. Individualized Medicine[Mesh:NoExp]
17. "individualised medicine"[Title/Abstract]) OR "individualized medicine"[Title/
Abstract]
18. "personalised medicine"[Title/Abstract]) OR "personalized medicine"[Title/
Abstract]
19. predict*[Title/Abstract]
20. Predictive Value of Tests[Mesh:NoExp]
21. Sensitivity and Specificity[Mesh:NoExp]
22. ROC Curve[Mesh:NoExp]
23. Remission Induction[Mesh:NoExp]
24. remission[Title/Abstract]
25. flar*[Title/Abstract]
26. scor*[Title/Abstract]
27. observ*[Title/Abstract]
28. Observer Variation[Mesh:NoExp]
29. stratification[Title/Abstract]
30. discrimination[Title/Abstract]
31. discriminate[Title/Abstract]
32. c-statistic[Title/Abstract]
33. "c statistic"[Title/Abstract]
34. "area under the curve"[Title/Abstract]
35. AUC[Title/Abstract]
36. calibration[Title/Abstract]
37. indices[Title/Abstract]
38. algorithm[Title/Abstract]
39. multivariable[Title/Abstract]
40. or/ 14-39
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Tapering 41. Drug Administration Schedule[Mesh:NoExp]
42. Dose-Response Relationship, Drug[Mesh:NoExp]
43. "down titration"[Title/Abstract]
44. "dose titration"[Title/Abstract]
45. "dose reduction"[Title/Abstract]
46. "dose de-escalation"[Title/Abstract]
47. withdraw*[Title/Abstract]
48. discontinu*[Title/Abstract]
49. taper*[Title/Abstract]
50. "biologic free"[Title/Abstract]
51. spac*[Title/Abstract]
52. cessation[Title/Abstract]
53. stop*[Title/Abstract]
54. "interval widening"[Title/Abstract]
55. or / 41-54
56. 13 and 40 and 55 
EMBASE
search strategy
RA AND bDMARD 1. rheumatoid arthritis/
2. (rheumatoid adj2 arthritis).tw
3. (rheumatoid adj2 arthritis).kw
4. 1 or 2 or 3
5. antirheumatic agent/dt
6. (abatacept or adalimumab or certolizumab or etanercept or golimumab or 
infliximab or rituximab or tocilizumab).tw.
7. abatacept/ 
8. adalimumab/
9. certolizumab pegol/
10. etanercept/
11. golimumab/
12. infliximab/
13. rituximab/
14. tocilizumab/
15. tumor necrosis factor inhibitor/dt
16. monoclonal antibody/dt
17. (anti-tnf or anti-tumor necrosis factor alpha or anti-tumour necrosis factor alpha 
or (tnf adj3 inhibition).tw. 
18 biologic$.tw 
19. or / 5-18
20. 4 and 19
Prediction 21. biological marker/
22. (biomarker? or marker?).tw
23. personalized medicine/
24. ((individuali?ed or personali?ed) adj2 medicine).tw.
25. predict$.tw.
26. predictive value/
27. “sensitivity and specificity”/
28. receiver operating characteristic/ 
29. remission induction/
30. remission/
31. remission.tw
32. flar$.tw
33. scor$.tw
34. observ$.tw
35. observer variation/ 
36. stratification.tw.
37. discrimination.tw.
38. discriminate.tw.
39. c-statistic.tw.
40. c statistic.tw.
41. (area adj3 curve).tw.
42. AUC.tw
43. calibration.tw.
44. indices.tw.
45. algorithm.tw.
46. multivariable.tw.
47. or / 21-46
Tapering 48. drug dose reduction/
49. (down adj3 titrat$).tw
50. (dose adj3 titrat$).tw
51. (dose adj3 reduc$).tw
52. (dose adj3 de-escalation).tw
53. withdraw$.tw
54. discontinu$.tw
55. taper$.tw
56. (biologic adj2 free).tw
57. spac$.tw
58. cessation.tw
59. stop$.tw
60. (interval adj3 widening).tw
61. or / 48-60
62. 20 and 47 and 61                          
COCHRANE 
LIBRARY
search strategy
RA AND bDMARD 2. rheumatoid near/2 arthritis:ti,ab,kw 
3. #1 or #2 
4. MeSH descriptor: [Antirheumatic Agents] this term only and with qualifier(s): 
[Therapeutic use - TU]
5. abatacept or adalimumab or certolizumab or etanercept or golimumab or 
infliximab or rituximab or tocilizumab:ti,ab 
6. MeSH descriptor: [Tumor Necrosis Factor-alpha] this term only and with 
qualifier(s): [Antagonists & inhibitors - AI]
7. MeSH descriptor: [Antibodies, Monoclonal] this term only and with qualifier(s): 
[Therapeutic use - TU]
8. MeSH descriptor: [Antibodies, Monoclonal, Humanized] this term only and with 
qualifier(s): [Therapeutic use - TU]
9. MeSH descriptor: [Antibodies, Monoclonal, Murine-Derived] this term only and 
with qualifier(s): [Therapeutic use - TU]
10. anti-tnf or anti-tumor necrosis factor alpha or anti-tumour necrosis factor alpha 
or (tnf near/2 inhibition):ti,ab 
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11. biologic*:ti,ab 
12. {or #4-#11} 
13. #3 and #12 
Prediction 15. biomarker? or marker?:ti,ab 
16. (individuali?ed or personali?ed) near/2 medicine:ti,ab 
17. predict*:ti,ab 
18. MeSH descriptor: [Predictive Value of Tests] this term only
19. MeSH descriptor: [Sensitivity and Specificity] this term only
20. MeSH descriptor: [ROC Curve] this term only
21. MeSH descriptor: [Remission Induction] this term only
22. remission:ti,ab 
23. flar*:ti,ab 
24. scor*:ti,ab 
25. observ*:ti,ab 
26. MeSH descriptor: [Observer Variation] this term only
27. stratification:ti,ab 
28. discrimination:ti,ab 
29. discriminate:ti,ab 
30. c statistic:ti,ab 
31. c-statistic:ti,ab 
32. area near/3 curve:ti,ab 
33. AUC:ti,ab 
34. calibration:ti,ab 
35. indices:ti,ab 
36. algorithm:ti,ab 
37. multivariable:ti,ab 
38. {or #14-#37} 
Tapering 40. MeSH descriptor: [Dose-Response Relationship, Drug] this term only
41. (down near/3 titrat*):ti,ab 
42. (dose near/3 titrat*):ti,ab 
43. (dose near/3 reduc*):ti,ab 
44. (dose near/3 de-escalation):ti,ab 
45. withdraw*:ti,ab 
46. discontinu*:ti,ab 
47. taper*:ti,ab 
48. (biologic near/2 free):ti,ab 
49. spac*:ti,ab 
50. cessation:ti,ab 
51. stop*:ti,ab 
52. (interval near/3 widening):ti,ab 
53. {or #39-#52} 
54. #13 and #38 and #53 
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Supplementary file 3a. Overview of biomarkers studied multiple times for successful dose reduction of 
a bDMARD
Category Biomarker Study Association measure 
provided by study
Potential 
predictor 
(OR or HR    
>2.0 or <0.5 
and/or
p <0.05)
Patient 
characteristics
Age van der Maas, 201225 Univariate OR (95% CI): 
1.0 (0.95-1.05), p = 0.98
No
Marks, 201526 p = 0.07* No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Chen, 201529 Textual conclusion: NS No
Naredo, 201531 p = 0.25* No
Gender van der Maas, 201225 Univariate OR (95% CI): 
1.1 (0.36-3.51), p = 0.83
No
Marks, 201526 p = 0.07* No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Chen, 201529 Textual conclusion: NS No
Naredo, 201531 p = 0.33* No
Disease duration van der Maas, 201225 Univariate OR (95% CI): 
0.9 (0.86-1.01), p = 0.10
No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Chen, 201529 Textual conclusion: NS No
Naredo, 201531 p = 0.01* Yes
Smoking van der Maas, 201225 Univariate OR (95% CI): 
5.3 (0.6-46.6), p = 0.08
Yes
Marks, 201526 p = 0.99* No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Naredo, 201531 p = 0.36* No
Treatment 
characteristics
Number previous 
csDMARDs
van Herwaarden, 
2015a27
Textual conclusion: NS No
Marks, 201526 p = 0.69* No
Naredo, 201531 p = 0.003* Yes
Number previous 
bDMARDs
van Herwaarden, 
2015a27
Textual conclusion: NS No
Naredo, 201531 p = 0.23* No
Time from 
symptom onset 
to bDMARD 
Naredo, 201531 p = 0.36* No
Marks, 201526 p = 0.31* No
Category Biomarker Study Association measure 
provided by study
Potential 
predictor 
(OR or HR    
>2.0 or <0.5 
and/or
p <0.05)
Duration 
current bDMARD 
treatment before 
tapering
van der Maas, 201225 Univariate OR (95% CI): 
0.9 (0.73-1.15), p = 0.46
No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Chen, 201529 p < 0.001* (remission),     
p < 0.01* (LDA)
Yes
Concomitant 
csDMARD 
van der Maas, 201225 Univariate OR (95% CI): 
1.0 (0.25-4.28), p = 0.95
No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Naredo, 201531 p = 1.00* No
Marks, 201526 p = 0.45* No
Methotrexate van der Maas, 201225 Univariate OR (95% CI): 
1.3 (0.40-4.38), p = 0.65
No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Chen, 201529 Textual conclusion: NS No
Glucocorticoids van Herwaarden, 
2015a27
Textual conclusion: NS No
Chen, 201529 Textual conclusion: NS No
Naredo, 201531 p = 0.07* No
Disease 
activity 
characteristics
DAS28-ESR at 
tapering
van der Maas, 201225 Univariate OR (95% CI): 
0.6 (0.26-1.21), p =  0.12
No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Chen, 201529 p < 0.001* (remission)     
p < 0.01* (LDA)
Yes
Naredo, 201531 p = 0.01* Yes
Laboratory 
characteristics
Rheumatoid 
factor
van der Maas, 201225 Univariate OR (95%CI): 
1.3 (0.30-5.57), p = 0.72
No
Marks, 201526 p = 0.03* Yes
van Herwaarden, 
2015a27
Textual conclusion: NS No
Chen, 201529 Textual conclusion: NS No
Naredo, 201531 p = 0.11* No
Fautrel, 201530 Multivariate HR (95% 
CI): 1.99 (1.03-3.83),
p < 0.05 
Yes
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Category Biomarker Study Association measure 
provided by study
Potential 
predictor 
(OR or HR     
>2.0 or <0.5 
and/or
p <0.05)
ACPA van der Maas, 201225 Univariate OR (95% CI): 
0.7 (0.16-3.18), p = 0.64
No
Marks, 201526 p = 0.28* No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Chen, 201529 Textual conclusion: NS No
Naredo, 201531 p = 0.21* No
ESR van Herwaarden, 
2015a27
Textual conclusion: NS No
Chen, 201529 Textual conclusion: NS No
CRP van Herwaarden, 
2015a27
Textual conclusion: NS No
Chen, 201529 p < 0.001* Yes
Adalimumab 
trough level 
van Herwaarden, 
2015b28
ROC AUC (95% CI): 0.86 
(0.58-1.00)
Yes
Chen, 201529 ROC AUC (95% CI): 0.995 
(0.93-1.00),
p < 0.001
Yes
Statistical significance was assessed by chi-square test, Fisher’s exact test, t-test, Mann-Whitney test or Wilcoxon rank sum 
test as appropriate. 
ACPA,  Anti-Citrullinated Peptide Antibodies; AUC, Area Under the Curve; bDMARD, biological Disease-Modifying Anti-
rheumatic Drug; CI, Confidence Interval; CRP, C-Reactive Protein; csDMARD,  conventional synthetic DMARD; DAS, Disease 
Activity Score; ESR, Erythrocyte Sedimentation Rate; HR, Hazard Ratio; NS, Not Significant; OR, Odds Ratio; ROC, Receiver 
Operating Characteristics.
Supplementary file 3b. Overview of biomarkers studied multiple times for successful discontinuation of 
a bDMARD
Category Biomarker Study Association measure 
provided by study
Potential 
predictor 
(OR or HR
>2.0 or <0.5 
and/or
p <0.05)
Patient 
characteristics
Age Aguilar-Lozano, 
201332
Textual conclusion: NS No
Iwamoto, 201433 p = 0.33* No
Tanaka, 201037 p = 0.01* Yes
Tanaka, 201524 Univariate OR (95% CI) 
0.955 (0.907-1.007),
p = 0.09
No
van den Broek, 201123 Univariate HR (95% CI): 
1.00 (0.98-1.02)
No
Brocq, 200938 p = 0.8* No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Gender Aguilar-Lozano, 
201332
Textual conclusion: NS No
Iwamoto, 201433 p = 0.44* No
Nishimoto, 201334 Univariate HR (95% CI): 
0.61 (0.37-1.00)
No
Tanaka, 201037 p = 0.47* No
van den Broek, 201123 HR (95% CI): 1.1 (0.6-2.0) No
Brocq, 200938 p = 0.6* No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Disease duration Aguilar-Lozano, 
201332
Textual conclusion: NS No
Iwamoto, 201433 p = 0.81* No
Nishimoto, 201334 Univariate HR (95% CI): 
0.81 (0.60-1.10)
No
Saleem, 201035 Univariate logistic 
regression: p < 0.0001
Yes
Tanaka, 201037 p = 0.02* Yes
Tanaka, 201524 p = 0.0488* Yes
van den Broek, 201123 Univariate HR (95% CI): 
1.02 (1.01-1.03)
Yes
Brocq, 200938 p = 0.7* No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Systematic review of prediction of biologic tapering in RAChapter 2
22
4544
Category Biomarker Study Association measure 
provided by study
Potential 
predictor 
(OR or HR    
>2.0 or <0.5 
and/or
p <0.05)
Remission 
duration
Iwamoto, 201433 p = 0.58* No
Saleem, 201035 Textual conclusion: NS No
Brocq, 200938 p = 0.04* Yes
Smoking van den Broek, 201123 Univariate HR (95% CI): 
2.4 (1.4-4.3)
Yes
van Herwaarden, 
2015a27
Textual conclusion: NS No
BMI van den Broek, 201123 Univariate HR (95% CI): 
1.04 (0.96-1.12)
No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Treatment
characteristics
Number previous 
csDMARDs
van Herwaarden, 
2015a27
Textual conclusion: NS No
Brocq, 200938 p = 0.2* No
Number previous 
bDMARDs
van Herwaarden, 
2015a27
Textual conclusion: NS No
Brocq, 200938 p = 0.8* No
Time from 
symptom onset 
to bDMARD 
Saleem, 201035 Univariate logistic 
regression: p = 0.003
Yes
van den Broek, 201123 Univariate HR (95% CI): 
2.0 (1.1-3.7)
Yes
Duration 
current bDMARD 
treatment before 
tapering
van den Broek, 201123 HR (95% CI): 1.05 (1.02-
1.07)
Yes
Brocq, 200938 p = 0.01* Yes
van Herwaarden, 
2015a27
Textual conclusion: NS No
Tanaka, 201524 p = 0.03* Yes
Concomitant 
csDMARD 
van Herwaarden, 
2015a27
Textual conclusion: NS No
Brocq, 200938 p = 0.6* No
Methotrexate Iwamoto, 201433 p = 0.55* No
Tanaka, 201037 p = 0.32* No
Tanaka, 201524 p = 0.76* No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Category Biomarker Study Association measure 
provided by study
Potential 
predictor 
(OR or HR    
>2.0 or <0.5 
and/or
p <0.05)
Glucocorticoids Iwamoto, 201433 p= 0.67* No
Tanaka, 201037 p = 0.52* No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Nishimoto, 201334 Univariate HR (95% CI): 
0.64 (0.46-0.88)
Yes
Disease 
activity 
characteristics
HAQ Iwamoto, 201433 p = 0.72* No
Saleem, 201035 Univariate logistic 
regression: p = 0.01
Yes
Takeuchi, 201536 p = 0.04* Yes
Tanaka, 201037 p = 0.11* No
Tanaka, 201524 p = 0.35* No
van den Broek, 201123 Univariate HR (95% CI): 
1.25 (0.8-3.0)
No
Brocq, 200938 p = 0.3* No
Nishimoto, 201334 Univariate HR (95% CI): 
0.73 (0.53-0.99)
Yes
DAS28-ESR at 
discontinuation
Iwamoto, 201433 ROC AUC (95% CI): 0.55
(0.37-0.73), p = 0.30 
No
Nishimoto, 201334 Univariate HR (95% CI): 
0.59 (0.44-0.58)
Yes
Tanaka, 201037 p = 0.001* Yes
Tanaka, 201524 OR (95% CI): 0.09 (0.02-
0.44), p = 0.003
Yes
van Herwaarden, 
2015a27
Textual conclusion: NS No
DAS28-CRP at 
discontinuation
Iwamoto, 201433 p = 0.39* No
Tanaka, 201037 Textual conclusion: S Yes
van Herwaarden, 
2015a27
Textual conclusion: NS No
DAS28-ESR at 
start bDMARD
Tanaka, 201037 p = 0.91* No
Brocq, 200938 p = 0.35* No
TJC Tanaka, 201037 p = 0.58* No
van den Broek, 201123 Univariate HR (95% CI): 
1.08 (0.93-1.27)
No
van Herwaarden, 
2015a27
Textual conclusion: NS No
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Category Biomarker Study Association measure 
provided by study
Potential 
predictor 
(OR or HR    
>2.0 or <0.5 
and/or
p <0.05)
SJC Tanaka, 201037 p = 0.17* No
van den Broek, 201123 Univariate HR (95% CI): 
0.97 (0.77-1.22)
No
van Herwaarden, 
2015a27
Textual conclusion: NS No
VAS disease 
activity 
Tanaka, 201037 p = 0.95* No
van den Broek, 201123 Univariate HR (95% CI): 
1.01 (0.99-1.02)
No
SDAI Iwamoto, 201433 p = 0.18* No
Tanaka, 201524 p = 0.62* No
CDAI Iwamoto, 201433 p = 0.28* No
Tanaka, 201524 p = 0.80* No
Laboratory 
characteristics
Rheumatoid 
factor
Iwamoto, 201433 p = 0.68* No
Nishimoto, 201334 Univariate HR (95% CI): 
0.53 (0.33-0.85)
Yes
Tanaka, 201037 p = 0.52* No
Tanaka, 201524 OR (95% CI): 1.01 (0.998-
1.03), p = 0.09
No
van den Broek, 201123 Univariate HR (95% CI): 
1.2 (0.6-2.1)
No
Brocq, 200938 p = 0.3* No
van Herwaarden, 
2015a27
Textual conclusion: NS No
ACPA Iwamoto, 201433 p = 1.00* No
van den Broek, 201123 Univariate HR (95% CI): 
1.5 (0.8-3.1)
No
Brocq, 200938 p = 1.00 No
van Herwaarden, 
2015a27
Textual conclusion: NS No
ESR Tanaka, 201037 p = 0.16* No
Tanaka, 201524 p = 0.002* Yes
van den Broek, 201123 Univariate HR (95% CI): 
1.00 (0.98-1.02)
No
van Herwaarden, 
2015a27
Textual conclusion: NS No
CRP Takeuchi, 201536 p = 0.048* Yes
Tanaka, 201037 p = 0.55* No
Tanaka, 201524 p = 0.33* No
van den Broek, 201123 Univariate HR (95% CI): 
0.98 (0.93-1.02)
No
van Herwaarden, 
2015a27
Textual conclusion: NS No
Category Biomarker Study Association measure 
provided by study
Potential 
predictor 
(OR or HR    
>2.0 or <0.5 
and/or
p <0.05)
MMP-3 
concentration
Nishimoto, 201334 Univariate HR (95% CI): 
0.33 (0.24-0.46)
Yes
Tanaka, 201524 p = 0.11* No
Imaging 
characteristics 
SvdH total score van Herwaarden, 
2015a27
Textual conclusion: NS No
van den Broek, 201123 Univariate HR (95% CI): 
1.02 (1.00-1.03)
No
Tanaka, 201037 p = 0.02* Yes
Tanaka, 201524 p = 0.57* No
SvdH erosion 
score
van den Broek, 201123 Univariate HR (95% CI): 
1.03 (1.01-1.06)
Yes
Tanaka, 201037 p = 0.01* Yes
SvdH joint space 
narrowing score
van den Broek, 201123 Univariate HR (95% CI): 
1.03 (1.00-1.06)
No
Tanaka, 201037 p = 0.06* No
Yearly 
progression 
of SvdH at 
discontinuation
Tanaka, 201037 p = 0.58* No
van den Broek, 201123 Univariate HR (95% CI): 
1.07 (1.02-1.13)
Yes
Gray scale 
ultrasound 
examination
Iwamoto, 201433 ROC AUC (95% CI): 0.76 
(0.60-0.91), p = 0.01
Yes
Saleem, 201035 Textual conclusion: NS No
Power Doppler 
ultrasound 
examination
Iwamoto, 201433 ROC AUC (95% CI): 0.73 
(0.56-0.91), p = 0.001
Yes
Saleem, 201035 Textual conclusion: NS No
Statistical significance was assessed by chi-square test, Fisher’s exact test, t-test, Mann-Whitney test or Wilcoxon rank sum 
test as appropriate. 
ACP, Anti-Citrullinated Peptide Antibodies; AUC, Area Under the Curve; bDMARD, biological Disease-Modifying Anti-
Rheumatic Drug; BMI, Body Mass Index; CDAI, Clinical Disease Activity Index; CI, Confidence Interval; CRP, C-Reactive 
Protein; csDMARD, conventional synthetic DMARD; DAS, Disease Activity Score; ESR, Erythrocyte Sedimentation Rate ; HAQ, 
Health Assessment Questionnaire; HR, Hazard Ratio; MMP, Matrix MetalloProteinase; NS, Not Significant; OR, Odds Ratio; 
ROC, Receiver Operating Characteristics; SDAI, Simplified Disease Activity Index; S, Significant; SJC, Swollen Joint Count; 
SvdH, Sharp van der Heijde; TJC, Tender Joint Count; VAS, Visual Analogue Scale
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Supplementary file 4a. Overview of biomarkers studied once for successful dose reduction of a bDMARD
Category Biomarker Study Association measure 
provided by study
Potential 
predictor 
(OR or HR    
>2.0 or <0.5 
and/or
p <0.05)
Patient
characteristics
Caucasian Marks, 201526 p = 0.53* No
BMI van Herwaarden, 
2015a27
Textual conclusion: NS No
2011 ACR/EULAR 
remission
van Herwaarden, 
2015a27
Textual conclusion: NS No
Remission 
duration
Naredo, 201531 p = 0.17* No
Patients belief van der Maas, 201225 Univariate OR (95% CI): 
2.4 (0.71-7.76), p = 0.16
Yes
Employed van Herwaarden, 
2015a27
Textual conclusion: NS No
Travel distance van Herwaarden, 
2015a27
Textual conclusion: NS No
Treatment
characteristics
Time from 
symptom onset 
to csDMARD
Naredo, 201531 p = 0.06* No
Etanercept/ 
adalimumab
van Herwaarden, 
2015a27
Textual conclusion: NS No
Previous dose 
reduction 
attempt with 
current TNFi
van Herwaarden, 
2015a27
Textual conclusion: NS No
Previous 
csDMARD 
combination 
treatment
van Herwaarden, 
2015a27
Textual conclusion: NS No
Duration of 
csDMARD
Naredo, 201531 p = 0.22* No
Methotrexate 
dose
van Herwaarden, 
2015a27
Textual conclusion: NS No
Sulfasalazine Chen, 201529 Textual conclusion: NS No
Hydroxychloro-
quine
Chen, 201529 Textual conclusion: NS No
NSAID van Herwaarden, 
2015a27
Textual conclusion: NS No
Disease 
activity
characteristics
TJC van Herwaarden, 
2015a27
Textual conclusion: NS No
SJC van Herwaarden, 
2015a27
Textual conclusion: NS No
Category Biomarker Study Association measure 
provided by study
Potential 
predictor 
(OR or HR    
>2.0 or 
<0.5 and/or      
p <0.05)
DAS28-ESR at 
start bDMARD
Marks, 201526 Univariate OR (95% CI): 
2.04 (1.006-4.133), p = 
0.048
Yes
DAS28-CRP at 
tapering
van Herwaarden, 
2015a27
Textual conclusion: NS No
SDAI Naredo, 201531 p = 0.003* Yes
HAQ Fautrel, 201530 Multivariate HR (95% 
CI): 2.07 (1.23-3.49)
Yes
Laboratory 
characteristics
Anti-
adalimumab 
antibodies 
van Herwaarden, 
2015b28
Textual conclusion: NS No
Adalimumab 
random level 
van Herwaarden, 
2015b28
ROC AUC (95% CI): 0.51 
(0.32-0.71)
No
Etanercept 
random level 
van Herwaarden, 
2015b28
ROC AUC (95% CI): 0.36 
(0.23-0.49)
Yes
Etanercept 
intermediately 
timed level 
van Herwaarden, 
2015b28
ROC AUC (95% CI): 0.28 
(0.08-0.47)
Yes
Imaging
characteristics
Erosive van Herwaarden, 
2015a27
Textual conclusion: NS No
SvdH total score van Herwaarden, 
2015a27
Textual conclusion: NS No
Ultrasound SHI 
(0-108)
Naredo, 201531 p = 0.19* No
Ultrasound DSI 
(0-108)
Naredo, 201531 p < 0.0005* Yes
12-joint SHI Naredo, 201531 p = 0.03* Yes
12-joint DSI Naredo, 201531 p < 0.0005* Yes
WMAM SHI Naredo, 201531 p = 0.65* No
WMAM DSI Naredo, 201531 p < 0.0005* Yes
Statistical significance was assessed by chi-square test, Fisher’s exact test, t-test, Mann-Whitney test or Wilcoxon rank sum 
test as appropriate. 
ACR, American College of Rheumatology; AUC, Area Under the Curve; bDMARD, biological Disease-Modifying Anti-
Rheumatic Drug; BMI, Body Mass Index; CI, Confidence Interval; CRP, C-Reactive Protein; csDMARD, conventional synthetic 
DMARD; DAS, Disease Activity Score; DSI, Doppler Synovitis Index; ESR, Erythrocyte Sedimentation Rate; EULAR, European 
League Against Rheumatism; HAQ, Health Assessment Questionnaire; HR, Hazard Ratio; NS, Not Significant; NSAID, 
Non-Steroidal Anti-Inflammatory Drug; OR, Odds Ratio; ROC, Receiver Operating Characteristics; SDAI, Simplified Disease 
Activity Index; SHI, Synovial Hypertrophy Index; SJC, Swollen Joint Count; SvdH, Sharp van der Heijde; TNFi, Tumour Necrosis 
Factor inhibitor; TJC, Tender Joint Count; WMAM, Wrist-MCP-Ankle-MTP. 
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Supplementary file 4b. Overview of biomarkers studied once for successful discontinuation of a 
bDMARD
Category Biomarker Study Association measure 
provided by study
Potential 
predictor 
(OR or HR > 
2.0 or < 0.5 
and/or
p <0.05)
Patient 
characteristics
2011 ACR/EULAR 
remission
van Herwaarden, 
2015a27
Textual conclusion: NS No
Employed van Herwaarden, 
2015a27
Textual conclusion: NS No
Travel distance van Herwaarden, 
2015a27
Textual conclusion: NS No
Treatment
characteristics
Discontinued 
bDMARD
Iwamoto, 201433 p = 0.17* No
Etanercept/ 
adalimumab
van Herwaarden, 
2015a27
Textual conclusion: NS No
Infliximab dose 
increase
van den Broek, 201123 Univariate HR (95% CI): 
1.2 (0.7-2.2)
No
Previous dose 
reduction 
attempt with 
current TNFi
van Herwaarden, 
2015a27
Textual conclusion: NS No
Previous 
csDMARD 
combination 
treatment
van Herwaarden, 
2015a27
Textual conclusion: NS No
Methotrexate 
dose
van Herwaarden, 
2015a27
Textual conclusion: NS No
NSAID van Herwaarden, 
2015a27
Textual conclusion: NS No
Disease 
activity 
characteristics
VAS general 
health
van den Broek, 201123 Univariate HR (95% CI): 
1.00 (0.099-1.02)
No
VAS morning 
stiffness 
van den Broek, 201123 Univariate HR (95% CI): 
1.01 (1.00-1.02)
No
VAS pain van den Broek, 201123 Univariate HR (95% CI): 
1.01 (1.00-1.03)
No
VAS disease 
activity by 
physician
van den Broek, 201123 Univariate HR (95% CI): 
1.03 (1.01-1.06)
Yes
DAS28-CRP at 
start bDMARD
Tanaka, 201037 p = 0.55* No
DAS at 
discontinuation
van den Broek, 201123 Univariate HR (95% CI): 
1.1 (0.7-1.9)
No
Category Biomarker Study Association measure 
provided by study
Potential 
predictor 
(OR or HR    
>2.0 or <0.5 
and/or
p <0.05)
DAS < 1.6 vs     
DAS   ≤ 2.4 at 
discontinuation
van den Broek, 201123 Univariate HR (95% CI): 
0.98 (0.5-1.8)
No
Steinbrocker 
Stage (I+II vs 
III+IV)
Nishimoto, 201334 Univariate HR (95% CI): 
0.77 (0.57-1.04)
No
Steinbrocker 
Class (1+2 vs 3+4)
Nishimoto, 201334 Univariate HR (95% CI): 
0.82 (0.20-3.33)
No
RAQoL Saleem, 201035 Univariate logistic 
regression: p = 0.04
Yes
Laboratory 
characteristics
Shared epitope van den Broek, 
201123
Univariate HR (95% CI): 
3.9 (1.4-11.0)
Yes
IL-6 
concentration 
Nishimoto, 201334 Univariate HR (95% CI): 
0.37 (0.25-0.54)
Yes
Naives (% of 
CD4+ T cells)
Saleem, 201035 Univariate logistic 
regression: p < 0.0001
Yes
IRC (% of CD4+ T 
cells)
Saleem, 201035 Univariate logistic 
regression: p < 0.0001
Yes
Treg 
CD25highFOXP3+ 
(% of CD4+ T 
cells)
Saleem, 201035 Univariate logistic 
regression: p = 0.001
Yes
CD62L + Tregs (% 
of Tregs)
Saleem, 201035 Univariate logistic 
regression: p < 0.0001
Yes
Anti-
adalimumab 
antibodies 
van Herwaarden, 
2015b28
Textual conclusion: NS No
Adalimumab 
random level 
van Herwaarden, 
2015b28
ROC AUC (95% CI): 0.66 
(0.50-0.83)
No
Etanercept 
random level 
van Herwaarden, 
2015b28
ROC AUC (95% CI): 0.63 
(0.43-0.82)
No
Imaging
characteristics
Erosive van Herwaarden, 
2015a27
Textual conclusion: NS No
Yearly 
progression of 
SvdH at start 
bDMARD
Tanaka, 201037 p = 0.58* No
Statistical significance was assessed by chi-square test, Fisher’s exact test, t-test, Mann-Whitney test or Wilcoxon rank sum 
test as appropriate. 
ACR, American College of Rheumatology; bDMARD, biological Disease-Modifying Anti-Rheumatic Drug; CRP, C-Reactive 
Protein; csDMARD, conventional synthetic DMARD; DAS, Disease Activity Score; EULAR, European League Against 
Rheumatism; HR, Hazard Ratio; IL, Interleukin; IRC, Inflammation-Related Cells; RAQoL, RA Quality of Life Questionnaire; 
ROC, Receiver Operating Characteristics. 
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Introduction
The advantageous effects of biologic disease modifying anti-rheumatic drug (bDMARD) 
treatment in rheumatoid arthritis (RA) on clinical, functional and radiographic outcomes have 
been well documented. However, bDMARDs are associated with adverse events (e.g. (serious) 
infections) and high costs 1,2. With this in mind, dose optimization becomes important, which 
entails: 1) starting treatment when it is needed, 2) disease activity guided dose reduction to 
the lowest effective level when a patient is doing well, 3) discontinuing the drug when it is no 
longer required and 4) restarting or re-escalating in case of a flare. Disease activity guided dose 
reduction of tumor necrosis factor inhibitors (TNFi) in RA patients has proven to be feasible 
and safe3-5 and has recently been included in RA management recommendations6, however, 
data on disease activity guided dose optimization of non-TNFi bDMARDs are scarce. 
Abatacept is a human fusion protein that selectively modulates the CD80/CD86:CD28 
costimulatory signal required for full T cell activation. It is an effective treatment (either as 
monotherapy or in combination with a conventional synthetic DMARD (csDMARD)) in patients 
who are either csDMARD naïve or had an inadequate response to csDMARD or bDMARD 7-9. 
Tocilizumab is a humanized monoclonal antibody directed against the Interleukin-6 (IL-6) 
receptor and is an effective treatment option after failure of a csDMARD or bDMARD, either as 
monotherapy or in combination with a csDMARD 10-13. 
Few studies have been performed focusing on dose reduction or discontinuation of  abatacept 
or tocilizumab 14-19. With regard to abatacept, Takeuchi et al. observed abatacept-free remission 
in 22 of 34 (65%) patients after one year of discontinuation 15. Furthermore, in the AGREE study, 
a double-blind randomized controlled trial, the efficacy of reduction of intravenous abatacept 
from 10 to 5 mg/kg in early RA patients was investigated 16, showing that the proportions of 
patients who lost DAS28-defined remission status were similar between groups at month12. 
Also, the AVERT study showed that in early RA patients reaching low disease activity after 
abatacept treatment for 12 months, radiographic benefits were maintained at 6 months after 
withdrawal of abatacept17. 
With regard to tocilizumab, Nishimoto et al. investigated discontinuation of tocilizumab 
in patients with early RA treated with tocilizumab monotherapy in the DREAM study18. Low 
disease activity was maintained in 35% after 6 months and in 13% after one year. Furthermore, 
the effects of dose reduction of tocilizumab were described in a small retrospective study in 
22 patients 19. Dose reduction was successful in 55% of patients after 6 months and all patients 
with worsening of disease activity after dose reduction regained low disease activity after 
dose escalation. 
Thus, data on disease activity guided dose reduction of abatacept or tocilizumab in RA 
is limited. Moreover, most studies have focused on early RA patients enrolled in clinical 
trials, leaving uncertainty to its’ feasibility in daily clinical practice. Therefore we aimed to 
retrospectively investigate the feasibility (including frequency of dose reduction attempts 
and persistence), effectiveness and safety of tapering of abatacept and tocilizumab in RA 
patients in daily practice. 
 
Abstract
Objective
As data on disease activity guided dose optimization of abatacept and tocilizumab are scarce, 
we explored the feasibility, effectiveness and safety of dose optimization of these bDMARDs in 
rheumatoid arthritis (RA) patients in daily practice.  
Methods
RA patients who were treated with abatacept or tocilizumab ≥ 6 months, with DAS28 <3.2 were 
included. Four groups were identified: abatacept dose reduction (DR) and usual care (UC), and 
tocilizumab DR and UC. Successful DR and discontinuation entailed being on lower dose than 
at baseline or having discontinued abatacept or tocilizumab, whilst maintaining DAS28 <3.2. 
Proportions of patients with successful DR or discontinuation at 12 months were described. 
DR maintenance was investigated using Kaplan-Meier curves. Between-group differences in 
mean DAS28 and HAQ-DI change (Δ) over 6 and 12 months were estimated. 
Results
119 patients were included. DR was attempted in 13/28 (46%, 95% CI 28-66%) abatacept 
and 64/91 (70%, 60-79%) tocilizumab patients. At 12 months, 3/11 (27%, 6-61%) abatacept 
and 20/48 (42%, 28-57%) tocilizumab patients were successfully tapered. 1/11 (9%, 0-41%) 
abatacept and 5/48 (10%, 3-23%) tocilizumab patients were successfully discontinued. Mean 
ΔDAS28 and ΔHAQ-DI at month 6 and 12 were not significantly different between DR and UC. 
For tocilizumab, DAS28 was significantly higher in the DR compared to UC group at 6 months. 
Adverse events were comparable between groups. 
Conclusion
Abatacept and tocilizumab DR appears to be feasible,and safe in clinical practice. No benefits 
in terms of fewer adverse events in the DR group were observed. Furthermore, DR was 
suboptimal, since all patients were eligible for DR but in a substantial number of patients, no 
DR was attempted.
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Methods
Study design and participants
SONATA (Study ON Abatacept and Tocilizumab Attenuation) is a retrospective explorative 
mono-center controlled cohort study, investigating disease activity and functioning in 
RA patients that reached low disease activity on abatacept or tocilizumab treatment and 
attempted dose reduction, compared with control groups of patients that reached low disease 
activity on abatacept or tocilizumab treatment but never attempted dose reduction. All 
patients at the rheumatology department of the Sint Maartenskliniek, a specialized hospital 
in Nijmegen, The Netherlands, that had been or were still treated with either abatacept or 
tocilizumab were screened for eligibility. Patients were considered eligible if they were 
diagnosed with RA according to the 1987 and/or 2010 ACR criteria and/or clinical diagnosis by 
the treating rheumatologist and were treated at any time with abatacept and/or tocilizumab, 
reached low disease activity (DAS28-ESR <3.2) after 6 months of treatment and had at least 6 
months of follow-up available.
Four cohorts were defined: abatacept dose reduction (DR) group, abatacept usual care 
(UC) group, tocilizumab DR group and tocilizumab UC group. Patients that attempted dose 
reduction because of low disease activity with or without adverse events were included in 
the DR group. Patients in whom DR was attempted solely because of adverse events were 
excluded. Patients who were eligible for DR but in whom no dose reduction attempt was 
undertaken (because of either patient or physician preference or unspecified reasons), were 
included in the UC group. Patients that were treated with both abatacept and tocilizumab 
were included in analyses only once for the first bDMARD used. 
All patients eligible for inclusion were asked for written informed consent for retrospective 
data collection. According to the Central Committee on Research involving Human Subjects 
(CCMO), this type of study does not require approval from an ethics committee in the 
Netherlands. 
Procedures
Abatacept and tocilizumab were started, according to registration specifications: for 
abatacept either intravenously (i.v.) 500, 750 or 1000 mg/4 weeks depending on body weight, or 
subcutaneously (s.c.) 125 mg/week. Tocilizumab was administered either i.v. 8 mg/kg/4 weeks 
or s.c. 162 mg/week. Both were used as monotherapy or in combination with a csDMARD, 
preferably methotrexate. 
Since 2010, a dose optimization protocol is being used in the Sint Maartenskliniek, which 
includes DAS28 steered dose reduction when DAS28 <3.2 is reached in longstanding RA 
patients for at least 6 months (or DAS28 <2.6 if RA is diagnosed <3 years ago). This is done 
by tapering the dose for i.v. bDMARDs and by increasing the interval for s.c. bDMARDs. For 
abatacept and tocilizumab, the following dose reduction regimens are used: 1) Abatacept i.v.: 
dose reduction of 250 mg every 3 months until discontinuation, or dose reduction of 250 mg 
every 6 months until discontinuation in patients with a baseline dose of 500 mg, 2) Abatacept 
s.c.: increasing the interval every 3 months, from 125 mg/7 days, to once every 10, 14 and 21 
days, then discontinuation, 3) Tocilizumab i.v.: dose reduction every 3 months from 8 to 6 to 
4 mg/kg /4 weeks, then discontinuation, 4) Tocilizumab s.c.: increasing the interval every 3 
months, from 162 mg/7 days, to once every 10, 14 and 21 days, then discontinuation. 
All treatment choices were left to the discretion of the treating rheumatologists. If symptoms of 
loss of disease control occurred, temporary treatment with Non-Steroidal Anti Inflammatory 
Drugs (NSAIDs) or steroids was advised. If a flare persisted, either according to a flare criterion 
(DAS28 increase of >1.2 or >0.6 with current DAS28>3.2)20 or according to the judgement of 
the treating rheumatologist, the bDMARD was restarted or the dose was increased to the last 
efficacious dose. In case of persistently high disease activity, the dose was further reinstalled 
up to the registered dose, after which, if disease activity remained high, the bDMARD was 
switched. 
Outcomes
Patient-, disease- and treatment characteristics were collected, as well as data on disease 
activity (28 joint Disease Activity Score using erythrocyte sedimentation rate (DAS28)) and 
functioning (health assessment questionnaire, HAQ-DI). Data was collected at start of 
abatacept or tocilizumab, at baseline (t=0) and every 3 months thereafter. Baseline was 
defined as being eligible for dose reduction. In the DR group this moment was set at initiation 
of dose reduction. In the UC group this moment was set at reaching low disease activity 
and using abatacept or tocilizumab for at least 6 months (theoretical time of start of dose 
reduction). Successful dose reduction and discontinuation were defined as having a lower 
dose or longer interval than at baseline or complete withdrawal of the bDMARD, respectively, 
with concurrent low disease activity (DAS28 <3.2). Follow-up time was 12 months for all 
outcomes, except for survival analysis using the maximal follow up until censoring or stopping 
of abatacept or tocilizumab.
Statistical analyses
STATA/IC v13.1 was used for all analyses. Descriptive statistics were used for demographic 
data and provided with mean (± standard deviation, SD) or median (interquartile ranges, IQR) 
depending on distribution. Proportions and 95% confidence intervals (CI) of patients in whom 
DR and discontinuation was considered successful at 12 months were described. Median time 
of persistence of successful dose reduction and discontinuation was calculated. A survival 
analysis was done using a Kaplan-Meier curve for time to re-escalation due to high disease 
activity in the DR group. Prevalence of patients switching to other bDMARDs within 12 months 
and reasons for switching were compared between the DR group and the UC group for both 
abatacept and tocilizumab. An unpaired t-test was used to assess differences in mean and mean 
change (Δ) in DAS28 and HAQ-DI at 6 and 12 months after becoming eligible in the DR versus 
UC group for abatacept and tocilizumab separately. Linear regression analyses for differences 
in DAS28 at 6 and 12 months between the DR and UC group were constructed to adjust for 
confounders specific for these outcomes. All baseline factors were checked for possible 
confounding. Because of low patient numbers in subgroups, abatacept and tocilizumab were 
combined in these analyses. Only factors that resulted in a change in beta >10% or (in case of 
too many factors relative to patient numbers) that were considered relevant were included 
in the final model. All factors were added to the model at once. Prevalence of pre-specified 
categories of serious adverse events were compared between the DR group and the UC group 
for both abatacept and tocilizumab. Frequencies of missing data were checked. In case of 
single missing values, single imputation was applied by last observation carried forward or 
calculation of the mean of the previous and next value. For linear regression analyses, missing 
baseline values were imputed using multiple imputation (10 times).
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Results
Patients
From January 2007 until June 2015, 320 patients were treated with abatacept and/or 
tocilizumab, of whom 119 patients were considered eligible. Twenty-eight patients were using 
abatacept: 13 (46%) in the abatacept DR group and 15 (54%) in the abatacept UC group. Ninety-
one patients were using tocilizumab: 64 (70%) in the tocilizumab DR group, and 27 (30%) in the 
tocilizumab UC group. Details and numbers of patients at follow-up are depicted in Figure 
1. Patient characteristics at start of abatacept or tocilizumab and at baseline are depicted 
in Table 1. No large between group differences were observed. At baseline, mean duration of 
abatacept use was 1.1 years (SD 0.4) in the abatacept DR group and 0.7 years (SD 0.3) in the 
abatacept UC group. For tocilizumab, mean duration of tocilizumab use at baseline was 1.4 
years (SD 0.4) in the tocilizumab DR group and 0.7 years (SD 0.3) in the tocilizumab UC group. 
Figure 1. Flow chart with patient disposition (*abatacept/tocilizumab)
Table 1. Patient characteristics at start of abatacept or tocilizumab
Abatacept DR
(n=13) 
Abatacept UC
(n=15)
Tocilizumab DR
(n=64)
Tocilizumab UC
(n=27)
Age, years (SD) 59 (14) 59 (12) 61 (11) 55 (17)
Female, n (%) 12 (92) 14 (93) 47 (73) 19 (70)
Weight, kg (SD) 73 (16) 74 (9) 75 (18) 75 (15)
Disease duration, years 
median [p25-p75]
15 [10-18] 17 [12-21] 12 [5-16] 9 [2-16]
Rheumatoid factor
positive, n (%)
12 (92) 12 (80) 51 (80) 19 (70)
Anti-CCP positive, n (%) 9 (69)* 12 (80)* 47 (73)* 17 (63)*
Erosive disease, n (%) 10 (77)* 9 (60)* 36 (56)* 10 (37)*
DAS28 (SD) 4.6 (0.9) 4.1 (1.4) 4.4 (1.2) 4.2 (1.1)
HAQ-DI (SD)† 1.8 (0.6) 1.5 (0.6) 1.5 (0.6) 1.7 (0.6)
I.v. administration, n (%) 11 (85) 9 (60) 56 (88) 19 (70)
S.c. administration, n (%) 2 (15) 6 (40) 8 (13) 8 (30)
Previous csDMARDs,
median [p25-p75]
4 [3-5] 5 [3-6] 3 [2-4] 2 [2-3]
Previous bDMARDs,
median [p25-p75]
4 [3-4] 4 [3-4] 3 [2-4] 3 [3-4]
Concomitant csDMARD,
n (%)
7 (54) 6 (40) 30 (47) 17 (63)
Concomitant MTX, n (%) 4 (31) 5 (33) 11 (17) 10 (37)
Concomitant 
glucocorticoid, n (%)
5 (38) 9 (60) 45 (70) 17 (63)
Anti-CCP: anti-cyclic citrullinated peptide; DAS28: 28 joints disease activity score-erythrocyte sedimentation rate; HAQ-
DI: health assessment questionnaire – disability index; I.v.: intravenous; S.c.: subcutaneous; csDMARD: synthetic disease-
modifying anti rheumatic drug; bDMARD: biologic DMARD; MTX: methotrexate. *Anti-CCP positivity: 14/119 (12%) missing 
data (2/13 abatacept DR; 2/15 abatacept UC; 8/64 tocilizumab DR; 2/27 tocilizumab UC). Erosive disease: 5/119 (4%) missing 
data (0/13 abatacept DR; 1/15 abatacept UC; 2/64 tocilizumab DR; 2/27 tocilizumab UC). †HAQ-DI: 33/119 (28%) missing data 
(4/13 abatacept DR; 3/15 abatacept UC; 21/64 tocilizumab DR; 5/27 tocilizumab UC).  
Medication use
At 12 months, 3/11 (27%, 95% CI 6% to 61%) patients in the abatacept DR group were successfully 
tapered, with the i.v. dose being lowered by 50% in all 3 patients (from 750 mg to 375 mg i.v. 
every 4 weeks in 2 patients and from 500 mg to 250 mg i.v. every 4 weeks in 1 patient). For the 
tocilizumab DR group, 20/48 (42%, 95% CI 28% to 57%) were successfully tapered at 12 months, 
with the baseline i.v. dose of 8 mg/kg being lowered by to 6 mg/kg in 4 patients, to 5 mg/kg in 1 
patient, to 4 mg/kg in 10 patients and to 2 mg/kg in 1 patient. For tocilizumab s.c., the dose was 
lowered from 162 mg/kg every 7 days to every 10 days in 1 patient, to every 14 days in 2 patients 
and to every 28 days in 1 patient. 1/11 (9%, 95% CI 0% to 41%) patients using abatacept and 
5/48 (10%, 95% CI 3% to 23%) using tocilizumab were successfully discontinued. Of these 
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successfully tapered patients, in all 3 abatacept patients and in 12 tocilizumab patients, 
subsequent discontinuation could have been attempted, since these patients were having 
persistent low disease activity, but this was not done for unknown reasons. In 1/13 (8%, 95% CI 
0% to 36%) patients in the abatacept DR group and 14/64 (22%, 95% CI 13% to 34%) patients 
in the tocilizumab DR group, more than one dose reduction attempt was made in the first 6 
months after baseline. Median time of dose reduction with concurrent low disease activity 
was 6 months [p25-75 6-24) for abatacept and 9 months [6-18] for tocilizumab. Median time of 
discontinuation with concomitant low disease activity was 3 months for abatacept (n=1) and 
3 [3-6] months for tocilizumab. 
Figure 2 shows a Kaplan-Meier curve for time until re-escalation to baseline dose for both 
abatacept and tocilizumab, showing tapering was persistent up to 72 months. 
In patients that attempted DR, 22/77 (29%, 95% CI 19 to 40%) patients that re-escalated 
again were having low disease activity at time of re-escalation. Of these, 1 patient using 
abatacept and 17 patients using tocilizumab re-escalated the dose because of a subjective 
increase in disease activity (more complaints, but no increase in swollen joint counts and 
ESR). Four patients using tocilizumab initially reduced the dose because of adverse events 
(in combination with low disease activity) and re-escalated again once the adverse event 
was resolved. None of the patients re-escalating ended up on a higher dose than at baseline. 
The median time to reach low disease activity again after re-escalation was 4.5 [3-6] months 
in the abatacept DR group and 3 [3-6] months in the tocilizumab DR group. In the DR group, 
5/13 (38%, 95% CI 14 to 68%) patients using abatacept were ultimately switched to another 
bDMARD: 2 were switched due to secondary inefficacy after the dose reduction attempt, 2 
were switched due to secondary inefficacy later on (after being back at baseline dose for a 
substantial amount of time) and 1 was switched due to adverse events. 13/64 (20%, 95% CI 
11 to 32%) patients using tocilizumab were ultimately switched to another bDMARD: 2 were 
switched due to secondary inefficacy after dose reduction, 8 were switched due to secondary 
inefficacy later on and 3 were switched due to adverse events. In the UC group, 2/15 (13%, 95% 
CI 2 to 40%) patients using abatacept were switched to another bDMARD, both due to adverse 
events. For tocilizumab, 4/27 (15%, 95% CI 4 to 34%) were switched to another bDMARD: 3 due 
to secondary inefficacy and 1 due to adverse events. 
Disease activity and functioning
Mean ΔDAS28 and ΔHAQ-DI at month 6 and month 12 were univariately not significantly 
different between DR and UC groups in both abatacept and tocilizumab (Figure 3), although 
confidence intervals were wide especially for abatacept. Absolute DAS28 scores were 
univariately significantly higher for tocilizumab in the DR group than in the UC group at 
6 months, but not at 12 months. No differences were seen for absolute DAS28 scores in the 
abatacept groups. However, adjusted for confounders no significant or relevant differences 
were seen for DAS28 course at 6 and 12 months: DAS28 difference adjusted for confounders 
(age, bDMARD (abatacept or tocilizumab), erosive disease, disease duration and DAS28 at 
baseline): +0.28 higher in DR group (-0.19 to 0.74) at 6 months and (adjusted for age, erosive 
disease, HAQ at start of the bDMARD, DAS28 at baseline) -0.34 lower in DR group (-0.98 to 0.29) 
at 12 months. 
Safety
In the DR groups, 4/13 (31%, 95% CI 9 to 61%) patients using abatacept and 38/64 (59%, 95% CI 
46 to 71%) using tocilizumab experienced at least one adverse event. In the control groups, 2/15 
(13%, 95% CI 2 to 40%) using abatacept and 14/27 (52%, 95% CI 32 to 71%) using tocilizumab 
experienced at least one adverse event. Incidence densities of different categories are depicted 
in Table 3, and were not significantly different between groups. 
Figure 2. Kaplan-Meier survival estimates until re-escalation to baseline dose for abatacept and 
tocilizumab
Hash marks indicate censored patients (end of follow-up)
Figure 3a. Mean DAS28 for abatacept and tocilizumab DR and UC groups from baseline to month 12
Low disease activity defined as DAS28 <3.2
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Figure 3b. Mean HAQ-DI for abatacept and tocilizumab DR and UC groups from baseline to month 12
Table 3. Incidence densities of different adverse event categories per 100 patient years
Incidence densities Abatacept DR Abatacept UC Tocilizumab DR Tocilizumab UC
Infections 11 (2.2 to 31) 0 19 (12 to 29) 28 (14 to 51
Malignancies 0 3.8 (0.1 to 21) 1.5 (0.2 to 5.4) 5.1 (0.6 to 5.2)
Cardiovascular 0 3.8 (0.1 to 21) 1.5 (0.2 to 5.4) 0
Allergic reaction 0 3.8 (0.1 to 21) 0.7 (0.0 to 4.2) 2.6 (0.1 to 14)
Leucopenia 0 0 14 (8.5 to 22) 7.7 (1.6 to 23)
ALT increase 3.6 (0.1 to 20) 3.8 (0.1 to 21) 5.2 (2.1 to 11) 5.1 (0.6 to 19)
Surgery 7.1 (0.9 to 26) 7.7 (0.9 to 28) 0.7 (0.0 to 4.2) 2.6 (0.1 to 14.3)
Death 0 0 1.5 (0.2 to 5.4) 0
Other 11 (2.2 to 31) 7.7 (0.9 to 28) 9.7 (5.2 to 17) 10 (2.8 to 26)
Incidence density per 100 patient years. Abatacept DR: 28 observed person-years; abatacept UC: 26 observed person-years; 
tocilizumab DR: 134 observed person-years; tocilizumab UC: 39 observed person-years.
Discussion
To our knowledge, this is the first study to investigate the feasibility, effectiveness and safety 
of the implementation of a dose optimization strategy of abatacept and tocilizumab in RA 
patients in daily clinical practice. We could confirm that disease activity, functioning and 
safety were comparable between patients in whom a dose reduction attempt was undertaken 
and patients that never attempted dose reduction, with the exception of a significantly higher 
DAS28 at 6 months in the tocilizumab DR group as compared to the UC group. Furthermore, in 
the majority of patients that were successfully tapered at 12 months, the dosage was lowered 
at least 50% or the interval between injections was doubled (or longer). Also, dose reduction 
seems to be persistent in up to 30% of patients. However, the number of patients in whom 
dose reduction was attempted was lower than expected and tapering was not always done 
according to prespecified protocolised tapering steps. Also, in both the abatacept DR and UC 
group, mean DAS28 rose above the level of low disease activity during follow-up in contrast 
to tocilizumab where DAS28 remained low. We would like to discuss these findings in more 
detail. 
We found that change in disease activity, functioning and safety were comparable between 
patients who tapered and patients who did not taper. This finding is comparable to other 
studies showing that tapering is feasible and safe in abatacept and tocilizumab 15,16,18,19,21-24 
and to disease activity guided tapering in TNFi 3-5. However, direct comparison of results is 
hampered by the differences in tapering strategies (gradual tapering versus discontinuation 
without tapering first and dose lowering versus injection interval prolongation), criteria for 
successful tapering or discontinuation (low disease activity versus remission and necessity to 
use steroids or csDMARDs), open label versus blinded tapering, and follow-up time used in the 
studies. 
The number of patients in whom a dose reduction attempt was undertaken was lower than 
expected, considering that all included patients were eligible for dose reduction. Furthermore, 
in the DR groups, duration of abatacept and tocilizumab use before a dose reduction attempt 
was made was much longer than in the UC groups. A reason for these low numbers and 
longer time before tapering could be timing. Dose reduction protocols have only been fully 
implemented in our clinic since 2014. Although dose reduction was done multiple times in trial 
settings in our clinic, it could be postulated that the absence of an outpatient clinic protocol 
and lack of experience with dose reduction outside of trial settings in the early years may have 
led to doctors being hesitant to dose reduction. Furthermore, in contrast to subcutaneous 
TNFi, where tapering consists of injection interval prolongation, dose reduction by lowering 
the dose has less obvious advantages to a patient, as the number of infusions needed remains 
the same. Thus, patients may have been more motivated to attempt dose reduction after 
subcutaneous abatacept and tocilizumab have become available. This argument is supported 
by a recent study showing that tapering of subcutaneous tocilizumab by injection spacing 
was more successful than tapering of intravenous tocilizumab by reduction of the dose 25. 
Another possible explanation for the low percentage of dose reduction attempts is the fact 
that abatacept and tocilizumab were initially reserved for RA patients being refractory to 
other bDMARDs. Selection of a worse patient population may induce hesitation from patients 
and physicians to attempt tapering, when improvement in disease activity has proven to be 
a difficult goal to reach in the first place. This might especially be true for discontinuation 
attempts, which were not done in the majority of DR patients. Finally, patients might have 
negative expectations about dose reduction which may cause hesitation to dose reduce or 
induce negative symptoms during dose reduction, the so-called nocebo response 26,27. All these 
factors are ‘real world’ issues and future studies should investigate these facilitators and 
barriers for dose optimization. 
Remarkably, we observed a rise in disease activity above the level of low disease activity in 
both abatacept groups during follow-up, where DAS28 remained below low disease activity 
in both tocilizumab groups. An explanation could be that in our center, abatacept patients 
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are more refractory to treatment than tocilizumab and thus a (small) rise in disease activity 
may be accepted more often than in patients using tocilizumab. It could also be that DAS28 
is underestimated in the tocilizumab groups due to the inhibitory effects of tocilizumab on 
inflammation parameters. However, this would be most noticeable in DAS28-CRP whereas we 
used DAS28-ESR. All in all, the apparent rise in disease activity in abatacept patients might 
constitute a spurious finding , explained by small patient numbers in the abatacept groups as 
compared to the tocilizumab group. 
With regard to adverse events, we expected to find a lower incidence of adverse events in the 
DR groups, especially fewer infections, but cumulative incidences were comparable with the 
UC groups. This may be explained by the retrospective, explorative design of this study (with 
probable underreporting of less severe adverse events) and the small numbers of patients in 
the subgroups. However, leucopenia was observed more often in both tocilizumab groups, 
which is a well-known adverse event of this bDMARD and this may suggest that adverse 
events were reported properly. We did not, however, investigate radiographic progression, 
which would have provided further data on safety of tapering of abatacept and tocilizumab, 
especially in the long term. 
Lastly, successful dose reduction appears to be persistent in this study. A recent study 
reported persistent response up to 2 years in patients prolonging the tocilizumab interval 
from 4 to 5 or 6 weeks 28. Other studies reported outcomes with fixed follow-up time of 6 to 
18 months15,16,18,19,21-24, and our study adds that successful dose reduction or discontinuation 
persists up to 72 months in a subset of patients. Although we did not investigate medication 
cost, one may infer that this is associated with a significant cost reduction. 
Our study has some important limitations. Firstly, due to the relatively small patient numbers, 
confidence intervals are large and results should be interpreted with caution. Of course, 
although superiority tests could not demonstrate differences, this cannot be interpreted 
as proof of equivalence, as the latter needs comparison of the confidence interval with an a 
priori chosen non-inferiority margin. Furthermore, at baseline, the prevalence of concomitant 
csDMARD use was low. However, abatacept and tocilizumab are equally effective as 
monotherapy compared to combination therapy, and indeed are registered in the USA as 
such29,30. Furthermore, at least for tocilizumab it is shown that tapering is equally successful in 
patients with and without concomitant methotrexate 23. Also, concomitant csDMARD use has 
been shown not to be a predictor for successful dose reduction 30. 
In contrast to most other studies, we used low disease activity (DAS28 <3.2) instead of remission 
to define successful dose reduction or discontinuation. This was done since remission is only 
reached in 30-80% of patients 32-35, because remission is not always attainable, and because 
protocol adherence of a physician to adjust medication in case disease activity rises above 
remission level is suboptimal (around 65%) 36, reflecting discordance with this strict goal. 
Furthermore, lower disease activity before tapering has not shown to be a predictor for higher 
chance of successful tapering 31. 
Conclusion
All in all, dose optimization of abatacept and tocilizumab in daily clinical practice appears 
to be feasible and safe in a clinical practice setting. However, no benefits in terms of fewer 
adverse events in the dose reduction groups were yet observed. Future research should 
provide further information on possible predictors of successful dose reduction, long-term 
effects of dose optimization of these drugs, as well as the risk of radiographic joint damage. 
Furthermore, protocol adherence may be improved by research on possible facilitators and 
barriers of dose optimization. 
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Abstract
Objective
Previous studies have shown that serum calprotectin is correlated with clinical and laboratory 
markers of disease activity in rheumatoid arthritis (RA). The aim of our study was to investigate 
the predictive value of baseline serum calprotectin for clinical response after respectively 
starting and tapering of a TNF inhibitor (TNFi) in RA.
Methods
Serum samples and clinical outcomes were derived from the BIO-TOP study and DRESS 
study. At baseline (starting or tapering of respectively adalimumab or etanercept), serum 
calprotectin levels were determined by ELISA. In the BIO-TOP study, treatment effect was 
assessed 6 months after start using the EULAR response criteria (good versus moderate/no 
response). In the DRESS study, patients were classified at 18 months after start of tapering 
as being successfully dose reduced, discontinued or not able to reduce the dose. Area under 
the receiver operating characteristic curves (AUCs) were generated to evaluate the predictive 
value of calprotectin and logistic prediction models were created to assess the added value of 
calprotectin. 
Results
In the BIO-TOP study, baseline calprotectin levels were higher in responders (n=50: 985 ng/mL 
[p25-p75: 558-1417]) compared to non-responders (n=75: 645 ng/mL [p25-p75: 415-973], p=0.04). 
The AUC for predicting EULAR good response was 0.61 (95% CI: 0.50 to 0.71). The prediction 
model with calprotectin (AUC 0.77, 95% CI: 0.68 to 0.85) performed similarly to the baseline 
model (AUC 0.74, 95% CI: 0.65 to 0.82, p=0.29).
In the DRESS study, baseline calprotectin levels were similar between patients who 
successfully reduced (n=47), patients who successfully discontinued (n=19) and patients who 
could not reduce the dose (n=36): 599 ng/mL [p25-p75: 473-965], 629 ng/mL [p25-p75: 454-896] 
and 624 ng/mL [p25-p75: 514-931], p=0.80. Calprotectin was not predictive for successful dose 
reduction (AUC 0.52, 95%CI: 0.40 to 0.63), successful discontinuation (AUC 0.53, 95%CI: 0.39 to 
0.67) and not able to reduce the dose (AUC 0.54, 95% CI: 0.42 to 0.66).
Conclusion
Serum calprotectin has some predictive value for clinical response after starting anti-TNF 
treatment, although it has no added value to other clinical factors. In patients with low 
disease activity, serum calprotectin is not predictive for clinical response after tapering anti-
TNF treatment.
Introduction
The introduction of biological disease-modifying anti-rheumatic drugs (bDMARDs) has 
improved the treatment outcomes of rheumatoid arthritis (RA). However, approximately 
60% of RA patients do not achieve good clinical response after 6 months of treatment with 
a bDMARD, including TNF inhibitors (TNFi’s).1 Furthermore, tapering TNFi has been shown 
feasible in a large proportion of RA patients with low disease activity but again, not in all 
patients.2 Non-responding after the start of a TNFi or flaring after tapering of a TNFi are both 
undesirable, since a (short) period of high disease activity might cause worsening of physical 
functioning and radiographic joint damage.3,4
The ability to accurately predict individual response after starting or tapering of a TNFi 
might improve treatment outcomes compared to the current “trial-and-error” treatment. 
In patients who are unlikely to respond to (a certain) TNFi, starting another TNFi or bDMARD 
with another mode of action might potentially be more effective. In addition, when it can be 
predicted that tapering will be unsuccessful in a patient, tapering would not be attempted 
thereby preventing disease flares, minimising physician efforts and easing uncertainty in 
patients. Notably, in both scenarios, the gains would be better treatment outcomes, not lower 
direct costs per se. 
Calprotectin (also known as S100A8/A9 and MRP8/14) might be a promising biomarker to 
predict clinical response to anti-TNF treatment. In contrast to acute phase proteins which 
are mainly of hepatic origin, calprotectin is released predominantly by granulocytes at 
sites of inflammation.5 It also diffuses easily from inflamed joints into the blood circulation 
because of its relatively low molecular weight.6 Previous studies have indeed shown that 
serum calprotectin is cross-sectionally correlated with clinical and laboratory markers of 
disease activity in RA.7-11 Studies that have investigated the longitudinal predictive value of 
calprotectin for clinical response to bDMARDs show however conflicting results. Choi et 
al demonstrated that serum calprotectin at baseline predicts response to treatment with 
respectively adalimumab, infliximab and rituximab.12 However, in other studies baseline 
calprotectin could not predict responsiveness to treatment with a bDMARD.8,13-15 On the other 
hand, decreased calprotectin levels after 4 weeks of bDMARD treatment were consistently 
predictive of clinical response.12,13 And in juvenile idiopathic arthritis (JIA) patients in clinical 
remission, high calprotectin levels at the moment of discontinuation of etanercept were 
associated with subsequent flare.16 This association has not yet been investigated in RA. 
Although serum calprotectin seems like a promising biomarker, it has to meet certain 
requirements before it can be used in therapeutic decision-making in daily practice; 
calprotectin has to have added value on top of routine measurements (e.g. Disease Activity Score 
in 28 joints using C-reactive protein (DAS28-CRP)) and the prediction should have therapeutic 
consequences. Since achieving good response after treatment start and maintaining response 
after tapering are both clinical important scenarios with uncertainty on clinical outcome, we 
prospectively investigated the predictive value of baseline serum calprotectin for clinical 
response after starting and tapering anti-TNF treatment in 2 longitudinal studies of patients 
with RA.
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Methods
Study population
Baseline serum samples and clinical outcomes of RA patients starting adalimumab (ADA) or 
etanercept (ETN) were derived from the Biologic Individual Optimised Treatment Outcome 
Prediction (BIO-TOP) study (Dutch trial register, NTR4647).17 In this prospective longitudinal 
prediction study, RA patients >18 years starting with or switching to a bDMARD were enrolled 
between 2014 and 2016. The same data were collected of RA patients included in the dose 
tapering arm of the Dose REduction Strategies of Subcutaneous TNF inhibitors (DRESS) study 
(Dutch trial register, NTR3216)18: an 18-month open randomised clinical trial investigating non-
inferiority of a dose reduction strategy of ADA or ETN compared with usual care. In the DRESS 
study, RA patients using ADA or ETN at any stable dose and interval for at least 6 months with 
stable low disease activity at 2 subsequent visits were enrolled in 2011 and 2012. Full details 
of this study have been reported previously.19 The studies were performed in 2 hospitals in the 
Netherlands (Sint Maartenskliniek Nijmegen and Maartenskliniek Woerden) and were both 
approved by the local ethics committee (CMO region Arnhem-Nijmegen, NL47946.091.14 and 
NL37704.091.11).
Clinical assessments
In the BIO-TOP study, treatment effect was assessed at month 6 with the commonly used 
DAS28-CRP based European League Against Rheumatism (EULAR) response criteria (good 
versus moderate/no response).20 In the DRESS study, 3 clinical outcomes were defined at 
month 18: successful dose reduction, successful discontinuation and not able to reduce dose. 
Successful dose reduction was defined as using the TNFi at a longer interval or lower dose 
than at enrolment with concurrent low disease activity. In both studies, calprotectin levels 
were not available when disease activity was assessed, preventing expectation bias. 
Serum calprotectin measurement
Serum samples were collected at baseline (starting or tapering of a TNFi) and stored at -80°C 
until analysis took place (October 2016). Calprotectin levels were measured in the laboratory of 
the University of Münster using an enzyme-linked immunosorbent assay (ELISA), as described 
previously.21 The readers of the assay were blinded for the disease activity and medication use 
of patients.
Statistical analysis
Descriptive statistics are reported as either mean (± standard deviation (SD)), median 
(interquartile range [p25-p75]) or frequency depending on data distribution. Baseline 
characteristics were compared using Student’s t-test (or, if not normally distributed, Wilcoxon 
rank sum) and χ2 test for continuous and categorical data, respectively. Correlations between 
calprotectin and clinical variables (i.e. age, gender, disease duration, rheumatoid factor 
(RF), anti-citrullinated protein antibodies (ACPA), DAS28-CRP and its components, CRP and 
erythrocyte sedimentation rate (ESR)) were cross-sectionally explored by Spearman correlation 
analysis. In the BIO-TOP study, discontinuation of the TNFi before 6 months due to lack of 
effect was regarded as non-response and for discontinuation due to other reasons the clinical 
response at month 3 was carried forward. Area under the receiver operating characteristic 
curves (AUCs) were generated to evaluate the predictive value of baseline serum calprotectin 
levels for respectively EULAR good response [yes versus no], successful dose reduction [yes 
versus no], successful discontinuation [yes versus no] and not able to reduce dose [yes versus 
no]. For AUCs with a 95% confidence interval lower bound >0.5, we additionally performed 
logistic prediction modelling. First, univariate logistic regression analyses were performed 
to assess which demographic-, disease- and treatment specific variables at baseline were 
associated with the treatment outcome. Variables that showed an association in the 
univariate analyses were entered in a multivariate logistic regression analysis using stepwise 
backwards selection to construct a baseline prediction model taking into account the rule 
of thumb of 1 predictor per 10 patients. Subsequently, we added calprotectin to the baseline 
model and tested the equality of the 2 AUCs by using the algorithm suggested by DeLong et 
al.22 Missing data in this analysis were addressed using multiple imputation. A p value <0.05 
was considered statistically significant. All analyses were performed using STATA V.13.1.
Results
Baseline characteristics
Baseline serum samples and 6-month clinical outcome data were available of 50 patients 
starting ADA and 75 patients starting ETN in the BIO-TOP study. Additionally, 102 of 121 (84%) 
patients randomised to the tapering arm of the DRESS study had available baseline serum 
samples of whom 38 patients were treated with ADA and 64 patients with ETN. Baseline 
characteristics of the included patients in both cohorts are summarised in Table 1.
Table 1. Baseline characteristics
BIO-TOP study
N=125
DRESS study
N=102
Demographics
Age, years‡ 57 (12) 59 (10)
Female gender 81 (65) 62 (61)
Disease duration, years† 4 [1-10] 11 [6-17]
RF positive 74/123 (60) 80 (78)
ACPA positive 65/116 (56) 73 (72)
Disease characteristics
DAS28-CRP‡ 4.0 (1.1) 2.2 (0.6)
TJC† 4 [2-9] 0 [0-1]
SJC† 4 [1-7] 0 [0-0]
PGA, VAS 0 – 100mm‡ * 62 (20) 23 (17)
CRP, mg/L† 5 [1-19] 3 [3-3]
ESR, mm/h †* 17 [7-31] 12 [7-20]
Calprotectin, ng/mL† 680 [433-1252] 612 [475-927]
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Treatment characteristics
N of previous bDMARDs† 0 [0-1] 0 [0-1]
Current TNFi 
   ADA
   ETN
50 (40)
75 (60)
38 (37)
64 (63)
Duration current TNFi, years† N/A 3 [2-6]
Concomitant treatment use
   csDMARDs
   MTX 
   NSAIDs 
   Oral glucocorticoids
97 (78)
66 (53)
80 (64)
22 (18)
59 (58)
46 (45)
57 (56)
5 (5)
Data presented as number (%) unless otherwise noted. ‡Mean (SD). †Median [p25-p75].
*Missing data BIO-TOP study: in 8 patients (6%) PGA is missing and in 9 patients (7%) ESR is missing.
If PGA was missing, DAS28-CRP was calculated with 3 variables: TJC, SJC and CRP.
ACPA, Anti-Citrullinated Protein Antibodies; ADA, adalimumab; bDMARD, biological Disease-Modifying Anti-Rheumatic 
Drug; CRP, C-reactive protein; csDMARD, conventional synthetic Disease-Modifying Anti-Rheumatic Drug; DAS28-CRP, 
28-joint count Disease Activity Score using CRP; ESR, Erythrocyte Sedimentation Rate; ETN, etanercept; MTX, methotrexate; 
NSAID, Non-Steroidal Anti-Inflammatory Drug; PGA, patient global assessment of disease activity; RF, Rheumatoid Factor; 
SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale. 
Serum calprotectin at baseline was similar between patients who started TNFi and patients 
who tapered TNFi: 680 ng/mL [p25-p75: 433-1252] versus 612 ng/mL [p25-p75: 475-927] (p=0.15). 
In the BIO-TOP study, calprotectin levels were weakly to moderately significantly correlated 
with DAS28-CRP (rs 0.32, p<0.001), ESR (rs 0.41, p<0.001) and CRP (rs 0.57, p<0.001) at baseline. 
Also, calprotectin was significantly higher in RF-positive patients (rs 0.19, p=0.03). In the DRESS 
study, calprotectin levels were only significantly correlated with CRP (rs 0.21, p=0.03).
Baseline calprotectin levels and correlation with response to treatment
Fifty of 125 (40%) patients starting a TNFi achieved EULAR good response at month 6. Baseline 
calprotectin levels were higher in responders (985 ng/mL [p25-p75: 558-1417]) compared to 
non-responders (645 ng/mL [p25-p75: 415-973], p=0.04) (Figure 1A). Responders also had a 
higher DAS28-CRP (4.4 (SD 0.8) versus 3.8 (SD 1.2), p=0.003) and a higher CRP (8 mg/L [p25-p75: 
2-25] versus 3 mg/L [p25-p75: 0-14], p=0.008) at baseline. More patients achieved good response 
after ETN treatment (38 of 75 (51%) patients) compared to ADA treatment (12 of 50 (24%) 
patients) (p=0.003). This can be explained by the fact that in our hospital ADA was reserved for 
patients who had failed on ETN treatment. As a consequence, patients treated with ADA were 
presumably more refractory to treatment with a TNFi.
Of the patients who tapered ADA or ETN, 47 (46%) patients successfully reduced their TNFi 
dose, 19 (19%) patients successfully discontinued their TNFi and 36 (35%) patients could not 
reduce their TNFi dose. Calprotectin levels at baseline were similar between these groups: 
599 ng/mL [p25-p75: 473-965], 629 ng/mL [p25-p75: 454-896] and 624 ng/mL [p25-p75: 514-931] 
(p=0.80) (Figure 1B). The patient group that could not reduce the dose had a lower percentage 
of RF-positive patients (24 of 36 (67%) versus 56 of 66 (85%), p=0.03) and had a near significantly 
higher DAS28-CRP at baseline (2.4 (SD 0.7) versus 2.1 (SD 0.6), difference +0.3 (95% CI: -0.001 to 
0.51)).
 
Figure 1. Distribution of baseline serum calprotectin levels by outcome   
     
A (left panel). BIO-TOP study: 125 RA patients who started a TNFi.  
B (right panel). DRESS study: 102 RA patients who tapered a TNFi.
Predictive value of calprotectin for clinical response after starting a TNFi 
AUC for predicting EULAR good response versus EULAR moderate/no response using baseline 
serum calprotectin was 0.61 (95% CI: 0.50 to 0.71), while for respectively baseline DAS28-CRP 
and CRP AUCs were: 0.68 (95%CI: 0.58 to 0.77) and 0.64 (95%CI: 0.54 to 0.74). Subgroup analyses 
were performed for serum calprotectin in which the AUC tended to be greater in patients who 
started treatment with ADA (0.68, 95% CI: 0.49 to 0.88) compared to patients who started ETN 
(0.49, 95% CI: 0.36 to 0.63) (p=0.11). There were no statistically significant differences in AUCs 
for concomitant csDMARD use [yes versus no] or oral glucocorticoid use [yes versus no]. The 
prediction model with calprotectin (AUC 0.77, 95% CI: 0.68 to 0.85) performed similarly to the 
baseline model (backward selected variables: patient global assessment of disease activity, 
DAS28-CRP, used TNFi [ADA versus ETN] and interaction between calprotectin and used TNFi) 
(AUC 0.74, 95% CI: 0.65 to 0.82, p=0.29) (Figure 2). 
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Figure 2. Added predictive value of calprotectin for clinical response after starting a TNFi 
 
Predictive value of calprotectin for clinical response after tapering a TNFi
Serum calprotectin was not predictive for clinical response after tapering anti-TNF treatment. 
AUCs were 0.52 (95% CI: 0.40 to 0.63) for predicting successful dose reduction, 0.53 (95% 
CI: 0.39 to 0.67) for successful discontinuation and 0.54 (95% CI: 0.42 to 0.66) for not able to 
reduce dose. Also, DAS28-CRP and CRP were not predictive for the 3 treatment outcomes 
with corresponding AUCs varying from 0.54 to 0.61 for DAS28-CRP and 0.46 to 0.56 for CRP. 
Subgroup analyses showed no statistically significant differences in AUCs for used TNFi [ADA 
versus ETN], concomitant csDMARD use [yes versus no] or oral glucocorticoid use [yes versus 
no]. Logistic prediction modelling was deemed unnecessary, since the univariate AUCs already 
demonstrated no predictive value. 
Discussion
To our knowledge, this is the first study to investigate the predictive value of baseline serum 
calprotectin for clinical response after both starting and tapering of anti-TNF treatment in 
RA patients in daily practice. We have shown that serum calprotectin has some predictive 
value for clinical response after starting anti-TNF treatment, although it has no added value 
to other clinical factors, such as DAS28-CRP. Moreover, serum calprotectin was not predictive 
for clinical response after tapering anti-TNF treatment in patients with low disease activity. 
Our study supports the previous findings of a meta-analysis which showed that serum 
calprotectin levels were positively correlated to clinical disease activity measures including 
DAS28-CRP and CRP.23 However, in our study calprotectin levels at baseline were not 
significantly higher in the patient group with high disease activity that started a TNFi compared 
to the patient group with low disease activity that tapered a TNFi. Secondly, we could confirm 
in accordance with a previous study that baseline serum calprotectin levels were higher in 
responders to anti-TNF treatment compared to non-responders.12 Next, we demonstrated 
that calprotectin has some predictive value for clinical response after starting a TNFi, but has 
no added value to clinical factors routinely measured in RA in daily practice, such as DAS28-
CRP. This lack of added value of calprotectin was observed before in prediction of response 
after starting a TNFi in JIA.16 Thus, measuring baseline serum calprotectin levels seems 
unable to help optimising therapeutic decision-making in daily practice due to its substantial 
overlap with already used disease activity measures (DAS28-CRP and CRP). Calprotectin 
tended to be a better predictor for response to ADA treatment than ETN treatment, but this 
was not significant due to the lower group sizes. This finding might indicate that a serum 
calprotectin level without previous treatment with a TNFi has less predictive value than a 
serum calprotectin level after previous treatment with a TNFi for clinical response to the next 
TNFi. This seems to match with previous findings in other studies showing that decreased 
calprotectin levels after 4 weeks of bDMARD treatment were consistently predictive of clinical 
response to the same bDMARD.12,13
In patients who tapered treatment with a TNFi, we found no differences in baseline 
calprotectin levels between the 3 treatment outcome groups. Also, calprotectin had similar 
AUC characteristics as DAS28-CRP and CRP. We assume that calprotectin behaves like an acute 
phase protein. Since tapering was only performed in patients with a low disease activity, there 
was correspondingly a low inter-variability in CRP and calprotectin levels at baseline. As a 
result, measuring serum calprotectin levels seems unable to distinguish patients who are 
doing well while using a TNFi from those who are doing well because of a TNFi.  
A strength of our study is that we investigated the predictive value of serum calprotectin 
for clinical response after both starting and tapering of ADA and ETN in a large number 
of RA patients treated in the same hospital. We specifically focused on the added value of 
calprotectin for starting a TNFi and to the best of our knowledge were the first to investigate 
serum calprotectin for clinical response after tapering a TNFi in RA. 
A limitation of our study might be that we have not longitudinally measured calprotectin 
levels after starting or tapering TNFi. Although other studies have shown that decreased 
calprotectin levels after 4 weeks of bDMARD treatment were predictive of clinical response12,13, 
we believe that a biomarker measured after starting or tapering of a bDMARD is less relevant, 
because the treatment decision is then already made and future treatment decisions can be 
based on actual clinical response rather than changes in biomarkers. Preferably, a biomarker 
would be identified that can prevent starting or tapering of a bDMARD in patients who are 
likely to fail on it. Another limitation might be the considerable coefficient of variation (CV) 
for calprotectin due to its limited linearity range.7 We tried to minimalise it by measuring each 
sample in 3 different dilutions and accepting results as reliable if all values coincided after 
recalculation. Additionally, we collected serum instead of plasma samples since a systematic 
review demonstrated that CV was lowest in studies using sera.7
Also, calprotectin levels are not a specific marker for RA activity. Calprotectin levels might 
be affected by the presence of cardiovascular disease and obesity complicating prediction 
of clinical response to treatment of RA.24,25 Furthermore, we included only patients with 
established RA and therefore our results might not be valid for patients with early RA, especially 
since it has been shown that calprotectin is a better predictor of response to methotrexate 
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therapy in patients with early RA (<1 year) as compared with later onset of disease (>1 year).10 
This difference might be explained by the fact that neutrophil granulocytes are more prevalent 
in early RA.26 However, the heterogeneity in treatment duration in our study population allows 
translation of the results in daily practice. 
So far, studies have failed to consistently identify a single biomarker that can predict 
individual treatment response after starting or tapering TNFi with sufficient predictive value 
to be used in the individual RA patient.27,28 We presume that prediction of clinical response to 
treatment is difficult due to the complex pathobiology of RA and the not fully known effects 
of TNFi’s. As a consequence, measuring random laboratory markers is associated with a low 
a-priori chance of finding a biomarker. Furthermore, clinical response (based on changes in 
the DAS28 compared to baseline) is not solely the result of inflammatory RA activity but can 
be confounded by many other factors (e.g. psychosocial) troubling prediction by a biomarker.  
Conclusion
Serum calprotectin has some predictive value for clinical response after starting anti-TNF 
treatment in RA, although it has no added value to other clinical factors, such as DAS28-CRP. In 
patients with low disease activity, serum calprotectin was not predictive for clinical response 
after tapering anti-TNF treatment.
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Abstract
Objective
Clinical data suggest that the response of rheumatoid arthritis patients to treatment with 
golimumab is much lower among those who switched from adalimumab than among 
those who switched from etanercept. To elucidate the mechanism behind this difference in 
response to sequential bDMARD treatment, we examined the effect of TNF inhibitors on ex-
vivo cytokine production profiling.
Methods
In a prospective cohort study, blood samples were obtained from patients before the start 
of a bDMARD. Peripheral blood mononuclear cells were pre-incubated for 1 hour with the 
therapeutic in-vivo concentration of adalimumab, etanercept or golimumab and stimulated 
for 24 hours with heat killed Candida albicans or Pam3Cys. Cytokine concentrations of IL-1β, 
IL-6 and TNFα were determined by ELISA. 
Results
Ex-vivo cytokine profiling was performed in 71 patients. Golimumab, adalimumab and 
etanercept significantly (p<0.01) decreased Candida albicans-induced IL-1β and IL-6 
production and Pam3Cys-induced IL-6 production. In contrast to etanercept, golimumab 
and adalimumab decreased the concentration of TNFα below the detection limit. Absolute 
changes in cytokine levels after inhibition by golimumab or adalimumab were all significantly 
correlated (Spearman rank rs 0.52-0.99, p<0.001). These correlations were much lower or non-
significant between etanercept and either golimumab or adalimumab.
Conclusion
High similarity between ex-vivo inhibited cytokine profiling by golimumab and adalimumab, 
compared to etanercept, may explain the previously found inferior treatment response to 
golimumab after adalimumab failure. This suggests that patients who are non-responsive to 
adalimumab should preferably not switch to golimumab and vice versa.
Ex-vivo drug-inhibited cytokine profiling in RA
Introduction
Treatment of rheumatoid arthritis (RA) consists of the introduction of a biological disease-
modifying anti-rheumatic drug (bDMARD) after failure of a conventional DMARD (csDMARD). 
According to the 2013 update of the EULAR recommendations, no preference of one over 
another bDMARD should be expressed, because evidence does not suggest any one bDMARD 
to be better than another one when active disease prevails despite treatment with the initial 
bDMARD.1 This implies that if a first TNF inhibitor (TNFi) has failed, patients may start with 
any other TNFi (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) or a 
bDMARD with another mode of action (abatacept (CTLA4-Ig fusion protein), rituximab (anti-
CD20 monoclonal antibody) or tocilizumab (anti-IL-6 receptor antibody)). 
Since the update of the EULAR recommendations, new data on sequential bDMARD treatment 
have been published. In the randomised controlled trial (RCT) GO-AFTER, the efficacy of 
golimumab and methotrexate after prior TNFi use was evaluated. Post-hoc analyses showed 
that among 137 RA patients who had received one prior TNFi (adalimumab, n=33; etanercept, 
n=47; infliximab, n=57), week 24 ACR20 rates were 30%, 47% and 51% respectively and thus 
much lower among those who previously failed on adalimumab.2 This finding is relevant for 
clinical practice, because it seems that RA patients who are non-responsive to adalimumab 
should preferably not switch to golimumab and perhaps vice versa. 
Determining the ex-vivo effect of a TNFi on cytokine production (‘inhibited cytokine profiling’) 
in blood samples taken before the start of a next TNFi could be a promising way to examine the 
mechanism of action and possibly chance of response, since it might resemble the actual drug 
effect in RA patients. Furthermore, to our knowledge, TNFi-mediated inhibition of cytokine 
production has not been investigated before in RA. Therefore, the aim of our study was to 
compare the ex-vivo effects of adalimumab, etanercept and golimumab on multi-cytokine 
profiles of RA patients to elucidate the potential reduced clinical response to golimumab after 
being treated with adalimumab. 
Methods
Study population
Blood samples of patients included in the prospective longitudinal cohort study BIO-TOP 
[Biologic Individual Optimized Treatment Outcome Prediction] were used. In this study, RA 
patients >18 years, treated in the Sint Maartenskliniek (Nijmegen, the Netherlands) who were 
going to start with or switch to a bDMARD were included. The BIO-TOP study was approved by 
the local ethics committee (CMO region Arnhem-Nijmegen, NL47946.091.14) and a detailed 
description is available in the Dutch trial register (NTR4647).3
Ex-vivo cytokine production assay
At baseline (before start bDMARD), venous blood was collected into three 10mL EDTA tubes. 
Within 24 hours peripheral blood mononuclear cells (PBMCs) were isolated by density 
gradient centrifugation of PBS diluted blood (1:1) over Ficoll-Paque, washed twice with saline 
and suspended in culture medium (RPMI 1640 supplemented with 2 mM glutamax, 50 µg/mL 
gentamicin and 1 mM pyruvate). Cells were counted in a Coulter counter. Subsequently, 5×105 
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PBMCs in a volume of 100μL were pre-incubated in round bottom 96-well plates for 1 hour at 
37°C with therapeutic in-vivo concentrations of adalimumab, etanercept, golimumab. Taking 
into account the different half-life times, dosing and treatment intervals, and therapeutic 
concentration ranges of the TNFi’s, the same concentration of 5µg/mL was added for all 3 
TNFi.4-6 Human IgG was used as negative control. Thereafter, cells were stimulated with RPMI 
1640+, Pam3Cys (a TLR2 agonist) or heat killed Candida albicans (ATCC MYA-3573 (UC 820)). 
After 24 hours of stimulation, supernatants were harvested and stored at -20°C until assayed. 
Cytokine concentrations of IL-1β and TNFα (R&D Systems, Abingdon, UK) and IL-6 (Sanquin, 
Amsterdam, the Netherlands) were determined by ELISA. 
Statistical analysis
Comparisons between the ex-vivo cytokine production of stimulated, and stimulated 
and TNFi inhibited PBMCs were analysed with the Wilcoxon signed-rank test. Statistical 
significance was considered when p<0.01. The absolute changes in cytokine levels 
after inhibition by each TNFi were calculated and analysed by means of Spearman rank 
correlations (rs). They were interpreted according to a commonly used classification: 
rs <0.20: very weak, rs 0.20-0.39: weak, rs 0.40-0.59: moderate, rs 0.60-0.79: strong and rs >0.80: 
very strong correlation.7 All analyses were performed using STATA V.13.1.
Results
Baseline characteristics
Ex-vivo cytokine profiling was performed in 71 patients (66% female, age (mean ± SD): 58 ± 11 
years, disease duration (median [p25-p75]: 6 [2-14] years). Median number of prior bDMARDs 
was 1 [p25-p75: 0-2]. BDMARDs were started because of active disease, represented by the high 
DAS28-CRP at baseline (mean ± SD): 4.1 ± 1.2.
 
Ex-vivo inhibited cytokine production
The cytokine production of IL-1β, IL-6 and TNFα after inhibition by IgG, golimumab, 
adalimumab or etanercept and stimulation with heat killed Candida albicans or Pam3Cys are 
depicted in Figure 1. 
All RPMI values were below detection limit, indicating a comparable baseline quality. Pre-
incubation with either golimumab, adalimumab or etanercept significantly (p<0.01) decreased 
Candida albicans-induced IL-1β and IL-6 production and Pam3Cys-induced IL-6 production. 
In contrast to etanercept, golimumab and adalimumab decreased the concentration of TNFα 
below the detection limit. This can be explained by the specific binding site of golimumab 
and adalimumab to TNFα, which prevents detection of TNFα with ELISA. The absolute change 
in cytokine concentration of IL-1β and IL-6 between PBMCs that were only stimulated and 
PBMCs that were stimulated and inhibited by golimumab, adalimumab or etanercept of each 
patient is depicted in Figure 2. 
Figure 1. Effect of golimumab, adalimumab and etanercept on ex-vivo cytokine production.  
Data presented as mean + standard error of the mean (SEM). P values calculated using Wilcoxon signed-
rank test. *p<0.01.
Figure 2. Absolute changes in cytokine production after inhibition by golimumab, adalimumab or 
etanercept. Y-axis represents the log transformed values.   
 
Ex-vivo drug-inhibited cytokine profiling in RAChapter 5
55
9392
Correlations of cytokine profiles
The absolute changes in IL-1β, IL-6 and TNFα levels after inhibition by golimumab were 
significantly (rs 0.52-0.99, p<0.001) correlated with the absolute changes after inhibition by 
adalimumab. These correlations were much lower and/or non-significant between etanercept 
and either golimumab or adalimumab (Figure 3).
Figure 3. Spearman rank correlations of cytokine profiles. *all correlations p<0.001.
 
Discussion
To our knowledge, this is the first study in which the ex-vivo effect of TNFi’s on stimulated 
cytokine production of RA patients has been investigated. We have demonstrated that the 
cytokine profiles after inhibition by golimumab or adalimumab were moderately to highly 
correlated with each other, while the correlation with the cytokine profiles after inhibition 
by etanercept was lower for both. These data suggest similar mechanisms for inhibiting the 
biological target by golimumab and adalimumab and may serve as an explanation for the 
previously found inferior treatment response to golimumab after adalimumab failure in RA.
Our findings may represent the pathophysiological link between the known structural 
resemblance of golimumab and adalimumab and the observed similarity in clinical response. 
Both golimumab and adalimumab are fully human IgG1 anti-TNFα monoclonal antibodies 
and they neutralise soluble and transmembrane TNFα in the same extent.8 It might also be 
that golimumab and adalimumab bind TNFα at a nearby epitope. In contrast to golimumab 
and adalimumab, etanercept is a soluble dimeric TNFR2 IgG1–Fc fusion protein which binds 
both TNFα and TNFβ.8 We have not included infliximab in our study, as its use is decreasing. 
However, it would have been interesting to see whether this apparent association between 
interdrug ex-vivo cytokine profile correlation and clinical efficacy extends also to other TNFi’s.
In addition to our primary finding, our results lend support to the concept of using ex-vivo 
inhibited cytokine profiling as a test for in-vivo efficacy, for example in predicting treatment 
response. This is currently being investigated in the BIO-TOP study. An important benefit 
of ex-vivo testing could be the optimal response of freshly isolated PBMCs, as it has been 
demonstrated that freezing affects PBMC proliferation and cytokine secretion.9 On the other 
hand, a possible limitation of ex-vivo testing is the required logistics to execute each test 
within 24 hours after blood collection. Furthermore, a possible limitation of the test itself as 
currently used is the requirement of stimuli to reduce the risk of floor effects in the detection 
of cytokine levels, as this deviates from the in-vivo pathophysiology. 
The finding that all TNFi’s are equal, but some are more equal than others, has interesting 
implications.10 Recently, the ROC trial and the SWITCH-RA study have demonstrated higher 
efficacy of a non-TNFi in comparison to a second TNFi in patients with insufficient response to 
the first TNFi.11,12 Based on our results, the inferiority of a second TNFi might be due to inferior 
responses when switching from adalimumab to golimumab and vice versa. In contrast to 
the GO-AFTER trial2, these two studies have not made a distinction between the sort of first 
and second TNFi and golimumab was not included in the ROC trial. Therefore, the hypothesis 
of different chances of good response to combinations of first and second TNFi’s needs 
confirmation.  
Conclusion
The high similarity between ex-vivo inhibition of cytokine production by golimumab and 
adalimumab may explain the previously found inferior treatment response to golimumab 
after adalimumab failure in RA. This suggests that RA patients who are non-responsive to 
adalimumab should preferably not switch to golimumab and vice versa. Further research is 
needed to replicate if ex-vivo inhibited cytokine profiling correlates with clinical response to 
TNFi’s in RA patients.
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Abstract
Objective
To investigate ex-vivo drug-inhibited cytokine production before the start of a biological 
DMARD (bDMARD) as predictor of treatment response in rheumatoid arthritis (RA).
Methods
In a prospective RA cohort study [BIO-TOP], blood samples were obtained from patients 
before the start of a bDMARD (abatacept, adalimumab, etanercept, rituximab or tocilizumab). 
Peripheral blood mononuclear cells were pre-incubated for 1 hour with the therapeutic in-vivo 
concentration of the bDMARD and stimulated for 24 hours with heat-killed Candida albicans 
or Pam3Cys. Concentrations of IL-1β, IL-6, TNFα, IL-17 and IFNγ were determined by ELISA. 
EULAR response (good versus moderate/no) was assessed at month 6. Area under the receiver 
operating characteristic curves (AUCs) were generated to evaluate the predictive value of 
baseline characteristics and ex-vivo cytokine production (including stimulated cytokine 
concentrations and absolute changes after inhibition by a bDMARD). Logistic prediction 
models were created to assess the added value of potential cytokine predictors.
Results
277 RA patients were included with 330 blood samples. Good response was reached in 39% of 
the cases. DAS28-CRP was predictive for response to adalimumab (AUC 0.70, 95%CI: 0.57 to 
0.83), etanercept (AUC 0.68, 95%CI: 0.58 to 0.78) and rituximab (AUC 0.76, 95%CI: 0.65 to 0.86). 
ACPA was modestly predictive for response to abatacept (AUC 0.63, 95%CI: 0.52 to 0.75). In the 
ex-vivo analysis, 4 of 64 (6%) tests showed some predictive value but these had no added value 
to clinical factors routinely measured in RA, such as DAS28-CRP.
Conclusion
Ex-vivo inhibition of cytokine production by bDMARDs is unable to help prediction of 
treatment response to bDMARDs in RA.  
Introduction
Treatment of rheumatoid arthritis (RA) consists of a “trial-and-error” approach, attempting 
to obtain good response with disease-modifying anti-rheumatic drugs (DMARDs) tried 
consecutively. Approximately 60% of RA patients do not achieve good clinical response after 6 
months of treatment with a biological DMARD (bDMARD).1 As a consequence, non-responding 
RA patients have a prolonged high disease activity which can cause worsening of physical 
functioning and radiographic joint damage.2,3 It would therefore be desirable to predict, 
before the start of treatment, which bDMARD has the highest chance of good response in 
an individual RA patient. This would improve timely disease control.4 A valuable predictor 
of treatment response should change the a-priori probability of 40% of good response to a 
bDMARD to a clearly higher or lower post-test probability. Also, the response chance should be 
different between bDMARDs to have clinical utility.
Unfortunately, so far studies have failed to consistently identify a biomarker that can predict 
individual treatment response to bDMARDs with sufficient predictive value to be used in daily 
practice.5
In a previous study, we have demonstrated that the ex-vivo effects of adalimumab and 
golimumab on IL-1β, IL-6 and TNFα production were highly similar, while the effects of 
etanercept were much different.6 We suggested that this high similarity between the ex-vivo 
effects of adalimumab and golimumab might explain the much lower response to golimumab 
after adalimumab failure compared to etanercept failure found in RA patients in the GO-
AFTER trial.7
Determining the ex-vivo effects of bDMARDs on cytokine production (“drug-inhibited cytokine 
production”) might be a promising way to predict treatment response, since it might resemble 
the actual drug effect in RA patients. The aim of this study was to investigate ex-vivo drug-
inhibited cytokine production in blood samples taken before the start of bDMARD treatment 
as predictor of clinical response after 6 months in RA patients.
Methods
Study population
Consenting patients with RA (based on 2010 and/or 1987 American College of Rheumatology 
criteria and/or clinical diagnosis by the treating rheumatologist) who started or switched 
to a bDMARD (abatacept, adalimumab, etanercept, rituximab and tocilizumab) in the Sint 
Maartenskliniek (Nijmegen, the Netherlands) were included in a prospective exploratory 
longitudinal cohort study [Biologic Individual Optimized Treatment Outcome Prediction, 
BIO-TOP]. These bDMARDs were chosen, since they are used most frequently and encompass 
the available modes of action (CTLA4-Ig fusion protein, human IgG1 anti-TNFα monoclonal 
antibody, soluble dimeric TNFR2 IgG1–Fc fusion protein, anti-CD20 monoclonal antibody and 
anti-IL-6 receptor antibody). The study was approved by the local ethics committee (CMO 
region Arnhem-Nijmegen, NL47946.091.14) and a description is available in the Dutch trial 
register (NTR4647).8
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Clinical assessments
Demographic-, disease- and treatment specific data were collected at baseline (just before 
first bDMARD administration) and during outpatient clinical visits performed in usual care 
after 3 and 6 months (±1 month). Treatment choices about starting or discontinuing DMARDs, 
non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids were left to the treating 
rheumatologist. Primary outcome was the European League Against Rheumatism (EULAR) 
response criteria (good versus moderate/no response).9 
Ex-vivo cytokine production assay
At baseline, 30mL venous blood was collected into 3 EDTA tubes. Since it has been shown that 
freezing peripheral blood mononuclear cells (PBMCs) affects the secretion of cytokines10, 
we freshly isolated PBMCs within 24 hours by density gradient centrifugation of PBS 
diluted blood (1:1) over Ficoll-Paque, washed them twice with saline and suspended them in 
culture medium (RPMI 1640 supplemented with 2mM glutamax, 50µg/mL gentamicin, 1mM 
pyruvate). Cells were counted in a Coulter counter. Subsequently, 5×105 PBMCs in a volume of 
100μL were pre-incubated in round bottom 96-well plates for 1 hour at 37°C with therapeutic 
in-vivo concentrations of abatacept (Css 24 µg/mL), adalimumab (Css 5 µg/mL), etanercept 
(Css 5 µg/mL), rituximab (Cmax 450 µg/mL with 10% human pool serum) or tocilizumab (Css 
20 µg/mL). Human IgG was used as negative control. Thereafter, cells were stimulated with 
RPMI 1640+ (control), heat-killed Candida albicans (C. albicans) (ATCC MYA-3573 (UC820)) or 
Pam3Cys (TLR2 agonist) enabling robust production of cytokines. Supernatants were collected 
after 24 hours and 7 days to determine IL-1β, IL-6, TNFα and IL-17 and IFNγ concentrations with 
enzyme-linked immunosorbent assays (ELISA) (TNFα, IL-1β, IL-17: R&D Systems Abingdon UK; 
IL-6, IFNγ: Sanquin Amsterdam the Netherlands). We chose a-priori not to measure ex-vivo 
effects of adalimumab and etanercept on TNFα (binding of TNF inhibitors to TNFα interferes 
with TNFα detection) and IL-17 and IFNγ (both below detection limit after 24 hours). Also, we 
chose not to measure IL-17 and IFNγ after stimulation with Pam3Cys, since it does not induce 
a T cell response. Assay results were not available when disease activity was assessed, thereby 
preventing expectation bias.
Statistical analysis
Effect size calculations have shown that with 80 patients per bDMARD group and an EULAR 
good response of 40%, the 95% confidence interval around the point estimate of the sensitivity 
and specificity is ±0.13. Absolute changes in cytokine concentrations after inhibition by each 
bDMARD were calculated. In total, our ex-vivo analysis consisted of 64 tests: 3 bDMARDs 
(abatacept, rituximab, tocilizumab) x (8 stimulated cytokine concentrations + 8 absolute 
changes in cytokine concentrations) + 2 bDMARDs (adalimumab, etanercept) x (4 stimulated 
cytokine concentrations + 4 absolute changes in cytokine concentrations). Discontinuation 
of the bDMARD before 6 months due to lack of effect was regarded as non-response and for 
discontinuation due to other reasons the clinical response at month 3 was carried forward. 
Area under the receiver operating characteristic curves (AUCs) were generated to evaluate the 
predictive value of baseline characteristics (depicted in Table 1) and both stimulated cytokine 
concentrations and absolute changes in cytokine concentrations after inhibition by a bDMARD 
for EULAR good response [yes versus no] to the corresponding bDMARD at month 6. We did not 
apply a multiple testing correction, since our study had an exploratory design. For potential 
ex-vivo cytokine predictors (AUC confidence interval contains no 0.50), we performed logistic 
prediction modelling by adding the ex-vivo test to a baseline model of clinical factors and 
tested the equality of the 2 AUCs (Figure 2).11 Analyses were performed using STATA V.13.1.
Results
Baseline characteristics
Between June 2014 and February 2017, 277 patients were included in this study (Table 1). In 
total, a bDMARD was started 330 times (36 patients with 2 consecutive bDMARDs, 7 patients 
with 3 bDMARDs and 1 patient with 4 bDMARDs during the study).
Table 1. Baseline characteristics
 N=330 baselines in 277 patients
Demographics
Age, years‡ 59 (12)
Female gender 226 (69%)
Disease duration, years† 7 [2-15]
RF positive 212 / 325 (65%)
ACPA positive 198 / 306 (65%)
Erosive 154 (47%)
Disease characteristics
DAS28-CRP‡ 3.9 (1.1)
TJC† 4 [2-8]
SJC† 3 [1-6]
PGA, VAS 0-100mm† 65 [50-80] 
CRP, mg/L† 7 [1-25]
ESR, mm/h† 19 [10-36] 
Treatment characteristics
N of previous bDMARDs† 1 [0-2]
Starting bDMARD at baseline
   abatacept
   adalimumab
   etanercept
   rituximab
   tocilizumab
25 (8%)
62 (19%)
117 (35%)
88 (27%)
38 (11%)
Concomitant treatment use
   csDMARDs
   MTX 
   NSAIDs 
   Oral glucocorticoids
225 (68%)
150 (45%)
203 (62%)
83 (25%)
Data presented as number (%) unless otherwise noted. ‡Mean (SD). †Median [p25-p75].
Missing data: PGA is missing in 7 cases (2%) and ESR is missing in 24 cases (7%).
If PGA was missing, DAS28-CRP was calculated with 3 variables: TJC, SJC and CRP.
ACPA, Anti-Citrullinated Protein Antibodies; bDMARD, biological Disease-Modifying Anti-Rheumatic Drug; CRP, C-reactive 
protein; csDMARD, conventional synthetic DMARD; DAS28-CRP, 28-joint count Disease Activity Score using CRP; ESR, 
Erythrocyte Sedimentation Rate; MTX, methotrexate; NSAID, Non-Steroidal Anti-Inflammatory Drug; PGA, patient global 
assessment of disease activity; RF, Rheumatoid Factor; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue 
scale.
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Baseline ex-vivo cytokine concentrations
Almost all RPMI values were below detection limit, indicating good baseline control quality. 
Pre-incubation with either abatacept, adalimumab, etanercept, rituximab or tocilizumab 
resulted generally in decreased or unchanged C. albicans-induced and Pam3Cys-induced 
cytokine productions (Supplementary file 1).
Clinical response to bDMARD treatment
From 23 of 330 (7%) samples the corresponding treatment response to the bDMARD could 
not be defined due to respectively treatment duration <2 months (n=20) and bDMARD 
discontinuation at month 3 due to adverse events with no DAS28-CRP measured at month 3 
(n=3). In 120 of 307 (39%) cases bDMARD treatment resulted in EULAR good response at month 
6. The percentage of EULAR good responders varied between bDMARDs (following order 
represents bDMARD preference policy at our hospital): etanercept 50 of 112 (45%), adalimumab 
16 of 56 (29%), rituximab 28 of 86 (33%), abatacept 5 of 21 (24%) and tocilizumab 21 of 32 (66%).
Predictive value of baseline characteristics for treatment response to a bDMARD
All baseline characteristics from Table 1 were tested for their predictive value for EULAR good 
response to treatment with a bDMARD. DAS28-CRP was predictive for response to adalimumab 
(AUC 0.69, 95%CI: 0.56 to 0.83), etanercept (AUC 0.68, 95%CI: 0.58 to 0.78) and rituximab (AUC 
0.76, 95%CI: 0.65 to 0.86). It also tended to be predictive in abatacept (AUC 0.70, 95%CI: 0.45 
to 0.95) and tocilizumab (AUC 0.66, 95%CI: 0.43 to 0.90), but these sample sizes were smaller. 
Anti-citrullinated protein antibodies (ACPA) status was modestly predictive for response to 
abatacept (AUC 0.63, 95%CI: 0.52 to 0.75) and rheumatoid factor (RF) tended to be predictive 
for response to abatacept (AUC 0.59, 95%CI: 0.49 to 0.69) and rituximab (AUC 0.59, 95%CI: 0.48 
to 0.69).
Predictive value of ex-vivo cytokine production for treatment response to a bDMARD
In the ex-vivo cytokine analysis, 4 of 64 (6%) tests did not contain 0.50 in the AUC confidence 
interval: C. albicans-induced IL-17 production for response to rituximab (AUC 0.67, 95%CI: 
0.54 to 0.80), change in C. albicans-induced IL-17 production after inhibition by rituximab 
for response to rituximab (AUC 0.35, 95%CI: 0.21 to 0.49), change in C. albicans-induced IL-1β 
production after inhibition by abatacept for response to abatacept (AUC 0.85, 95%CI: 0.60 to 
1.00) and C. albicans-induced IFNγ production for response to tocilizumab (AUC 0.18, 95%CI: 
0.03 to 0.33) (Supplementary file 2). However, the prediction models of the 4 potential cytokine 
predictors performed similarly to their baseline models (Figure 1). 
 
Figure 1. Added predictive value of potential ex-vivo cytokine predictors for treatment response to a 
bDMARD
For potential ex-vivo cytokine predictors (AUC confidence interval contains no 0.50), we performed logistic prediction 
modelling. By univariate logistic regression analyses, baseline characteristics that were associated with treatment response 
were identified. These were entered in a multivariate logistic regression analysis using stepwise backwards selection to 
construct a baseline model. Then, we added the potential ex-vivo predictor to the baseline model and tested the equality of 
the AUCs.22
A. Can_IgG_IL-17: C. albicans-induced IL-17 production for response to rituximab (n=83).
B. Can_change_IL-17: change in C. albicans-induced IL-17 production after inhibition by rituximab for response to rituximab 
(n=83).
C. Can_IgG_IFNγ: C. albicans-induced IFNγ production for response to tocilizumab (n=31).
D. Can_change_IL-1β: change in C. albicans-induced IL-1β production after inhibition by abatacept for response to abatacept 
(n=21) (ACPA was omitted since ACPA != 1 predicted failure perfectly). 
DAS28-CRP, 28-joint count Disease Activity Score using C-reactive protein; RF, rheumatoid factor [yes versus no].
Discussion
To our knowledge, this is the first study in which the ex-vivo effects of bDMARDs on stimulated 
cytokine production of isolated PBMCs from RA patients has been investigated. The internal 
validity of our study seems to be good. The percentage of EULAR good response to a bDMARD 
in our study (39%) closely corresponds with the previously described percentage of 40% in 
literature.1 The chance of EULAR good response was lower for bDMARDs that were given in a 
later treatment stage (except for tocilizumab), possibly due to the selection of patients who 
are more refractory to treatment. 
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In our ex-vivo cytokine analysis, 4 of 64 tests showed some predictive value for treatment 
response to a bDMARD. This is a low number, since it is close to the 1 in 20 chance of test 
positivity due to chance. Two of the 4 potential ex-vivo predictors concerned IL-17 production 
for response to rituximab (C. albicans-induced IL-17 production and decrease in IL-17 
production by rituximab). It has been previously reported that rituximab strongly reduces 
(≈50%) C. albicans induced IL-17 production in-vitro and that this is accompanied by an 
improvement in DAS28-CRP.12 Our study suggests that ex-vivo IL-17 (change) may be predictive 
for clinical response to rituximab. We were not able to validate the findings of the 4 potential 
ex-vivo predictors in a separate cohort, since the number of included patients for abatacept, 
rituximab and tocilizumab was too low. However, we have shown that all 4 potential ex-vivo 
predictors have no added value to clinical factors routinely measured in RA, such as DAS28-
CRP. 
A strength of our study is that we took the effort to examine ex-vivo drug-inhibited cytokine 
production as a predictor of bDMARD response in a large group of RA patients treated in 
daily practice. Another strength is that the baseline characteristics which showed predictive 
value in our study were in line with previous studies (DAS28-CRP for all bDMARDs13, ACPA for 
abatacept14 and RF for rituximab5).  
A limitation of our study is the suboptimal inclusion for abatacept, adalimumab and 
tocilizumab which is a consequence of the preference policy of bDMARDs at our hospital. Also, 
external clinical parameters might have influenced the ex-vivo assay such as  inflammatory 
marker levels and concomitant treatments. However, in the designing phase of this study we 
decided not to use strict exclusion criteria since we wanted our cohort to reflect the general 
RA population. 
Conclusion
We postulated that predictive biomarkers for bDMARD treatment would most likely be 
derived from differences in modes of action of bDMARDs since the chance of good response 
should differ between bDMARDs to have clinical utility. Measuring the effects of bDMARDs on 
cytokine production as a predictor for clinical response seemed therefore promising. However, 
our pragmatically designed ex-vivo assay is unable to help prediction of treatment response 
to bDMARDs in daily practice, since it yields only a few potential cytokine predictors and these 
have no added value to already used disease activity measures.
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Supplementary file 1. Ex-vivo cytokine production dataset.
RPMI + IgG: Negative control.
C. albicans + IgG: Stimulation with C. albicans.
C. albicans + bDMARD: Stimulation with C. albicans and inhibition by a bDMARD.
Pam3Cys + IgG: Stimulation with Pam3Cys.
Pam3Cys + bDMARD: Stimulation with Pam3Cys and inhibition by a bDMARD.
Data presented as mean + standard error of the mean (SEM). 
P values calculated using Wilcoxon signed-rank test. * p<0.05, ** p<0.01, *** p<0.001.
A. RA patients who started treatment with abatacept (n=25).
B (left panel). RA patients who started treatment with adalimumab (n=62).
C (right panel). RA patients who started treatment with etanercept (n=117).
 
D. RA patients who started treatment with rituximab (n=88).
E. RA patients who started treatment with tocilizumab (n=38).
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Supplementary file 2. Predictive value of ex-vivo cytokine production for clinical response to a biological 
DMARD in RA patients
Abatacept
N=21
Adalimumab
N=55
Etanercept
N=112
Rituximab
N=86
Tocilizumab
N=32
Can_IgG_ IL-1β
AUC 0.30 (0.07-0.53)
Can_IgG_IL-1β
AUC 0.37 (0.22-0.52)
Can_IgG_IL-1β
AUC 0.49 (0.38-
0.60)
Can_IgG_IL-1β
AUC 0.42 (0.29-0.56)
Can_IgG_IL-1β
AUC 0.48 (0.26-0.71)
Can_change_IL-1β 
AUC 0.85 (0.60-
1.00)
Can_change_IL-1β 
AUC 0.53 (0.35-0.70)
Can_change_IL-1β 
AUC 0.42 (0.31-0.52)
Can_change_IL-1β 
AUC 0.38 (0.25-0.51)
Can_change_IL-1β 
AUC 0.41 (0.20-0.62)
Pam_IgG_IL-1β
AUC .59 (0.30-0.88)
Pam_IgG_IL-1β
AUC 0.64 (0.47-
0.81)
Pam_IgG_IL-1β
AUC 0.53 (0.43-
0.64)
Pam_IgG_IL-1β
AUC 0.53 (0.40-0.66)
Pam_IgG_IL-1β
AUC 0.42 (0.22-0.66)
Pam_change_IL-1β
AUC 0.43 (0.11-0.75)
Pam_change_IL-1β 
AUC 0.37 (0.19-0.55)
Pam_change_IL-1β 
AUC 0.41 (0.31-0.52)
Pam_change_IL-1β 
AUC 0.48 (0.34-0.61)
Pam_change_IL-1β 
AUC 0.60 (0.41-0.80)
Can_IgG_IL-6
AUC 0.41 (0.09-0.73)
Can_IgG_IL-6
AUC 0.48 (0.31-
0.66)
Can_IgG_IL-6
AUC 0.48 (0.38-
0.59)
Can_IgG_IL-6
AUC 0.61 (0.48-0.74)
Can_IgG_IL-6
AUC 0.48 (0.27-0.69)
Can_change_IL-6 
AUC 0.59 (0.18-1.00)
Can_change_IL-6 
AUC 0.53 (0.35-0.71)
Can_change_IL-6 
AUC 0.47 (0.36-
0.58)
Can_change_IL-6 
AUC 0.41 (0.26-0.55)
Can_change_IL-6 
AUC 0.42 (0.21-0.63)
Pam_IgG_IL-6
AUC 0.51 (0.16-0.87)
Pam_IgG_IL-6
AUC 0.50 (0.32-
0.68)
Pam_IgG_IL-6
AUC 0.53 (0.42-
0.63)
Pam_IgG_IL-6
AUC 0.52 (0.39-0.65)
Pam_IgG_IL-6
AUC 0.47 (0.26-0.68)
Pam_change_IL-6 
AUC 0.65 (0.16-1.00)
Pam_change_IL-6 
AUC 0.56 (0.39-0.73)
Pam_change_IL-6 
AUC 0.46 (0.36-
0.57)
Pam_change_IL-6 
AUC 0.49 (0.36-0.62)
Pam_change_IL-6 
AUC 0.56 (0.34-0.78)
Can_IgG_TNFα
AUC 0.70 (0.42-0.98)
Can_IgG_TNFα
AUC 0.42 (0.29-0.55)
Can_IgG_TNFα
AUC 0.38 (0.17-0.60)
Can_change_TNFα 
AUC 0.40 (0.06-0.74)
Can_change_TNFα 
AUC 0.47 (0.34-0.60)
Can_change_TNFα 
AUC 0.61 (0.39-0.83)
Pam_IgG_TNFα 
AUC 0.68 (0.29-0.96)
Pam_IgG_TNFα
AUC 0.45 (0.30-0.59)
Pam_IgG_TNFα 
AUC 0.46 (0.25-0.67)
Pam_change_TNFα 
AUC 0.35 (0.07-0.63)
Pam_change_TNFα 
AUC 0.58 (0.44-0.72)
Pam_change_TNFα 
AUC 0.63 (0.43-0.82)
Can_IgG_IL-17
AUC 0.58 (0.24-0.92)
Can_IgG_IL-17
AUC 0.67 (0.54-
0.80) N=84
Can_IgG_IL-17
AUC 0.54 (0.33-0.76) 
N=31
Can_change_IL-17 
AUC 0.31 (0.05-0.56)
Can_change_IL-17 
AUC 0.35 (0.21-0.49) 
N=84
Can_change_IL-17 
AUC 0.46 (0.25-0.68) 
N=31
Can_IgG_IFNγ
AUC 0.49 (0.15-0.82)
Can_IgG_IFNγ N=84 
AUC 0.48 (0.35-0.60)
Can_IgG_IFNγ 
AUC 0.18 (0.03-
0.33) N=31
Can_change_IFNγ 
AUC 0.57 (0.25-0.89)
Can_change_IFNγ 
AUC 0.46 (0.33-0.59) 
N=84
Can_change_IFNγ 
AUC 0.51 (0.26-0.77) 
N=31
Area under the receiver operating characteristic curves (AUCs) were generated to evaluate the predictive value of ex-vivo 
cytokine production (including both stimulated cytokine concentrations and absolute changes in cytokine concentrations 
after inhibition by the administered bDMARD) for EULAR good response [yes versus no] at month 6. Data presented as AUC 
(95% CI). 
Can_IgG_IL-1β, C. albicans-induced IL-1β production for clinical response to the bDMARD; Can_change_IL-1β, change in C. 
albicans-induced IL-1β production after inhibition by the administered bDMARD for response to the bDMARD; Pam_IgG_IL-
1β, Pam3Cys-induced IL-1β production for clinical response to the bDMARD; Pam_change_IL-1β, change in Pam3Cys-induced 
IL-1β production after inhibition by the administered bDMARD for response to the bDMARD. 
The other definitions are composed in the same way. 
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Abstract
Objective
To evaluate drug survival, effectiveness, pharmacokinetics, immunogenicity and safety after 
transitioning treatment from originator infliximab (Remicade®, REM) to biosimilar infliximab 
(CT-P13) in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis in 
daily practice.
Methods
Of the initial 222 REM-treated patients, 192 agreed to transition to CT-P13 and were included 
in this multicentre prospective cohort study. Changes in scores on the Disease Activity Score 
in 28 joints using the C-reactive protein level (DAS28-CRP) and Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI) were assessed after six months and CRP levels, infliximab 
trough levels and anti-infliximab antibodies were measured. Adverse events (AEs) were also 
documented. Drug survival and prognostic factors were analysed using Kaplan–Meier and Cox 
regression analyses.
Results
During six months follow-up, 24% of the patients (n=47) discontinued CT-P13. Thirty-seven 
patients restarted REM, 7 patients switched to another bDMARD and 3 patients continued 
without a bDMARD. DAS28-CRP remained stable from baseline to month 6: 2.2 (SD 0.9) to 2.2 
(SD 0.8) (difference 0.0, 95%CI: -0.1 to 0.2). BASDAI increased from 3.8 (SD 2.0) to 4.3 (SD 2.1) 
(difference +0.5, 95%CI: 0.1 to 0.9). CRP and (anti-) infliximab levels did not change. Just prior 
to CT-P13 discontinuation, DAS28-CRP components tender joint count and patients’ global 
assessment of disease activity, as well as BASDAI were increased compared to baseline. Most 
frequently reported AEs were arthralgia, fatigue, pruritus and myalgia. A shorter REM infusion 
interval (hazard ratio 0.77, 95%CI: 0.62 to 0.95) at baseline was predictive of discontinuing CT-
P13.
Conclusion
In our cohort, one-fourth of patients discontinued CT-P13 during 6 months of follow-up, 
mainly due to an increase in subjective features of the tender joint count and the patients’ 
global assessment of disease activity and/or subjective AEs, possibly explained by nocebo and/
or incorrect causal attribution effects.
Introduction
In September 2013, CT-P13 became the first biosimilar to be approved by the European 
Medicines Agency (EMA) for the treatment of rheumatic diseases.1,2 CT-P13 is a biosimilar of 
infliximab (a chimeric human-murine monoclonal antibody against the pro-inflammatory 
cytokine tumour necrosis factor alpha).3 Rigorous comparability exercises (including bio-
analytical, preclinical and clinical analyses ([Programme Evaluating the Autoimmune Disease 
Investigational Drug CT-P13 in Rheumatoid Arthritis Patients (PLANETRA) and Programme 
Evaluating the Autoimmune Disease Investigational Drug CT-P13 in Ankylosing Spondylitis 
Patients (PLANETAS) trials])4,5 demonstrated that CT-P13 was highly similar in terms of quality, 
efficacy and safety to originator infliximab (Remicade®, [REM]; Janssen) thereby meeting the 
definition of a biosimilar.6
In February 2015, CT-P13 was launched as Remsima® (Celltrion) and as Inflectra® (Hospira) 
in 12 European countries including the Netherlands. Remsima® and Inflectra® received 
approval for the same therapeutic indications as REM, including rheumatoid arthritis (RA), 
psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).1,2 Since CT-P13 introduced price 
competition, transitioning from REM to CT-P13 could reduce the healthcare expenditures for 
costly biological treatments without any difference in health outcomes, which is important 
from a social perspective.7,8
After marketing approval, the NOR-SWITCH trial (a 52-week randomised double-blind trial) 
demonstrated that transitioning from REM to CT-P13 was non-inferior to continued treatment 
with REM in patients with RA, PsA, axSpA, Crohn’s disease, ulcerative colitis and plaque 
psoriasis.9 This study added to the body of evidence that REM and CT-P13 are pharmacological 
equivalent. Since blinded transitioning to a biosimilar is not allowed in daily practice, the 
effects of open-label transitioning to CT-P13 are of interest. However, these data are still 
scarce.10-12 
We therefore decided to collect the clinical outcomes of patients who transitioned treatment 
from REM to CT-P13 in our practices in a multicentre prospective cohort study, the Biosimilar 
Infliximab Options, Strengths and Weaknesses of Infliximab Treatment Change [BIO-SWITCH] 
study. The aim of our study was to prospectively evaluate drug survival, effectiveness, 
pharmacokinetics, immunogenicity and safety after open-label transitioning treatment from 
REM to CT-P13 in patients with RA, PsA or axSpA.       
Methods
Study population
In July 2015, treatment was transitioned from REM to CT-P13 at 4 departments of 
rheumatology in the Netherlands: Sint Maartenskliniek Nijmegen, Maartenskliniek Woerden, 
Radboud University Medical Center Nijmegen and Rijnstate Arnhem. Transitioning was done 
in accordance with the stance of the Dutch Medicines Evaluation Board, which states that 
transitioning between an originator and a biosimilar is permitted if physicians and patients 
are properly informed and adequate clinical monitoring is performed.13 All patients treated 
with REM were informed by a letter about the option to transition to CT-P13. A week before the 
next planned REM infusion, patients were contacted by telephone to ask whether they agreed. 
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If a patient agreed, the next infusion was CT-P13. If not, REM was continued. CT-P13 was open-
label administered with the same dosage and interval as REM. Patients ≥18 years of age with 
a clinical diagnosis of either RA, PsA or axSpA who agreed to transition to CT-P13 (transition 
group) or who did not (control group) were both eligible for inclusion in the BIO-SWITCH study. 
Study design
The BIO-SWITCH study was a multicentre prospective cohort study. The study was approved 
by the local ethics committee (CMO region Arnhem-Nijmegen) and was registered at the 
Dutch trial register (NTR5279).14 Written informed consent was obtained from all patients. 
During the study, patients received usual care. This consisted of routinely monitoring of the 
disease activity, setting targets for low disease activity and changing treatment until the 
treatment goal was reached. Treatment choices about starting or discontinuing disease-
modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs) 
or glucocorticoids were left to the discretion of the treating rheumatologist. 
Clinical assessments
On the day of the first infliximab infusion during the study (baseline), demographic, disease- 
and treatment specific data were collected. Each patient was monitored for 6 months. 
Primary outcome was change in disease activity at month 6 (±2 months) relative to baseline. 
Disease activity in RA and PsA patients was measured with the Disease Activity Score in 28 
joints using the C-reactive protein level (DAS28-CRP) and its individual components15. Disease 
activity in axSpA patients was measured with the Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI).16 Secondary outcomes included the CRP level, erythrocyte sedimentation 
rate (ESR), infliximab trough levels, anti-infliximab antibodies and safety. At baseline and at 
6-month follow-up, a 10mL serum sample was obtained and stored frozen at -80°C. After all 
samples were collected, they were analysed at Sanquin Biologicals Laboratory in Amsterdam 
the Netherlands. Infliximab trough levels were determined by a previously validated enzyme 
linked immunosorbent assay (ELISA).17 Low trough levels were defined as <1.0 μg/mL and high 
levels as >5.0 μg/mL. Both cut-offs are consistent with previously reported group threshold 
levels.18 If the trough level was low, antidrug antibodies against infliximab were detected by 
a previously validated radioimmunoassay (RIA).19 Safety was evaluated on each infusion day 
by having the patient complete a short questionnaire. Safety endpoints included incidence 
and type of adverse events (AEs) and serious AEs (SAEs). Reasons for discontinuation of CT-P13 
were recorded, and a distinction was made between objective measurements (e.g. laboratory 
abnormalities) and subjective health complaints (i.e. symptoms perceptible only to the 
patient, such as arthralgia, fatigue, headache).20 Any changes in the use of DMARDs, NSAIDs 
and glucocorticoids during the follow-up period were documented. 
Statistical analysis 
Descriptive statistics are reported as either mean (± standard deviation (SD)), median 
(interquartile range [p25-p75]) or frequency depending on data distribution. A Kaplan-Meier 
curve was plotted to depict the drug survival of CT-P13 over 6 months. Primary effectiveness 
analyses were performed on the intention-to-treat population. We intended that non-
transitioning patients would be a quasi-experimental control group. However, due to the 
high acceptance rate for transitioning, the control group was too small. Differences between 
continuous variables at baseline versus month 6 were analysed using paired t-test or Wilcoxon’s 
signed-rank test, depending on distribution. For the pharmacokinetics and immunogenicity 
analyses, only patients with available samples at baseline and at month 6 who were still 
taking infliximab (REM or CT-P13) were included. AEs were reported as cumulative incidences 
and incidence densities per 100 patient-years. In patients who discontinued treatment, AEs 
that were reported up to the restart of REM or start of another bDMARD or up to day 38 after 
the last CT-P13 dose (>4 times the half-life of 9.5 days) were included. To identify independent 
predictors of CT-P13 discontinuation, patient-, disease- and treatment specific variables that 
showed an association (p<0.10) with discontinuation of CT-P13 in the univariate analyses were 
entered in a multivariate Cox regression analysis using a backward elimination procedure with 
the lowest Akaike information criterion as selection criterion. All analyses were performed 
using STATA V.13.1.
Results
Baseline characteristics
In July 2015, 222 REM-treated patients with RA, PsA or axSpA were informed about the option 
to transition to CT-P13. In total, 196 patients (88%) agreed to transition treatment to CT-P13 of 
whom 192 patients gave informed consent for the collection of their clinical outcomes in the 
transition group of the BIO-SWITCH study. Of the 26 patients who did not agree to transition, 
19 patients gave informed consent for the participation in the control group of the BIO-
SWITCH study (Figure 1). 
Figure 1. Study flowchart
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The first patients were included in July 2015 and the last 6-month evaluation was performed 
in May 2016. Due to the small sample size, we did not further analyse the data of the control 
group. Baseline characteristics of the transition group are depicted in Table 1. 
Table 1. Baseline characteristics of transition group
Diagnosis Total
RA
(N=75)
PsA
(N=50)
axSpA
(N=67) (N=192)
Demographics
Age, years‡ 63 (13) 53 (11) 48 (11) 55 (14)
Female 53 (71) 27 (54) 19 (28) 99 (52)
Body mass index, kg/m2‡* 26 (4) 27 (5) 27 (5) 27 (5)
Disease duration, years† 19 [11-26] 13 [8-18] 12 [9-20] 14 [9-22]
Disease specific characteristics
DAS28-CRP‡ 2.1 (0.8) 2.3 (1.0) . .
BASDAI‡ . . 3.8 (2.0) .
CRP, mg/l† 2 [1-5] 1 [0-4] 2 [0-6] 2 [0-5]
ESR, mm/u†* 14 [9-25] 7 [5-12] 10 [5-20] 12 [5-22]
Treatment specific characteristics
N of previous bDMARDs† 0 [0-0] 0 [0-2] 0 [0-1] 0 [0-1]
REM treatment duration, years† 9 [6-13] 5 [4-8] 6 [4-8] 7 [4-9]
REM infusion interval, weeks† 8 [6-8] 7 [6-8] 8 [6-8] 8 [6-8]
REM dose, mg‡ 228 (107) 300 (111) 305 (110) 274 (114)
REM dose, mg/kg‡ 2.9 (1.3) 3.7 (1.3) 3.6 (1.0) 3.3 (1.2)
Concomitant treatment use
   csDMARDs
   MTX 
   NSAIDs 
   Oral glucocorticoids
60 (80)
45 (60)
35 (47)
10 (13)
27 (54)
25 (50)
26 (52)
2 (4)
15 (22)
8 (12)
34 (51)
1 (1)
102 (53)
78 (41)
95 (49)
13 (7)
All values are given as numbers (%) unless otherwise specified. ‡Mean (SD). †Median [p25-p75]. 
*Missing data: in 15 patients (8%) BMI is missing and in 1 patient (0.5%) ESR is missing. 
axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; bDMARD, biological Disease-
Modifying Anti-Rheumatic Drug; csDMARD, conventional synthetic DMARD; DAS, Disease Activity Score; REM, originator 
infliximab, Remicade®; MTX, methotrexate; N, Number; NSAID, Non-Steroidal Anti-Inflammatory Drug; PsA, psoriatic 
arthritis; RA, rheumatoid arthritis.
The group consisted of 75 RA, 50 PsA and 67 axSpA patients. Patients had longstanding 
rheumatic disease (median disease duration 14 years) and were treated with REM for a median 
of 7 years. On average, disease activity at baseline was low. Concomitant use of conventional 
DMARDs (csDMARDs) and oral glucocorticoids differed significantly between the rheumatic 
diseases, which can be explained by the different treatment guidelines for each disease. The 
proportion of patients continuing CT-P13 treatment during 6 months follow-up is depicted in 
Figure 2. 
Figure 2. Kaplan Meier curve demonstrating the proportion of patients remaining on CT-P13
 
In total, 47 of 192 patients (24%) discontinued CT-P13 due to respectively perceived lack 
of effect (n=26), AEs (n=11) or a combination thereof (n=10). Twenty-five of the 32 (78%) 
reported AEs could be categorised as subjective health complaints (Supplementary file 1). 
The discontinuation rate was not statistically significantly different between either the 3 
rheumatic disease groups (p=0.78) or the 4 rheumatology departments (p=0.55). Of the 47 
patients who discontinued CT-P13, 37 restarted REM, 7 switched to another bDMARD and 3 
continued without a bDMARD (Figure 1). The individual responses to these treatments are 
depicted in Supplementary file 1. Univariate Cox regression analyses showed that a shorter 
REM infusion interval, higher DAS28-CRP, higher DAS28-ESR, higher swollen joint count and 
higher patients’ global assessment of disease activity at baseline were associated with CT-P13 
discontinuation (Supplementary file 2). In the multivariate Cox analyses which included only 
RA and PsA patients (DAS28 not available in axSpA), a shorter REM infusion interval (in weeks) 
appeared to be the only significant predictor (hazard ratio 0.77, 95% CI: 0.62 to 0.95).
Effectiveness
Using the intention-to-treat analysis, mean DAS28-CRP in RA and PsA patients remained 
stable from baseline to month 6: 2.2 (SD 0.9) to 2.2 (SD 0.8) (difference 0.0, 95%: CI -0.1 to 0.2). 
In axSpA patients, mean BASDAI increased from 3.8 (SD 2.0) to 4.3 (SD 2.1) (difference +0.5, 95% 
CI: 0.1 to 0.9) Median levels of CRP did not change during follow-up: 2 mg/L [p25-75: 0-5] and 
1 mg/L [p25-75: 0-5] (difference +1, 95% CI: -1 to 3, n = 190). Median levels of ESR increased 
minimally during follow-up: 12 mm/h [p25-75: 5-22] and 13 mm/h [p25-75: 6-25] (difference  +3, 
95% CI: 1 to 5, n = 187).
The subgroup analyses (17 of 32 RA and PsA patients and 10 of 15 axSpA patients who 
discontinued CTP13) showed that prior to discontinuation of CT-P13, both DAS28-CRP and 
BASDAI were increased relative to baseline: from 2.6 [p25-p75: 2.1-3.2] to 3.7 [p25-p75: 3.2-
4.2] (difference +0.8, 95% CI: 0.3 to 1.3) and from 4.0 [p25-p75: 2.7-5.9] to 5.6 [p25-p75: 5.1-7.1] 
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(difference +1.8, 95% CI: 0.4 to 3.2). The increase in DAS28-CRP in this subgroup was caused by 
significant increases in tender joint count and patients’ global assessment of disease activity 
(i.e. subjective assessments), but not swollen joint count or CRP (i.e. objective assessments) 
(Figure 3).
Figure 3. DAS28-CRP components at baseline and prior to discontinuation of CT-P13. 
 
* Paired t-test: p<0.05. CRP, C-reactive protein; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale. 
Pharmacokinetics and immunogenicity
Paired samples were available of 136 of 192 (71%) patients. Infliximab trough levels were not 
significantly different between baseline and month 6: 2.0 μg/mL [range 0–25] versus 1.9 μg/
mL [range 0–22, p=0.45]. The percentages of patients with low, intermediate and high trough 
levels were 24%, 57% and 19% at baseline and 23%, 54% and 23% at month 6. Anti-infliximab 
antibodies were detected in 14 of 136 (10%) patients at baseline and in 9 (7%) patients at month 
6. Seven patients had detectable anti-infliximab antibodies at both time points. Two patients 
developed anti-infliximab antibodies and 7 patients lost detectable anti-infliximab antibodies 
at month 6. In the latter group, 2 patients received glucocorticoids (oral glucocorticoid 20mg/
day and intramuscular glucocorticoid injection 120mg) 1 week before blood sampling.  
Safety
AEs were reported in 141 of 192 (73%) patients and SAEs in 9 (5%) patients (6 planned surgeries, 
1 cardiovascular event, 1 pulmonary event and 1 malignancy). A total of 67 (35%) patients 
reported 2 or more AEs during the follow-up period. All AEs that were reported in more than 
1 patient are depicted in Table 2. The majority of these AEs could be categorised as subjective 
health complaints. Of note, 1 infusion reaction after CT-P13 was observed during follow-up.
Table 2. Reported AEs during follow-up period in transition group
Adverse event Cumulative incidence†  N=192 Incidence density (95% CI) ‡
Arthralgia* 79 (41%) 91 (72 to 114) 
Fatigue* 16 (8%) 18 (11 to 30)
Pruritus* 11 (6%) 13 (6 to 23)
Myalgia* 10 (5%) 12 (6 to 21)
Skin rash 10 (5%) 12 (6 to 21)
Influenza-like illness 9 (5%) 10 (5 to 20)
Arthritis 7 (4%) 8 (3 to 17)
Headache* 7 (4%) 8 (3 to 17)
Psoriasis exacerbation 7 (4%) 8 (3 to 17)
Malaise 6 (3%) 7 (3 to 15)
Coughing* 5 (3%) 6 (2 to 13)
Dry eyes* 4 (2%) 5 (1 to 12)
Dyspnea* 4 (2%) 5 (1 to 12)
Nausea* 4 (2%) 5 (1 to 12)
Paresthesia* 4 (2%) 5 (1 to 12)
Urinary tract infection 4 (2%) 5 (1 to 12)
Respiratory tract infection 4 (2%) 5 (1 to 12)
Diarrhea* 3 (2%) 3 (1 to 10)
Mood disturbances* 3 (2%) 3 (1 to 10)
Gastrointestinal complaints* 3 (2%) 3 (1 to 10)
Oral candidiasis 2 (1%) 2 (0 to 8)
Conjunctivitis 2 (1%) 2 (0 to 8)
Dizziness* 2 (1%) 2 (0 to 8)
Erysipelas 2 (1%) 2 (0 to 8)
Hypertension 2 (1%) 2 (0 to 8)
Mouth ulcers 2 (1%) 2 (0 to 8)
Rhinitis* 2 (1%) 2 (0 to 8)
Skin infection 2 (1%) 2 (0 to 8)
†Data are number of patients (%). AEs that occurred in only 1 patient are not shown. 
No AEs were reported twice in the same patient. ‡Data are number of AEs per 100 patient-years (95% CI). Transition group: 
87 observed patient-years. *Adverse event that could be categorised as subjective health complaint (i.e. symptoms only 
perceptible to the patient). 
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Co-medication
Concomitant csDMARD treatment was changed in 15 patients (8%, 95% CI: 0.05 to 0.12) during 
follow-up (6 dose reductions, 4 dose escalations, 4 discontinuations and 1 initiation of a 
csDMARD). At month 6, the percentage of patients using a NSAID was higher in comparison to 
baseline (54% versus 49%, p=0.004). Oral glucocorticoid use did not significantly change over 
the study period (9% versus 7%, p=0.29). Intramuscular glucocorticoid injections were given 
to 29 (15%) patients and intraarticular glucocorticoid injections to 9 (5%) patients. 
Discussion
This prospective cohort study shows that REM can be open-label transitioned to CT-P13 
in the great majority of RA, PsA and axSpA patients in daily practice without changes in 
effectiveness, (anti-) infliximab levels and safety. However, an interesting new finding in our 
study is that one-fourth of the patients discontinued CT-P13 after the open-label transition, 
which was mainly driven by an increase in the subjective tender joint count and patients’ 
global assessment of disease activity and/or in subjective AEs rather than by an increase in 
objective signs and symptoms.
Although our control group was too small to analyse, the discontinuation rate of 24% in the 
transition group is much higher than expected based on existing data on long-term treatment 
with REM. For example, in the Anti-Rheumatic Therapy in Sweden (ARTIS) register and the 
Danish Registry for Biologic Therapies in Rheumatology (DANBIO), respectively 9% and 5% of 
patients discontinued REM during the fifth and seventh years of treatment.21,22 Interestingly, 
other recently published open-label studies on transitioning REM to CT-P13 in patients with 
rheumatic diseases also found an increased dropout rate. In the DANBIO register, 15% (117 of 
768) of patients discontinued CT-P13 during a 1-year follow-up period. The most frequently 
reported reasons for discontinuation were lack of efficacy (n=51) and AEs (n=34), but these 
were not described in detail (i.e. objective versus subjective complaints) and in contrast to our 
study restarting REM was not an option in the Danish study.23 In a small Finish cohort study, 
28% (11 of 39) of patients discontinued CT-P13 during a median of 11 months. Six patients 
discontinued due to subjective reasons; five of them restarted REM treatment.10 Comparing 
our safety data (with a follow-up duration of 6 months) with those of the CT-P13 group in the 
blinded NOR-SWITCH trial (with a follow-up duration of 1 year) shows that the occurrence 
of SAEs (5% versus 9%), infections (urinary tract infection: 2% versus 3%, respiratory tract 
infection: 2% versus 4%) and infusion-related reactions (0.5% versus 2%) were similar.9 
However, both the percentage of patients in which AEs resulted in CT-P13 discontinuation 
(11% in our study versus 3% in the NOR-SWITCH trial) and the occurrence of subjective health 
complaints (e.g. arthralgia (41% versus 3%) were higher in our study. This demonstrates that 
although the efficacy, pharmacokinetics, immunogenicity and safety after transitioning from 
REM to CT-P13 was non-inferior to continued REM treatment in the blinded NOR-SWITCH 
trial, in open-label studies, the discontinuation rate of CT-P13 is increased due to subjective 
health complaints. 
In our view, the reason for the substantial discontinuation rate in open-label studies is the 
awareness on the part of both physicians and patients of the transition to the biosimilar. Two 
recent surveys investigating patient perspectives on biosimilars in diabetes and inflammatory 
bowel disease showed that the majority of respondents had doubts and concerns about 
the effectiveness and safety of biosimilars.24,25 Some respondents equated lower costs with 
diminished quality. Also, respondents had more trust in prescription of biosimilars by their 
treating physician than by regulatory agencies, highlighting the importance of a good 
physician-patient relationship. 
Pre-treatment expectancy has long been recognised as a factor that strongly shapes 
treatment outcome.26,27 Patients’ own negative expectations may induce negative symptoms 
(hyperalgesia or AEs) during treatment, the so-called nocebo response.28 Increases in disease 
activity or AEs that occur independent of the transition may be falsely attributed to the 
transition (defined as incorrect causal attribution).29 It is noteworthy that in our hospitals, 
groups of patients received their infliximab infusions together in a room for years. When a 
patient restarted REM treatment because of complaints, the other patients observed this, 
potentially leading to the “groupthink” effect that CT-P13 is inferior and that REM should be 
restarted. 
To our knowledge, this is one of the first large multicentre cohort studies on open-label 
transitioning REM to CT-P13 in patients with a rheumatic disease in daily practice. A strength 
of our study is that we closely followed the national guidelines on the use of biosimilars 
(e.g. informed consent, monitoring, possibility of restarting REM).13 Also, our cohort was 
heterogeneous in terms of diagnosis, treatment duration and disease activity allowing 
translation of the results to daily practice.
We assessed individual treatment responses to restarting REM treatment and switching 
to another bDMARD in the patients who did. We found that all reported AEs resolved after 
discontinuation of CT-P13. Second, we found that some patients mentioned that their 
arthralgia had decreased after restarting REM and this was accompanied by lower disease 
activity scores at month 6 and 12. However, it is important to realise that this does not directly 
mean that REM is superior to CT-P13 in these patients. It is more likely that the decrease in 
number of tender joints, patients’ global assessment of disease activity and subjective health 
complaints (most frequently increased at CT-P13 discontinuation) could be assigned to the 
placebo effect (opposite of nocebo effect) or regression to the mean. Also, worth mentioning 
is that there were some patients in whom the disease activity did not improve after restarting 
REM and in which REM was nevertheless still being taken at month 12. These patients 
received an intramuscular glucocorticoid injection or agreed to a “wait-and-see” strategy. 
This highlights the fact that similar disease activity scores resulted in different treatment 
decisions by the treating rheumatologist and patient with regard to discontinuation of CT-P13 
and continuation of REM, respectively. 
A limitation of our study is that the number of patients that did not transition to a 
biosimilar was too small to be included as control group. However, as mentioned above, the 
pharmacologic equivalence of continuing and transitioning was previously demonstrated in a 
large independent blinded trial.9 Because blinded transitioning to a biosimilar is not allowed 
in daily practice, the major aim of this study was indeed to examine the results after open-
label transitioning to CT-P13. 
Disease activity was not measured at the time of discontinuation in all patients who 
discontinued CT-P13. We believe that these missing values did not bias our finding that 
discontinuation due to inefficacy was mainly driven by the subjective components of the 
DAS28-CRP, because most missing values were derived from patients who discontinued CT-
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P13 due to subjective AEs. In fact, physicians were instructed to measure the disease activity 
during an outpatient visit if a patient experienced lack of efficacy. In the case of subjective AEs, 
an outpatient visit was not always made.   
Furthermore, we could not correlate infliximab trough levels and anti-infliximab antibodies 
with disease activity and AEs at CT-P13 discontinuation, since we did not collect serum 
samples at the time of discontinuation. However, we believe that it is unlikely that changes in 
immunogenicity at the time of discontinuation would have been found, since the NOR-SWITCH 
trial demonstrated similar infliximab trough drug levels and anti-infliximab antibodies 
incidences in the REM continuation and CT-P13 transitioning arms. Also, if immunogenicity 
had caused CT-P13 discontinuation, we would have expected to find more patients with 
objectively active disease and/or allergic infusion reactions. 
Since non-informed transitioning to biosimilars is not allowed in daily practice, the only 
way to improve acceptance and persistence rates after transitioning is to optimise the way 
in which the transition is communicated. By sending a brief letter followed by telephone 
contact, we have shown that the acceptance rate for transitioning is already high. However, 
continuing with CT-P13 treatment was much lower than expected. Our observation that a 
substantial number of patients discontinued CT-P13 because of subjective health complaints 
seems relevant for the implementation of open-label transitioning to all currently approved 
and upcoming biosimilars in daily practice for two reasons. First, it might imply that 
physicians’ and patients’ beliefs about transitioning to a biosimilar are associated with the 
persistence of a biosimilar (i.e. negative beliefs about a biosimilar might be associated with a 
lower persistence of a biosimilar). In this study, we did not measure these beliefs at baseline, 
but our observation that a shorter REM infusion interval (and not pharmacokinetics) was the 
only baseline characteristic that was predictive of CT-P13 discontinuation may support the 
hypothesis that patients who are treated with a shorter infusion interval feel more dependent 
on REM and are consequently more prone to experiencing a nocebo effect. This seems valid on 
the face of it, because at the time, the interval shortening of REM infusions had probably been 
due to a perceived lack of effect of the registered dose. Therefore, future research should focus 
on measuring with validated questionnaires the tendency to experience a nocebo response 
as well as on causal attributions. Second, the rate of continuation on biosimilar treatment 
might be improved by providing a “soft-skills” training and communication protocol for 
rheumatology and pharmacy staff about how to assuage patient concerns regarding the 
effectiveness and safety of a biosimilar and how to respond if a patient has subjective health 
complaints (e.g. discuss the potential occurrence of nocebo and incorrect causal attributions 
effects, suggest a “wait-and-see” strategy instead of immediately restarting the originator).
Conclusion
All things considered, the substantial discontinuation rate of CT-P13 due to subjective health 
complaints after open-label transitioning might be explained by nocebo and/or incorrect 
causal attribution effects. As a result, communication seems to be the determining factor of 
the success of transitioning to a biosimilar in daily practice. 
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Supplementary file 2. Predictive clinical baseline factors for discontinuation of CT-P13 in transition 
group
Predictive factor HR 95% CI P value
Age (years) 0.99 0.97 to 1.01 0.40
Female gender 0.70 0.39 to 1.26 0.24
Body mass index (kg/m2) 0.83 0.45 to 1.51 0.54
Disease duration (years) 0.99 0.96 to 1.02 0.56
Diagnosis (referencegroup = PsA)
   RA
  axSpA
0.84 
0.79 
0.42 to 1.68
0.38 to 1.64
0.62
0.52
REM treatment duration (years) 0.94 0.87 to 1.02 0.14
REM infusion interval (weeks) 0.79 0.66 to 0.94 0.008
REM dose (mg) 1.00 0.997 to 1.0 0.94
REM dose (mg/kg) 1.02 0.82 to 1.27 0.87
csDMARD use 1.01 0.57 to 1.80 0.97
Infliximab trough level (µg/ml) 1.03 0.97 to 1.10 0.28
ADA positive 0.63 0.20 to 2.03 0.44
ESR (mm/u) 1.00 0.98 to 1.02 0.96
CRP (mg/l) 0.99 0.96 to 1.03 0.69
DAS28-ESR 1.35 0.96 to 1.90 0.08
DAS28-CRP 1.69 1.20 to 2.39 0.003
TJC 1.06 0.98 to 1.15 0.13
SJC 1.40 1.05 to 1.85 0.02
VAS disease activity (mm) 1.02 1.00 to 1.03 0.03
BASDAI 0.90 0.70 to 1.17 0.43
P values <0.10 are marked bold. 
ADA, Anti-Drug Antibodies against infliximab; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease 
Activity Index; CI; Confidence Interval; CRP, C-reactive protein; csDMARD, conventional synthetic Disease-Modifying 
Anti-Rheumatic Drug; DAS, Disease Activity Score; ESR, Erythrocyte Sedimentation Rate; HR, Hazard Ratio; REM, originator 
infliximab, Remicade®; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count; VAS, 
visual analogue scale.
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Abstract
Objective
To evaluate the effects of non-mandatory transitioning from originator etanercept (ENB) to 
biosimilar etanercept (SB4) on drug survival and effectiveness in a controlled cohort study of 
patients with an inflammatory rheumatic disease. 
Methods
In 2016, 642 ENB-treated patients were asked to transition to SB4 by a structured 
communication strategy with opt-out option. Consenting patients were eligible for the current 
study [BIO-SPAN]. ENB-treated patients in 2014 were recruited as historical cohort. Drug 
survival was compared by Cox regression analyses adjusting for age, gender, diagnosis, ENB 
treatment duration, ENB dose interval, csDMARD and CRP, using a robust variance estimator 
to account for repeated subjects. Adjusted differences in CRP, DAS28-CRP and BASDAI change 
over 6 months were assessed. 
Results
635 of 642 (99%) patients agreed to transition of whom 625 patients (433 RA, 128 PsA, 64 
axSpA) were included in the study. 600 patients were included in the historical cohort. Crude 
6-months persistence rates of SB4 and ENB were: 90% (95%CI: 88% to 93%) versus 92% 
(95%CI: 90% to 94%). The transition cohort had a statistically significantly higher relative 
risk of discontinuation (adjusted HR 1.57, 95%CI: 1.05 to 2.36) and smaller decreases in CRP 
(adjusted diff 1.8 (95%CI: 0.3 to 3.2)) and DAS28-CRP (adjusted diff 0.15 (95%CI: 0.05 to 0.25)) 
over 6 months compared with the historical cohort. 
Conclusion
Non-mandatory transitioning from ENB to SB4 using a specifically-designed communication 
strategy showed a slightly lower persistence rate and smaller decreases in disease activity 
compared with a historical cohort, but these differences were considered as not being 
clinically relevant.
Introduction
During the past years, marketing exclusivity rights of several biological disease-modifying anti-
rheumatic drugs (bDMARDs) have expired providing the opportunity to launch biosimilars.  A 
biosimilar is defined by the European Medicines Agency (EMA) as a ‘biological medicine highly 
similar to another already approved biological medicine (the “reference medicine”)’ that 
shows ‘no clinically meaningful differences with the reference medicine in terms of safety, 
quality and efficacy’.1 The introduction of biosimilars may provide a reduction of healthcare 
costs due to higher discounts.2
Several biosimilar tumour necrosis factor-α (TNF) inhibitors have been approved by the 
EMA for the treatment of inflammatory rheumatic diseases (e.g. Inflectra®/Remsima® 
(biosimilar infliximab, CT-P13), Flixabi® (biosimilar infliximab, SB2), Benepali® (biosimilar 
etanercept, SB4), Erelzi® (biosimilar etanercept, GP2015), Amgevita®/Solymbic® (biosimilar 
adalimumab, ABP501), Imraldi® (biosimilar adalimumab, SB5)) and many other biosimilars are 
in development.3
In a randomised double-blind trial [NOR-SWITCH], transitioning from originator infliximab 
(Remicade®, REM) to CT-P13 was non-inferior to continued treatment with REM in patients 
with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).4 
However, since blinded transitioning to a biosimilar is not used in daily practice, the effects of 
open-label transitioning to a biosimilar are important. Open-label mandatory transitioning 
to CT-P13 in Denmark resulted in a slightly lower 1-year CT-P13 persistence rate than for REM 
in the historical cohort but had no negative impact on disease activity.5 In light of shared 
treatment decision-making between patients and physicians, non-mandatory transitioning 
might be preferable above mandatory transitioning. First attempts with non-mandatory 
transitioning unfortunately showed suboptimal CT-P13 acceptance and persistence rates in 
four cohort studies6-9 with discontinuation of CT-P13 being mainly driven by subjective health 
complaints9. Key difference between blinded and open-label transitioning is the awareness 
of patients and physicians of the transition. In open-label transitioning this awareness 
might induce negative expectations about transitioning to a biosimilar resulting in adverse 
symptoms during treatment (nocebo effect) and/or incorrect causal attributions.10-12 
Recently, a narrative review concluded that nocebo effects can be minimised by good 
informational and educational practices.13 Therefore, we decided to develop a structured 
communication strategy for transitioning to a biosimilar including proper patient information 
and healthcare providers’ education. We hypothesised that this strategy might positively 
influence the expectations of patients about transitioning to a biosimilar, resulting in optimal 
acceptance and persistence rates (by preventing possible nocebo and attribution effects). We 
set out to study this hypothesis, by applying our communication strategy during the open-
label non-mandatory transition from originator etanercept (ENB) to biosimilar etanercept 
(SB4) in patients with RA, PsA or axSpA and consecutively compared drug survival and 
effectiveness over six months with a historical cohort of patients who continued ENB. Also, we 
assessed whether patients’ expectations about transitioning to a biosimilar at baseline were 
associated with SB4 treatment persistence. 
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Methods
Study population
In 2015, the Sint Maartenskliniek Nijmegen, the Netherlands transitioned treatment from 
REM to CT-P13. Taking lessons from this transition into account, a structured communication 
strategy (Supplementary file 1) was implemented when the hospital initiated its second 
transition project from ENB to SB4 in June 2016. Adult patients treated with ENB (Enbrel® 50mg 
pre-filled pen or syringe) were informed by letter about the option to transition to SB4. At the 
time of the planned prescription refill, patients were contacted by a pharmacy technician to 
ask whether they agreed to transition to SB4. If so, SB4 was prescribed in the same dosage, 
interval and device (pen or syringe) as ENB. If not, patients were contacted by their treating 
rheumatologist to discuss the transition. For patients who still declined, ENB treatment was 
continued. Patients ≥18 years of age with a clinical diagnosis of either RA, PsA or axSpA who 
agreed to transition to SB4 were eligible for inclusion in the transition cohort. Additionally, 
a historical cohort was composed of patients with the same inclusion criteria who were 
treated with ENB in the same hospital in June 2014. Patients in both cohorts were included 
by an informed opt-out recruitment method, since concern was raised that an opt-in method 
could limit participation and introduce bias.14 This method was deemed appropriate, since we 
collected anonymous clinical data that had routinely been documented during outpatient 
visits performed in usual care.15
Study design
The BIOsimilar transition, Study on Persistence and role of Attribution and Nocebo [BIO-
SPAN] study was a prospective controlled cohort study. The study was judged as not requiring 
approval by the local ethics committee (CMO region Arnhem-Nijmegen, file number 2016-
2612) and was registered at the Dutch trial register (NTR5901).16 All treatment choices about 
starting or discontinuing DMARDs, non-steroidal anti-inflammatory drugs (NSAIDs) or 
glucocorticoids were left to the treating rheumatologist. 
Clinical assessments
Demographic-, disease- and treatment specific data were collected at baseline (day of first 
SB4 injection in transition cohort and June 1, 2014 in historical cohort) and during follow-up 
visits performed in usual care. Primary outcome was the adjusted hazard ratio (HR) between 
SB4 discontinuation in the transition cohort and ENB discontinuation in the historical cohort. 
Secondary outcomes included reasons for SB4 or ENB discontinuation, prediction of SB4 
discontinuation and differences in disease activity measures over six months. Reasons for SB4 
or ENB discontinuation were documented by the treating rheumatologists in the electronic 
patient records and these were collected for the study. Adverse events (AEs) were categorised 
into objective adverse events (e.g. laboratory abnormalities) and subjective health complaints 
(descriptive term of symptoms only perceptible to the patient, e.g. arthralgia, headache and 
nausea).17 We randomly sent half of the included patients in the transition cohort a set of 
questionnaires with an informed consent form before their first SB4 injection administration, 
this to be able to control for a possible priming effect of the questions with regard to nocebo. 
We allocated patients in the “questionnaires” group or “no questionnaires” group in a ratio of 
1:1 using a randomisation list generated by the computer. The set of questionnaires consisted of 
two questionnaires on treatment expectations (6-item Credibility/Expectancy Questionnaire 
(CEQ)18 and 6-item Stanford Expectations of Treatment Scale (SETS)19), a questionnaire 
on beliefs about prescribed medication (10-item Beliefs about Medication Questionnaire 
(BMQ-Specific)20 and a questionnaire on self-efficacy related to coping with pain and other 
symptoms associated with arthritis (11-item Arthritis Self-Efficacy Scale (ASES)21. With the 
support of two native speakers, the CEQ and SETS were forward translated, operationalised 
(replacing “treatment” into “transitioning to a biosimilar”) and reviewed until consensus was 
reached.22 Effectiveness was assessed at month 6 (±3 months) based on change from baseline 
in C-reactive protein (CRP) for all patients, Disease Activity Score in 28 joints using CRP (DAS28-
CRP) for RA and PsA patients and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
for axSpA patients. As baseline measurement, the most recent CRP, DAS28-CRP or BASDAI prior 
to the first SB4 injection (or June 1, 2014 in the historical cohort) with a maximum interval of 
six months was collected from the electronic patient records. 
Statistical analysis 
Descriptive statistics are reported as either mean (standard deviation (SD)), median 
(interquartile range, [p25-p75]) or frequency depending on data distribution. Baseline 
characteristics were compared using Student’s t-test (or, if not normally distributed, Wilcoxon 
rank sum) and χ2 test for continuous and categorical data. Included questionnaires were 
analysed according to previously published methods.18,19,21,23 Treatment persistence of SB4 and 
ENB were compared between cohorts. Patients who discontinued SB4 or ENB due to remission 
were not coded as event but censored at the time of discontinuation. Because the transition 
cohort and historical cohort might not be comparable at baseline in factors influencing 
treatment persistence, a multivariate Cox regression analysis was used to adjust the HR of 
discontinuation for differences in potential baseline confounders (i.e. age, gender, diagnosis, 
ENB treatment duration, ENB dose interval, concomitant conventional synthetic DMARD 
(csDMARD) [yes versus no] and CRP). As more discontinuation was expected in the first year of 
ENB use, ENB treatment duration was modelled by using it both as categorical (<0.5/ 0.5-1/ >1 
years) and continuous variable (in which year 1 was recoded as 0 and after that as year minus 
1). A robust variance estimator was applied in the Cox regression to account for repeated 
subjects (i.e. patients included in both the transition cohort and the historical cohort). 
In the transition cohort, univariate Cox regression analyses stratified by diagnosis were 
performed to assess if baseline characteristics were associated with SB4 discontinuation. 
Variables that showed an association (p<0.10) with SB4 discontinuation in the univariate 
analyses were entered in the multivariate Cox regression using stepwise backwards selection. 
SB4 treatment persistence among patients who completed questionnaires, patients who 
declined to fill in questionnaires and patients who were not selected to fill in questionnaires 
was explored with a log-rank test. In the subgroup of patients who completed questionnaires, 
univariate Cox regression analyses were performed to assess if the questionnaire outcomes 
were associated with SB4 discontinuation. Effectiveness analyses were performed on the 
intention-to-treat population. In the transition cohort, CRP, DAS28-CRP and BASDAI at 
baseline versus month 6 were analysed using Wilcoxon signed-rank test. Linear regression 
analyses were performed for differences in CRP, DAS28-CRP and BASDAI change over six 
months between the transition cohort and the historical cohort. Missing CRP, DAS28-CRP 
and BASDAI values at baseline and month 6 were addressed using multiple imputation (in 
which study cohort [transition cohort versus historical cohort], age, gender, disease duration, 
ENB treatment duration, ENB dose interval and concomitant csDMARD use [yes versus no] 
were considered as predictors of missing values). The number of imputations was set on 10. 
With this complete dataset, ∆ month 6 values (month 6 value minus baseline value) of CRP, 
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DAS28-CRP and BASDAI were generated. The difference in ∆ month 6 CRP, DAS28-CRP and 
BASDAI between the transition cohort and the historical cohort was adjusted for potential 
confounders (baseline value, age, gender, disease duration, ENB treatment duration, ENB dose 
interval and concomitant csDMARD use [yes versus no]) and a robust variance estimator was 
applied to account for repeated subjects. A p value <0.05 was taken as indicating statistical 
significance. All analyses were performed using STATA V.13.1.
Results
Baseline characteristics
In June 2016, 642 adult ENB-treated patients with RA, PsA or axSpA were informed about the 
option to transition to SB4. 635 (99%) patients accepted to transition to SB4 of whom 625 were 
included in the BIO-SPAN study (Figure 1A). The first patients were included in June 2016 and 
the last six months evaluation was performed in May 2017. Additionally, 600 patients were 
included in the historical cohort (Figure 1B), of whom 401 (67%) also had been included in the 
transition cohort. 
Figure 1. Flow chart showing the distribution of study patients from baseline to month 6 in the transition 
cohort and the historical cohort.
  
Baseline characteristics of both cohorts are depicted in Table 1. 
Table 1. Baseline characteristics
Transition cohort
N=625
Historical cohort
N=600
P value
Demographics
Female gender 341 (55) 338 (56) 0.52 
Age, years‡ 57 (14) 56 (14) 0.28 
Disease duration, years† 9 [4-16] 9 [3-15] 0.21 
Diagnosis 0.51
   RA 433 (69) 422 (70)
   PsA 128 (21) 109 (18)
   axSpA 64 (10) 69 (12)
Disease characteristics
CRP, mg/L† 1 [0-5]
N=577 (92%) 
3 [1-5]
N=546 (91%)
<0.001 
DAS28-CRP†* 1.9 [1.5-2.6]
N=521 (93%)
2.1 [1.6-2.9]
N=489 (92%)
<0.001
TJC† 0 [0-1] 
N=521 (93%)
0 [0-2]
N=489 (92%)
0.22
SJC† 0 [0-1] 
N=521 (93%)
0 [0-1]
N=489 (92%)
0.28
PGA, VAS 0-100 mm† 25 [10-45] 
N=465 (83%)
25 [10-50]
N=359 (68%)
0.69
BASDAI† 3.1 [1.8-5.4]
N=54 (84%)
3.1 [1.6-4.6]
N=35 (51%)
0.65
Treatment characteristics
bDMARD treatment number, ENB† 1 [1-1] 1[1-2] 0.23 
ENB treatment duration, years† 3 [2-6] 2 [1-4] <0.001
ENB treatment duration <0.001
   < 0.5 year 68 (11) 96 (16)
   0.5 – 1 year 47 (7) 81 (13)
   >  1 year 510 (81) 423 (71)
ENB dose interval, days† 7 [7-14] 7 [7-10] <0.001
Concomitant treatment use
   csDMARD 350 (56) 320 (53) 0.36 
   NSAID 354 (57) 349 (58) 0.57 
   Oral glucocorticoids 56 (9) 41 (7) 0.17
Data presented as number (%) unless otherwise noted. ‡Mean (SD), †Median [p25-p75].
*If PGA was missing, DAS28-CRP was calculated with 3 variables (TJC, SJC and CRP).  
Baseline characteristics were compared using Student’s t-test (or, if not normally distributed, Wilcoxon rank sum) and χ2 test 
for continuous and categorical data.
axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index (measured in axSpA); bDMARD, 
biological Disease-Modifying Anti-Rheumatic Drug; CRP, C-reactive protein; csDMARD, conventional synthetic Disease-
Modifying Anti-Rheumatic Drug; DAS28-CRP, 28-joint count Disease Activity Score using CRP (measured in RA and PsA); ENB, 
originator etanercept; NSAID, Non-Steroidal Anti-Inflammatory Drug; PGA, patient global assessment of disease activity; 
PsA, psoriatic arthritis; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.
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Most characteristics were similar between the cohorts, except for a longer ENB treatment 
duration (3 [p25-p75: 2-6] versus 2 [p25-p75: 1-4] years, p<0.001), longer ENB dose interval 
(7 [p25-p75: 7-14] versus 7 [p25-p75: 7-10] days, p<0.001), lower CRP (1 [p25-p75: 0-5] versus 3 
[p25-p75: 1-5] mg/L, p<0.001) and lower DAS28-CRP (1.9 [p25-p75: 1.5-2.6] versus 2.1 [p25-p75: 
1.6-2.9], p<0.001) in the transition cohort. Crude 6-months persistence rates of SB4 in the 
transition cohort and ENB in the historical cohort were: 90% (95%CI: 88% to 93%) versus 92% 
(95%CI: 90% to 94%) (Figure 2). 
Figure 2. Kaplan-Meier curves showing the proportion of patients who continued treatment over six 
months with respectively biosimilar etanercept (SB4) in the transition cohort and originator etanercept 
(ENB) in the historical cohort. Numbers in parentheses are the number of patients who discontinued 
respectively SB4 and ENB during the interval. 
The transition cohort had a significantly higher relative risk of discontinuation than the 
historical cohort (adjusted HR 1.57, 95%CI: 1.05 to 2.36). Considering the discontinuation rate 
of 8% in the historical cohort, this implies an adjusted discontinuation rate of 12.5% in the 
transition cohort. Reasons for discontinuing SB4 in the transition cohort (n=60) and ENB 
in the historical cohort (n=46) were: lack of effect (43% versus 61%), AEs (47% versus 28%), 
malignancy (3% versus 4%), pregnancy (4% versus 4%) and other (3% versus 3%). AEs resulting 
in SB4 and ENB discontinuation are listed in Table 2. 
Table 2. Adverse events resulting in discontinuation of respectively SB4 and ENB 
AE type SB4 discontinuation due to 
AEs in transition cohort N=28
ENB discontinuation due to 
AEs in historical cohort N=13
Total AEs 55 15
Objective adverse events 9 9
Skin rash 2 1
Unspecified injection site 
reaction 
1 .
Increased ALT 1 .
Upper respiratory tract 
infections 
1 1
Urinary tract infections 1 1
Uveitis 1 .
Total hip replacement infection 1 .
Jaw implant infection 1 .
Elbow replacement infection . 1
Wound infection foot . 1
Salmonella infection . 1
Hepatitis C . 1
Aortic aneurysm surgery . 1
Retrobulbar neuritis . 1
Subjective health complaints 46 6
Arthralgia 9 .
Painful injection 6 1
Malaise 5 .
Pruritus 4 1
Headache 3 .
Nausea 3 .
Coughing 2 1
Dizziness 2 .
Dyspnea 2 1
Fatigue 2 .
Paresthesia 2 .
Palpitations 2 .
Hair loss 1 .
Myalgia 1 .
Mood disturbances 1 .
Vision disturbances 1 .
Gastrointestinal complaints . 2
Adverse events (AEs) were categorised into objective adverse events and subjective health complaints (descriptive term of 
symptoms only perceptible to the patient).
ALT, alanine aminotransferase; ENB, originator etanercept; SB4, biosimilar etanercept.
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The number of AEs per patient in the transition cohort was higher compared with the historical 
cohort (1.5 [p25-p75: 1-3] versus 1 [p25-p75: 1-1], p=0.01) and more AEs were categorised as 
subjective health complaints (46 of 55 (84%) versus 6 of 15 (40%), p<0.001).
In the transition cohort, 17 patients restarted ENB, 32 patients switched to another bDMARD 
and 11 patients continued without a bDMARD. The occurrence of restarting ENB was 
significantly higher in patients who discontinued SB4 due to AEs (13 of 28 (46%)) compared 
with lack of effect (4 of 26 (15%), p=0.02). In the historical cohort, 29 patients switched to 
another bDMARD and 17 patients continued without a bDMARD. 
Prediction of SB4 discontinuation 
Shorter ENB treatment duration (in RA, PsA and axSpA), higher patient global assessment 
of disease activity (in RA) and higher CRP (in RA) at baseline were associated with SB4 
discontinuation in the transition cohort (Table 3). The 6-month SB4 persistence rate was 
comparable in the group that completed questionnaires (91%, 95%CI: 85% to 95%, n=168), 
the group that declined to fill in questionnaires (90%, 95%CI: 86% to 93%, n=145) and 
the group that was not selected to fill in questionnaires (90%, 95%CI: 83% to 94%, n=312, 
p=0.93). Patients who completed questionnaires had stronger necessity beliefs than concern 
beliefs about medication and stronger positive expectations than negative expectations on 
transitioning to a biosimilar (Supplementary file 2). A lower self-efficacy was associated with 
SB4 discontinuation (Table 3). 
Table 3. Baseline characteristics associated with SB4 discontinuation in transition cohort
Univariate 
analyses
HR
P value Multivariate model
HR
P value
RA patients (N=433)
Age, years 1.01 (0.99 to 1.04) 0.29
Gender, female vs man 1.19 (0.61 to 2.29) 0.61
Disease duration, years 0.94 (0.90 to 0.99) 0.011
ENB duration, ≤1 vs >1 yr 0.39 (0.21 to 0.73) 0.004 0.37 (0.18 to 0.77) 0.008
ENB dose interval, days 0.90 (0.83 to 0.98) 0.014
csDMARD use, yes vs no 0.56 (0.30 to 1.03) 0.061
DAS28-CRP (N=407) 1.59 (1.22 to 2.09) 0.001
TJC (N=407) 1.05 (0.98 to 1.14) 0.18
SJC (N=407) 1.07 (0.96 to 1.19) 0.25
PGA, VAS 0-100 (N=369) 1.02 (1.01 to 1.04) 0.007 1.02 (1.00 to 1.03) 0.036
CRP, mg/L (N=410) 1.02 (1.01 to 1.03) <0.001 1.02 (1.01 to 1.03) 0.004
Univariate 
analyses
HR
P value Multivariate model
HR
P value
PsA patients (N=128)
Age, years 1.00 (0.95 to 1.06) 0.91
Gender, female vs man 1.35 (0.38 to 4.80) 0.64
Disease duration, years 0.97 (0.88 to 1.07) 0.54
ENB duration, ≤1 vs >1 yr 0.11 (0.03 to 0.39) 0.001 0.17 (0.03 to 0.84) 0.03
ENB dose interval, days 0.96 (0.83 to 1.11) 0.57
csDMARD use, yes vs no 1.35 (0.39 to 4.66) 0.64
DAS28-CRP (N=114) 3.24 (1.68 to 6.26) <0.001
TJC (N=114) 1.19 (1.02 to 1.38) 0.03
SJC (N=114) 1.91 (1.47 to 2.49) <0.001
PGA, VAS 0-100 (N=96) 1.03 (1.00 to 1.07) 0.08
CRP, mg/L (N=120) 1.03 (0.99 to 1.08) 0.16
axSpA patients (N=64)
Age, years 0.98 (0.94 to 1.03) 0.44
Gender, female vs man 1.56 (0.39 to 6.26) 0.53
Disease duration, years 0.94 (0.86 to 1.02) 0.14
ENB duration, ≤1 vs >1 yr 0.22 (0.06 to 0.83) 0.025
ENB dose interval, days 0.79 (0.57 to 1.08) 0.14
CRP, mg/L (N=47) 0.99 (0.87 to 1.12) 0.87
BASDAI (N=54) 1.22 (0.92 to 1.62) 0.16
Questionnaire subgroup 
(N=168)†
BMQ necessity score 1.06 (0.87 to 1.28) 0.59
BMQ concern score 1.11 (0.91 to 1.35) 0.31
BMQ differential 0.98 (0.85 to 1.12) 0.73
SETS positive score 1.04 (0.58 to 1.85) 0.90
SETS negative score 1.35 (0.95 to 1.90) 0.09
CEQ credibility score 0.94 (0.86 to 1.04) 0.23
CEQ expectancy score 1.00 (0.89 to 1.12) 0.98
ASES pain score 0.34 (0.16 to 0.71) 0.004
ASES symptom score 0.34 (0.16 to 0.69) 0.003
Data presented as HR (95%CI). Cox regression analyses stratified by diagnosis. 
ENB treatment duration was dichotomised, because the categories “<0.5 year” and “0.5-1 year” were combined due to similar 
SB4 discontinuation rates in all 3 diagnosis subgroups. 
P values <0.10 are marked bold and were included in the multivariate analysis for RA and PsA using listwise deletion, since 
missings in baseline characteristics were considered at random. †Few items were missing in the set of questionnaires (1-5% 
missing per outcome).
A multivariate model was not made in this subgroup due to the low event rate of SB4 discontinuation (15 of 168 patients).
axSpA, axial spondyloarthritis; ASES, Arthritis Self-Efficacy Scale; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; 
BMQ, Beliefs about Medication Questionnaire; CEQ, Credibility/Expectancy Questionnaire; CRP, C-reactive protein; csDMARD, 
conventional synthetic Disease-Modifying Anti-Rheumatic Drug; DAS28-CRP, 28-joint count Disease Activity Score using 
CRP; ENB, originator etanercept; HR, hazard ratio; PGA, patient global assessment of disease activity; PsA, psoriatic arthritis; 
RA, rheumatoid arthritis; SB4, biosimilar etanercept; SETS, Stanford Expectations of Treatment Scale; SJC, swollen joint count; 
TJC, tender joint count; VAS, visual analogue scale (0-100 mm); yr, years. 
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Effectiveness
In the transition cohort, disease activity measures were similar between baseline and month 
6: CRP 1 [p25-p75: 0-5] versus 1 [p25-p75: 0-6] mg/L (p=0.13), DAS28-CRP 1.9 [p25-p75: 1.5-2.6] 
versus 1.9 [p25-p75: 1.4-2.6] (p=0.99) and BASDAI 3.1 [p25-p75: 1.8-5.4] versus 3.3 [p25-p75: 
1.9-5.3] (p =0.25). Compared with the historical cohort, the transition cohort had a smaller 
decrease in CRP (adjusted diff 1.8 (95%CI: 0.3 to 3.2)) and DAS28-CRP (adjusted diff 0.15 (95%CI: 
0.05 to 0.25)) over six months treatment (Table 4).
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Discussion 
To our knowledge, this is the first controlled cohort study evaluating non-mandatory 
transitioning from ENB to SB4 using a specifically-designed communication strategy to 
counter nocebo and attribution effects. Our study shows a near optimal acceptance rate of 
99% and an acceptable persistence rate of 90% at month 6. 
Compared with the historical cohort, our transition cohort had a slightly lower persistence 
rate and smaller decreases in CRP and DAS28-CRP after six months treatment. We postulate 
two explanations for this. Firstly, we found significantly more subjective health complaints as 
reason for SB4 discontinuation. Although it is challenging to demonstrate, we presume that 
the higher rate of subjective health complaints in the transitioning cohort is nocebo-related. 
Nocebo and attribution effects occur mainly in the first months after a change in treatment 
and in our study only the transition cohort experienced a change at baseline (i.e. different 
device). Secondly, the small differences might well be explained by calendar time bias. It is 
likely that in 2016 (at the time of the transition cohort) treatment was more strongly adherent 
to the “treat-to-target” principle than in 2014 (at the time of the historical cohort). According 
to the European League Against Rheumatism (EULAR) 2016 update, treatment should be aimed 
at reaching a target of sustained remission or low disease activity. If the treatment target is 
not achieved, switching to another bDMARD should be considered.24 This “treat-to-target” 
strategy is inseparably linked to lower drug survivals of individual bDMARDs and lower disease 
activity outcomes. Of note, the persistence rate of CT-P13 after mandatory transitioning in the 
DANBIO registry was also slightly lower than for REM in the historical cohort.5 Whatever the 
cause may be, we interpret the observed small differences relative to the historical cohort as 
not being clinically relevant. 
The acceptance rate of SB4 in this study is higher than that of CT-P13 in our first transitioning 
study (BIO-SWITCH study: acceptance rate 88%).25 The persistence rate of SB4 is also higher 
compared to results from previously published studies on non-mandatory transitioning from 
REM to CT-P13 (persistence rates varying from 76% at month 69, 74% at week 348 and 72% 
at month 126). Although SB4 and CT-P13 are biosimilars of 2 different TNF inhibitors (ENB 
versus REM), we hypothesise that the higher acceptance and persistence rates of SB4 could 
be attributed to the implementation of the structured communication strategy prior to the 
initiation of the transition to SB4. The strategy might have positively influenced patients’ 
expectations on transitioning to a biosimilar thereby reducing the occurrence of nocebo 
and attribution effects and consequently the chance of discontinuing SB4 due to subjective 
health complaints. Also, the different administration route might have reduced the possibility 
of groupthink effects.26 In our hospital, groups of patients received their infliximab infusions 
together in a room for years. When a patient restarted REM treatment after the transition, 
other patients observed this, potentially leading to the groupthink effect that CT-P13 is inferior 
and the desire to restart REM. These effects could not have occurred after the transition to 
SB4, since it is administered subcutaneously at home. And physicians might have had more 
confidence during the second transition project compared to the first.
Beyond that, we showed that non-mandatory transitioning using a specifically-designed 
communication strategy resulted in similar acceptance and persistence rates of SB4 compared 
to mandatory transitioning in the DANBIO registry.27
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Strengths of our study include that we evaluated the effects of non-mandatory transitioning 
in a large cohort of RA, PsA and axSpA patients in daily practice and that we were able to use 
a historical control group. Another strength is the detailed description of our implemented 
communication strategy. In our opinion, the way in which a transition is executed largely 
determines the acceptance and persistence rates and should be available for readers. Also, 
we added a set of questionnaires at baseline to offer insight into patients’ expectations on 
transitioning to a biosimilar. Patients who completed the questionnaires had stronger 
positive than negative expectations on transitioning to a biosimilar, which might be the 
result of our used communication strategy. Patients’ expectations were not associated with 
SB4 discontinuation after six months, but lower self-efficacy and shorter ENB treatment 
duration were. These seem plausible determinants, based on the fact that other studies 
also demonstrated self-efficacy to be negatively correlated with disease-related variables 
in RA28,29 and on the well-known association between longer treatment duration and higher 
persistence (healthy survivor bias). However, identifying specific determinants of biosimilar 
discontinuation turned out to be of less clinical importance since the acceptance and 
persistence rates of SB4 were already near optimal in this study. 
A limitation of our study is the non-randomised controlled design. We however controlled for 
important determinants of biosimilar discontinuation and a full scale randomised controlled 
trial was not feasible to perform. Also, nearly half of the patients in the “questionnaires” group 
did not return the questionnaires. Completing questionnaires at home and returning them in a 
self-addressed envelope takes a little effort which some patients may have not wanted to take 
or simply have forgotten to take. It could also be speculated that many patients felt no real 
incentive to return them, because the underlying reason of the questionnaires (investigating 
if treatment expectations might be associated with SB4 discontinuation) was not explained in 
depth to control for a possible priming effect of the questions with regard to nocebo.
Conclusion
Non-mandatory transitioning from ENB to SB4 using a specifically-designed communication 
strategy showed a slightly lower persistence rate and smaller decreases in disease activity 
compared with a historical cohort, but these differences were considered as not being 
clinically relevant. Furthermore, the acceptance and persistence rates of SB4 in our transition 
cohort were similar to those of mandatory transitioning. Since mandatory transitioning to a 
biosimilar is not acceptable in many countries, the use of a communication strategy which 
might optimise acceptance and persistence rates of non-mandatory transitioning seems 
attractive.
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External communication
Two information techniques were used in the patient information letter:1
- Positive framing: instead of calling SB4 a cheap version of originator etanercept, the reason 
of the transition was phrased as “Biosimilar etanercept has the same price as originator 
etanercept, but has higher discounts and is associated with less injection site reactions”. 
- Tailored information: a short letter describing why and how the hospital is going to transition 
signed by the patients’ treating rheumatologist. The letter was send simultaneously to all 
ENB-treated patients followed by a national news item on television the next day. Also, trained 
pharmacy technicians were available to answer questions of patients according to the Q&A 
file by telephone. The aim of this pro-active transparent approach was to prevent negative 
rumours in the hospital and society. 
Produce instructional materials 
Both materials for patients (i.e. patient information letter, biosimilar leaflet and instruction 
movie on how to inject) and personnel (i.e. process flow diagram, Q&A file and communication 
script in pharmacy) were reviewed by the steering group members until consensus was 
reached. The materials that we developed are now available online as part of the “NVZA 
toolbox biosimilars” of the Dutch Association for Hospital Pharmacists.2 Also, other supporting 
materials are available online (e.g. Q&A files on biosimilars of European Commission3 and 
International Association of Patient Organisations4).
Set timeframes for achieving goals
A start date (June 15, 2016) was scheduled and the goals of the transition project were defined 
(acceptance rate >90%, persistence rate >75% at month 6). The number of transitioning 
patients per week was estimated and accordingly sufficient staff capacity was employed (i.e. 1 
additional full-time equivalent (FTE) for pharmacy technicians during the first four weeks for 
answering questions). Regular evaluation moments with the steering group were scheduled 
with frequency decreasing over time (day 1, day 2, day 7, day 21, day 61, day 120 and day 180). 
Fixed agenda items were: 
- How do patients (and social media) react on the request to transition?   
- How many patients declined to transition and for what reasons? 
- Are adjustments necessary in the communication provided by medical staff? 
- Are the pharmaceutical care and logistics (e.g. injection instructions, purchase, delivery) in 
the pharmacy optimal?
- How many patients discontinued treatment with the biosimilar and why? 
Evaluate outcomes
Dutch regulatory guidelines recommend monitoring of patients who transition treatment to 
a biosimilar. As part of usual care, our digital pharmacy system collects patient- and treatment 
characteristics. During the transition, the pharmacist analysed these data monthly to provide 
an overview of the acceptance and persistence rates. Additionally, research assistants were 
employed to collect data on disease activity during follow-up providing all required data for 
our observational cohort study (BIO-SPAN). 
With our planned strategy both the intended acceptance and persistence rates were achieved 
and no modifications were made during the transition. Our strategy (characterised by a 
tight schedule, uniform communication, strict protocols and relatively little time and effort 
of medical staff) may serve as a template for other hospitals that consider non-mandatory 
transitioning to a biosimilar. 
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Supplementary file 1. Description of implemented communication strategy 
In 2015, the Sint Maartenskliniek Nijmegen, the Netherlands transitioned treatment from 
originator infliximab (REM) to biosimilar infliximab (CT-P13). Taking lessons from this 
transition into account, a structured communication strategy was applied in June 2016 
when the hospital initiated its second transition project from originator etanercept (ENB) to 
biosimilar etanercept (SB4). The components of this communication strategy are explained in 
detail below.
Form a multi-stakeholder steering group
Firstly, a multi-stakeholder steering group was formed. The group consisted of a project leader, 
pharmacist, rheumatologist, communication officer and a member of the board of directors. 
Patient representatives were also asked for their advice on the implementation plan. 
Use uniform communication
Communication was divided into two components:
Internal communication
It is important that all involved personnel (i.e. rheumatologists, pharmacists, resident 
physicians, pharmacy technicians, specialised nurses and doctor assistants) communicate 
uniformly about the transition. Therefore, 2 types of communication were designed:
- Content communication 
All healthcare providers working at the departments of rheumatology and pharmacy 
(including nurses, doctor assistants, secretaries) were informed about the planned transition 
from ENB to SB4. A 2-hour soft-skills training was provided by a communication officer to 
employees who communicated with patients about the decision to transition to a biosimilar 
(pharmacy technicians and rheumatologists) and the decision to discontinue a biosimilar 
(rheumatologists), since it was estimated that their gained knowledge would result in higher 
acceptance and persistence rates of the biosimilar. Since nurses were not directly involved in 
biosimilar treatment decisions, we estimated that their participation in the soft-skills training 
would not be necessary. In the soft-skills training, 2 major aspects were addressed by role 
plays. Firstly, how to act if a patient has doubts about transitioning to a biosimilar (e.g. do not 
try to convince a patient immediately, but take time to listen and ask questions). And secondly, 
how to assuage patient concerns regarding the effectiveness and safety of a biosimilar and 
how to act if a patient has subjective health complaints (e.g. discuss the potential occurrence 
of nocebo and attributions effects, suggest a “wait-and-see” strategy instead of restarting the 
originator). Additionally, the agreement was made that rheumatologists would discuss each 
patient who experiences health complaints after the transition in a weekly outpatient clinic 
meeting. All answers on potentially emerging questions were documented in a “questions and 
answers” (Q&A) file that had to be used by all healthcare providers working at the departments 
of rheumatology and pharmacy. 
- Process communication
A clear division of tasks was set up by the steering group and a flow diagram was designed to 
provide an overview of the final implementation process. 
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Supplementary file 2. Questionnaire outcomes at baseline in “questionnaires” group of transition cohort
Transition cohort
N=168
BMQ
Necessity beliefs (5-25)# 20 (3) 
Concern beliefs (5-25)# 14 (3) 
Necessity–concerns differential (-20 till +20)‡ 6 (4) 
Attitudinal profiles*
   Skeptical 
   Indifferent 
   Ambivalent 
   Accepting 
2 (1)
2 (1)
83 (51)
77 (47)
SETS
Positive expectancy score (1-7)# 5.2 (0.9) 
Negative expectancy score (1-7)# 3.2 (1.4) 
CEQ
Credibility score (3-27)# 18 (5) 
Expectancy score (3-27)# 20 (5) 
ASES 
Pain (1–5)# 3.4 (0.7) 
Symptoms (1–5)# 3.6 (0.6) 
Data presented as mean (SD) unless otherwise noted. *Number (%).
Almost no items were missing in the set of questionnaires (1-5% missing per outcome); thus imputation was deemed 
unnecessary.
#Higher scores indicate stronger beliefs, stronger expectancy, stronger credibility/expectancy, stronger self-efficacy 
concerning pain or symptoms. 
‡Differential = necessity score minus concern score.
ASES, Arthritis Self-Efficacy Scale; BMQ, Beliefs about Medication Questionnaire; CEQ, Credibility/Expectancy Questionnaire; 
SETS, Stanford Expectations of Treatment Scale.
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Chapter 9
Summary and general discussion
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Summary
The aim of this thesis is to explore possibilities to optimise treatment with biological disease-
modifying anti-rheumatic drugs (bDMARDs) of inflammatory rheumatic diseases in daily 
practice. In chapter 2, 4, 5 and 6 we describe the predictive value of biomarkers for clinical 
response after starting or tapering of bDMARDs in rheumatoid arthritis (RA), in chapter 3 
we describe the feasibility of tapering of a group of bDMARDs (non-tumour necrosis factor 
inhibitors (non-TNFi’s)) in RA, and in chapter 7 and 8 we present the results of open-label 
transitioning treatment from a bDMARD to a biosimilar in RA, psoriatic arthritis (PsA) and axial 
spondyloarthritis (axSpA). In summary, 4 main findings can be derived from the chapters of 
this thesis.   
Main finding I: No strong predictors of clinical response after respectively starting or 
tapering of a bDMARD were identified in RA patients
We have not identified a biomarker that can predict individual treatment response after 
respectively starting or tapering of a bDMARD with sufficient predictive value to be used in 
the individual RA patient. The results of the individual studies are summarised below.
In chapter 2, we systematically reviewed all prospective studies with a predefined tapering 
protocol to provide an overview of the investigated biomarkers for predicting successful 
dose reduction or discontinuation of bDMARDs in RA. Of 3,029 non-duplicate articles initially 
searched, 16 articles regarding 15 cohorts were included in our study. Overall, 17 biomarkers 
were studied multiple times for the prediction of successful dose reduction and 33 for the 
prediction of successful discontinuation of a bDMARD. A biomarker was classified as “potential 
predictor” if the univariate association was either strong (odds ratio or hazard ratio >2.0 or <0.5) 
or statistically signiﬁcant. Biomarkers that were defined in ≥75% of the studies as potential 
predictor were regarded as “predictor”. We identified only 3 biomarkers as predictor in just 2 
studies: higher adalimumab trough level for successful dose reduction; lower Sharp/van der 
Heijde erosion score and shorter symptom duration at the start of a bDMARD for successful 
discontinuation. The strength of the evidence is limited by the low quality of included studies 
and the likelihood of multiple testing and reporting bias.
In chapter 4, we investigated the added predictive value of serum baseline calprotectin 
(S100A8/A9) for clinical response to anti-TNF treatment (adalimumab or etanercept) and 
assessed its predictive value for clinical response after tapering TNFi in 2 longitudinal RA 
studies: the Biologic Individual Optimized Treatment Outcome Prediction [BIO-TOP] study 
and the Dose REduction Strategies of Subcutaneous TNF inhibitors [DRESS] study. We 
demonstrated that baseline serum calprotectin has some predictive value for clinical response 
to treatment with a TNFi (area under the receiver operating characteristic curve (AUC) for 
predicting European League Against Rheumatism (EULAR) good response of 0.61 (95% CI: 
0.50 to 0.71)), although it has no added value to other clinical factors, such as DAS28-CRP. In 
patients with low disease activity, serum calprotectin was not predictive for clinical response 
after tapering anti-TNF treatment. Thus, serum calprotectin does not seem to be a clinically 
useful baseline biomarker for individually tailored treatment in RA.
In chapter 5, we aimed to elucidate the mechanism behind the much lower clinical response 
to golimumab after adalimumab failure found in the GO-AFTER trial.1 We measured cross-
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sectionally the ex-vivo effects of adalimumab, etanercept and golimumab on cytokine 
production of IL-1β, IL-6 and TNFα in RA patients included in the BIO-TOP study. We discovered 
that the absolute changes in cytokine concentrations after inhibition by golimumab or 
adalimumab were all significantly correlated (rs 0.52-0.99, p<0.001). These correlations were 
much lower or non-significant between etanercept and either golimumab or adalimumab. 
The high similarity between ex-vivo inhibition of cytokine production by golimumab and 
adalimumab may explain the previously found inferior treatment response to golimumab 
after adalimumab failure. This may suggest that patients who are non-responsive to 
adalimumab should preferably not switch to golimumab and vice versa. Furthermore, these 
results lend support to the concept of using ex-vivo drug-inhibited cytokine production as a 
test for in-vivo efficacy of bDMARDs.
In chapter 6, we subsequently investigated ex-vivo drug-inhibited cytokine production 
before the start of treatment with a bDMARD as a predictor of individual treatment response. 
In the BIO-TOP study, RA patients >18 years, treated in the Sint Maartenskliniek who were 
going to start with or switch to a bDMARD (abatacept, adalimumab, etanercept, rituximab 
and tocilizumab) were included. In total, 307 baseline samples with 6-month clinical outcome 
data were collected (abatacept n=21, adalimumab n=56, etanercept n=112, rituximab n=86 
and tocilizumab n=32). In 120 of 307 (39%) cases starting a bDMARD resulted in EULAR good 
response at month 6. Baseline characteristics which showed predictive value in this study 
were in line with previous studies (disease activity score in 28 joints using C-reactive protein 
(DAS28-CRP) for all bDMARDs2, rheumatoid factor (RF) for rituximab3 and anti-citrullinated 
peptide antibodies (ACPA) for abatacept4), lending validity to our study. In the ex-vivo cytokine 
analysis, 4 of 64 (6%) tests showed some predictive value (i.e. AUC confidence interval 
contained no 0.50). This is a low number, since it is close to the 1 in 20 chance of test positivity 
due to chance. Additionally, we showed that all 4 tests have no added predictive value to 
clinical factors routinely measured in RA, such as DAS28-CRP. Thus, our pragmatically designed 
ex-vivo assay is unable to help prediction of treatment response to bDMARDs in daily practice.
Main finding II: Tapering of abatacept and tocilizumab in daily practice is feasible and 
safe
Dose reduction of TNFi’s in RA patients has proven to be feasible and safe5, but data on 
tapering of non-TNFi’s are scarce. Therefore, we conducted a retrospective controlled cohort 
study (Study ON Abatacept and Tocilizumab Attenuation [SONATA]) to evaluate the feasibility, 
effectiveness and safety of tapering of abatacept (a CTLA4-Ig fusion protein) and tocilizumab 
(an anti-IL-6 receptor antibody) in RA patients in daily practice and described the results in 
chapter 3. RA patients who were treated with abatacept or tocilizumab ≥6 months with 
DAS28 <3.2 were included. Four groups were identified: abatacept dose reduction, abatacept 
usual care, tocilizumab dose reduction and tocilizumab usual care. Tapering entailed stepwise 
dose reduction or interval prolongation and was attempted in 13 of 28 (46%) abatacept-
treated patients and 64 of 91 (70%) tocilizumab-treated patients. At 12 months, 3 of 11 (27%, 
95% CI: 6% to 61%) abatacept-treated patients and 20 of 48 (42%, 95% CI: 28% to 57%) 
tocilizumab-treated patients were successfully tapered. Mean change in DAS28 at month 
6 and 12 was not significantly different between the groups and safety was comparable. In 
conclusion, abatacept and tocilizumab tapering seems feasible and clinically non-inferior to 
full dose continuation. However, numbers of patients in whom tapering was attempted were 
suboptimal possibly due to the combination of incomplete implementation of tapering in 
earlier years and hesitation of physicians and patients since abatacept and tocilizumab were 
reserved for RA patients being refractory to TNFi’s.
Main finding III: In open-label transitioning, discontinuation of a biosimilar due to 
subjective health complaints might be caused by nocebo and/or incorrect causal 
attribution effects
In July 2015, 4 departments of rheumatology in the Netherlands (Sint Maartenskliniek 
Nijmegen, Maartenskliniek Woerden, Radboud University Medical Center Nijmegen and 
Rijnstate Arnhem) transitioned treatment from originator infliximab (REM) to biosimilar 
infliximab (CT-P13). In total, 196 of 222 (88%) REM-treated patients agreed to transition 
to CT-P13 of whom 192 patients (75 RA, 50 PsA, 67 axSpA) were included in a multicentre 
prospective cohort study (Biosimilar of Infliximab Options, Strengths and Weaknesses of 
Infliximab Treatment CHange [BIO-SWITCH]). In chapter 7, we present the 6-month results 
of this study. In the great majority of patients, REM could be open-label transitioned to CT-
P13 without changes in effectiveness, (anti-) infliximab levels and safety. However, one-fourth 
of patients discontinued CT-P13 during 6 months follow-up, mainly due to an increase in the 
subjective features of the tender joint count and the patients’ global assessment of disease 
activity and/or subjective adverse events (AEs). This substantial discontinuation rate of CT-P13 
due to subjective health complaints was also found in other open-label studies.6,7 In our view, 
the higher discontinuation rate in open-label studies compared to the blinded trial8 can be 
explained by the awareness of both physicians and patients of the transition to the biosimilar. 
This awareness might induce negative expectations about transitioning to a biosimilar, 
resulting in negative symptoms during treatment (nocebo effect) and/or the attribution of 
unrelated symptoms to the transition (incorrect causal attributions).9,10 Our hypothesis that 
nocebo and/or incorrect attribution effects might result in an increased discontinuation rate 
due to subjective health complaints seems relevant for the implementation of open-label 
transitions to other biosimilars, since it has been showed that these effects can be minimised 
by good informational and educational practices.11
Main finding IV: Acceptance and persistence rates of a biosimilar to open-label non-
mandatory transitioning can be optimised by using a structured communication 
strategy 
Taking lessons from the BIO-SWITCH study into account, we developed a structured 
communication strategy for the transition to a biosimilar including proper patient 
information and healthcare providers’ education. We hypothesised that this strategy might 
positively influence the expectations of patients about the transition to a biosimilar, resulting 
in optimal acceptance and persistence rates (by preventing possible nocebo and attribution 
effects). We set out to study this hypothesis by applying our communication strategy during 
the open-label non-mandatory transition from originator etanercept (ENB) to biosimilar 
etanercept (SB4) in the Sint Maartenskliniek Nijmegen in June 2016. Drug survival and 
effectiveness of the transition cohort were compared with a historical cohort (ENB-treated 
patients in June 2014) in the BIOsimilar switch, Study on Persistence and role of Attribution 
and Nocebo [BIO-SPAN] (chapter 8). In total, 635 of 642 (99%) ENB-treated patients agreed 
to transition to SB4 of whom 625 patients (433 RA, 128 PsA, 64 axSpA) were included in the 
transition cohort. Additionally, 600 patients were included in the historical cohort of whom 
401 (67%) also had been included in the transition cohort. Crude 6-month persistence rates of 
SB4 and ENB were: 90% (95%CI: 88% to 93%) versus 92% (95%CI: 90% to 94%). The transition 
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cohort had a significantly higher relative risk of discontinuation (adjusted hazard ratio 1.57, 
95%CI: 1.05 to 2.36) and a smaller decrease in DAS28-CRP (adjusted diff 0.15 (95%CI: 0.05 to 
0.25)) and CRP (adjusted diff 1.8 (95%CI: 0.3 to 3.2)) over 6 months compared with the historical 
cohort. The observed small differences relative to the historical cohort were interpreted as not 
clinically relevant and might well be explained by calendar time bias (more “treat-to-target” 
treatment in 2016 compared to 2014). Both the acceptance and persistence rate of SB4 in this 
study are higher than that of CT-P13 in our first transition study. Although SB4 and CT-P13 are 
biosimilars of 2 different TNFi’s (ENB versus REM), we hypothesise that the higher acceptance 
and persistence rates of SB4 could be attributed to the implementation of the structured 
communication strategy prior to the initiation of the transition to SB4. Also, physicians 
might have had more confidence during the second transition project compared to the first. 
Furthermore, the acceptance and persistence rates of the non-mandatory transition to SB4 
in the BIO-SPAN study were similar to the rates seen after the mandatory transition to SB4 in 
the DANBIO registry.12 Since mandatory transitioning is not acceptable in daily practice in the 
Netherlands and many other countries, using a specifically-designed communication strategy 
which might optimise acceptance and persistence rates of non-mandatory transitioning 
seems attractive. 
General discussion
Methodological considerations
The 7 articles which are part of this thesis are derived from 1 systematic review, 4 cohort studies 
and 1 randomised controlled trial. In total, 1,514 patients with an inflammatory rheumatic 
disease were included (BIO-TOP study n=277, DRESS trial tapering arm n=102, SONATA study 
n=119, BIO-SWITCH study n=192 and BIO-SPAN study n=824), although some patients might 
have participated in more than 1 study. These non-selective, large and heterogeneous cohorts 
allow translation of the results to daily practice. During the execution of our studies, we 
encountered some important methodological issues. These concerned general challenges in 
respectively performing prediction research and transitioning treatment to a biosimilar and 
will be discussed in more detail below. 
Personally, I did not realise at the beginning of my PhD project that many claimed predictors 
are based on false positive findings.13 The probability that a research finding is indeed true 
depends on the pre-study probability of it being true, the statistical power and the level of 
statistical significance.14 In inflammatory rheumatic diseases, the pre-study probability of a 
marker to be a predictor of clinical response is unfortunately very low due to several reasons. 
Firstly, the pathobiology of these diseases is complex and the effects of bDMARDs are not 
fully known. Currently investigated markers are mostly related to disease activity (e.g. 
CRP, calprotectin (S100A8/A9), multibiomarker disease activity (MBDA) score) or treatment 
(bDMARD trough levels or anti-bDMARD antibodies), while prediction studies actually aim to 
investigate if a bDMARD will be effective in an individual patient. Estimating which marker 
might be a predictor of this concept is challenging. 
Secondly, several prognostic markers have been discovered (e.g. RF, ACPA) and composite 
disease activity scores (e.g. DAS28-CRP) are already being used in daily practice. This entails 
that the chance of a marker to have added value to the current equiped practice (“ceteris 
paribus” – holding other things constant) is less than in the past (“law of diminishing returns”).15 
Thirdly, classification of clinical response is not as simple as it sounds. Outcome measures in 
RA prediction studies are usually based on changes in the DAS28 compared with baseline (i.e. 
EULAR response criteria, flare criteria). This might trouble prediction by a laboratory marker, 
since DAS28 components (especially tender joint count and patient global assessment of 
disease activity) can be confounded by many other factors than inflammatory RA activity. In 
literature, this is often referred to as “misclassification of response”.
Finally, we presume that the importance of the designing phase is not always realised. 
Not systematically reviewing existing literature and not accurately performing the assay 
validation process16 both diminish the pre-study probability of a marker to be a predictor of 
clinical response. Looking back, the use of our ex-vivo cytokine production assay in chapter 5 
and 6 might serve as an example of this. Before the inititiation of the study, possible external 
factors influencing the assay were not systematically thought-out in detail which may have 
resulted in an unfavourable “effect-to-bias” ratio.17 
Thus, predictive RA research has a very low pre-study probability of finding a biomarker. How 
is it than possible that the majority of published scientific articles report positive predictive 
values? 
Firstly, interpretation of predictive research is often solely based on the presence or absence 
of statistically significant differences. However, a p-value less than 0.05 is not per se clinically 
relevant. Any association, no matter how tiny, can produce a significant p-value if the sample 
size or measurement precision is high enough.18 Minimal summary measures of a clinically 
relevant predictive value are defined as: sensitivity and specificity >0.719, AUC >0.719 and odds 
ratio or hazard ratio >2.0 or <0.520. However, these association measures are rarely reported. 
Secondly, many findings are false positive due to multiple testing and/or reporting bias. 
Most prediction studies investigate the predictive value of several markers simultaneously, 
thereby increasing the probability of getting a signicant result simply due to chance. There 
are diverse methods to correct for multiple testing, but these are rarely applied.21 Reporting 
bias arise when the dissemination of research findings is influenced by the direction of results. 
Statistically significant “positive” results are more likely to be reported and more likely to be 
published.22 This is prejudicial, since “negative” results are as important as “positive” results 
when evaluating the totality of the evidence of a biomarker in a systematic review. 
Finally, the predictive values of potential biomarkers are often not replicated in a separate 
cohort (also known as “replication crisis”).23 According to a 2016 poll of 1,500 scientists, 60% 
of them had failed to reproduce one of their own experiments.24 A potential reason for this 
lack of replication might be that researchers are afraid of turning a “positive” finding into 
a “negative” one. A well-known example is that of researchers of Amgen who could only 
replicate 6 of 53 (11%) landmark oncology findings for potential drug targets.25 Our systematic 
review also showed that no markers that were investigated in more than 2 separate studies 
turned out to be predictors.
Unfortunately, not only are many predictive research findings false, but furthermore a lot 
of true findings are not useful.26 In 2009, it has been estimated that at least 50% of research 
articles were unusable, which represented a waste of tens of billions of dollars.27 It is unrealistic 
to expect that all scientific research immediately yields useful findings for improving daily 
practice. Fundamental research is first necessary to generate ideas and theories which 
form the basis for subsequent preclinical studies and clinical trials. Clinical research, as the 
words indicate, should pursue clinical utility. This means that it should aim at accomplishing 
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a favourable change in decision-making in clinical care of patients. For clinical prediction 
research, a test has to fulfil 5 requirements to be able to demonstrate clinical utility (Table 1: 
adapted from van Herwaarden et al 201728). 
Table 1. Five requirements for a test to demonstrate clinical utility
1 A test needs to be a feasible, reliable and precise measure of the variable it is supposed to measure. 
2 A test should be strongly associated with a relevant clinical outcome, and thus result in a clearly 
larger or smaller post-test chance for the outcome it predicts. 
3 A test should provide additional information (result in a clearly larger or smaller post-test chance 
for the relevant clinical outcome) beyond history taking, physical examination and simple routine 
testing. 
4 The use of a test should result in other medical treatment and/or follow-up (the result should have 
consequences) and thereby better outcomes for patients. 
5 The use of a test should be cost-effective. 
An overall observation in our thesis was that step 1 is rarely accurately performed and step 
2 often lacks appropriate assocation measures and replication. However if the two steps are 
fulfilled, a test is not per se useful. To demonstrate clinical utility, a test has to fullfil step 3, 
4 and 5. In current practice, step 3 is often not performed and when it is it usually shows no 
added value of potential biomarkers. Step 4 is particularly difficult to fulfil for prediction of 
response to bDMARD treatment, since response is a short-term measurable outcome. During 
treatment, response can be positively influenced by glucocorticoid bridging and if treatment 
turns out to be ineffective after 3 months another bDMARD can be started. Step 5 is in most 
cases not useful to perform anymore since the test has failed to fulfil one of the previous 
requirements. Being aware of these 5 steps could withhold researchers from initiating clinical 
prediction studies with a low a-priori chance of obtaining a clinically useful biomarker. 
Looking at research in general, a shift from “high-quantity, low-quality” research to “low-
quantity, high-quality” research seems desirable. The implementation of such a shift is a 
big challenge. Upon the responsibility of researchers to perform well-evidenced research, 
the complex and interdependent actions of several stakeholders (i.e. institutional directors, 
medical ethical committees, funding agencies and journal editors) are of great influence. The 
current competative research climate (including the pressure to publish and the rewarding of 
flashy results) is sadly counterproductive for the goal of achieving high-quality research with 
high probabilities of finding “true” and clinically useful results. Research is often performed 
for arbitrary and particular needs of physicians (e.g. finish PhD thesis), researchers (e.g. gain 
promotion and/or increase H-index) and institutions (e.g. receive grants). In the last decade, 
several leading researchers in the field have expressed their concerns about the current 
research climate.29 Ben Goldacre (writer of the books “Bad Science” and “Bad Pharma”) 
cofounded the AllTrials campaign, which pursues that all trials are registered and have their 
full methods and results made public. The AllTrials petition has already been signed by 90,774 
people and 734 organisations.30 Other initiatives that may support the implementation of a 
well-organised research climate are underway.31 Examples of initiatives that could be taken 
by the 4 major stakeholders are represented below:
- Institutions could set (and monitor) standards for performing high-quality research.
Reforming current practice would be an investment for institutions, but they would be repaid 
by larger rewards in research output and effects. Institutions could enhance the knowledge 
and skills of their researchers by offering education in research methods and evidence-based 
medicine. They could involve patient research partners to prevent a potential mismatch 
between patients’ wishes and needs and the scientific focus in research.32 Academics with 
different backgrounds (e.g. physicians, epidemiologists, statisticians) could be stimulated to 
share their knowledge and jointly approve full study protocols. Researchers could be requested 
to replicate positive results in a separate cohort and to describe all analyses and results in 
full study reports. From this reports, journal articles could be derived. Having these standards 
in place would not yet be enough. Next, it is important to ensure that those standards are 
really met by monitoring the efforts. Monitoring might include rewarding (e.g. promotion or 
tenure) of individual researchers who deliver high-quality research findings. In my opinion, 
PhD guidelines can also focus more on quality instead of quantity. Gaining knowledge of all 
research aspects in combination with performing a high-quality study from the beginning till 
the end seems more useful to me than publishing as many articles as possible without being 
aware of the bigger research context.  
- Medical ethical committees could demand high-quality research. 
In addition of reviewing whether clinical research is ethical, medical ethical committees 
could assess the pre-study probability of finding “true” and clinically useful results. If the 
probability is low, they could reject the application or sent it back for revision. To ensure that 
medical ethical committees have the knowledge to carry out this additional task thoroughly, 
the inclusion of an epidemiologist in the committees is recommended. 
- Funders could reward high-quality research. 
The publication of a full study protocol before initiating a study and a full study report after 
completing the study could be enforced by funding agencies as a condition of grant payment. 
These rewards would further encourage institutions to perform high-quality research. 
- Journal editors could identify and publish high-quality research. 
Most high-impact journals have already taken initiatives in the last years to enhance the 
quality and transparency of research. For instance, they recommend researchers to use 
available reporting guidelines (e.g. Consolidated Standards of Reporting Trials (CONSORT) 
statement for randomised trials, Standards for Reporting Diagnostic Accuracy (STARD) 
guideline for observational studies, and Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement for systematic reviews).33 And they demand researchers 
to registrate their clinical trials online before initiation of the study. Registration enables 
to distinguish between prespecified analyses (“hypothesis-testing” research) and post-hoc 
data explorations (“hypothesis-generating” research). However, a survey revealed that only a 
third of journal peer reviewers routinely crosscheck manuscripts with trial registry entries.34 
That this crosschecking is essential has been demonstrated by the Centre for Evidence Based 
Medicine Outcome Monitoring Project (COMPARE) team which found that only 9 of the 67 (13%) 
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clinical trials published in the top 5 general medicine journals were “perfectly reported”.35,36 
The next initiative of journals could therefore be to improve their peer review process by 
comparing each submitted article with the trial registry entry, full study protocol and full 
study report. Any unacknowledged discrepancies should be addressed to the researchers. This 
investment in the peer review proces would be repaid by the publication of more high-quality 
studies resulting in increased numbers of citations and consequently a higher impact factor 
of the journal. 
Apart from the methodological issues in predictive research, we also encountered some 
challenges during the execution of our open-label non-mandatory transitioning studies.
As mentioned previously, we hypothesise that the awareness of both physicians and patients 
of the transition to the biosimilar might induce negative expectations resulting in negative 
symptoms during treatment (nocebo effect) and/or the attribution of unrelated symptoms 
to the transition (incorrect causal attributions).9,10 But is there any scientific evidence which 
points to the existence of the nocebo effect? And if so, is it possible to reduce the occurrence 
of the nocebo effect? 
Firstly, the term “nocebo” was introduced by Walter P. Kennedy in 1961 to denote the 
counterpart to the use of placebo.37 The underlying mechanisms are both psychological 
(conditioning and negative expectations) and neurobiological (role of cholecystokinin, 
endogenous opioids and dopamine).11 Nocebo effects can lead to poor treatment adherence 
or even discontinuation of treatment. A well-known example of the nocebo effect is the 
occurrence of muscle-related symptoms during treatment with statins (cholesterol-lowering 
drugs). The Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA) 
compared rates of AEs during a blinded randomised therapy phase when statin was compared 
with placebo with those during a non-blinded non-randomised therapy phase when patients 
were offered open-label statin using an identical follow-up procedure. It showed an excess 
rate of reported muscle-related AEs in the non-blinded phase when patients and (physicians) 
were aware that statin therapy was being used and similar rates between statin and placebo 
in the blinded phase.38 Another interesting finding was recently done by Tinnerman et al; they 
discovered that labelling an inert treatment as expensive medication led to stronger nocebo 
hyperalgesia than labelling it as cheap medication. Accompanying functional MRI data 
showed that expensive cream testers had more activity in the area of the brain that processes 
expectations (prefrontal cortex).39 This suggests that the testers were not just imagining and 
reporting more pain, they were actually feeling it. The results of these 2 studies help to assure 
that AEs are not necessarily related to a particular drug, but emphasise that awareness of AEs 
and value information can strongly affect therapeutic effects.
Secondly, it can be questioned how much information physicians should provide to patients 
about transitioning treatment to a biosimilar, since awareness of the transition might trigger 
the occurrence of nocebo effects. This question raises an important ethical issue: on one hand 
physicians have to inform patients transparently about their treatment (“right to know”) and 
on the other hand physicians have to minimise health risks for patients (“primum non nocere” 
– first do no harm). In case of open-label transitioning, these two fundamental rights seem to 
collide. In my opinion, patients should be informed about the transition to a biosimilar and 
should have the right to decline. Subsequently, physicians have the responsibility to optimally 
communicate (both verbally and non-verbally) about the transition to their patients. A 
nocebo-conscious physician should educate patients about the proven pharmacological 
equivalence of the originator and biosimilar and should counter any negative expectations 
that patients may already have. Later in this chapter, possibilities to respectively reduce and 
investigate nocebo effects in the context of transitioning to a biosimilar are discussed.    
Clinical implications
The following clinical implications can be derived from this thesis:
Aim at optimal treatment of individual patients by optimising the implementation of the “treat-
to-target” strategy
As mentioned earlier, prediction research has a lot of challenges to overcome before it might 
be successful in identifying a useful predictor for clinical response to treatment. Moreover, 
a modelling study recently showed that adding a biomarker to a disease activity guided 
tapering strategy of TNFi in RA only becomes cost-effective when it has a sensitivity and 
specificity of at least 86%.40 These predictive thresholds are extremely difficult to achieve for 
a test, questioning the major efforts that research groups put in finding a useful predictive 
biomarker. In contrast, employing a “treat-to-target” strategy (i.e. measuring disease activity 
and adjusting treatment accordingly) significantly improves clinical outcomes41 and is part 
of the EULAR treatment recommendations since 201042.  The implementation of the “treat-
to-target” strategy has been shown to be suboptimal in many clinical practices43, as also 
demonstrated by the suboptimal number of patients who tapered treatment with abatacept 
and tocilizumab in our cohort study (chapter 3). Several reasons might be formulated for the 
suboptimal use of “treat-to-target” in daily practice: insufficient knowledge about it, lack of 
personell and/or time and inappropriate instruments for monitoring of the disease activity. 
Lesuis et al have demonstrated that an intervention strategy aimed at rheumatologists can 
lead to improved adherence to tight control-based treatment and increased bDMARD dose 
optimisation in RA, PsA and axSpA patients.44 We hypothesise therefore that optimising the 
implementation of “treat-to-target” after starting a bDMARD (in patients who failed on 
csDMARD therapy) or tapering a bDMARD (in patients with low disease activity) has more 
potential for improving clinical outcomes in daily practice than continuing the search for a 
predictive biomarker to select patients in which starting or tapering of a bDMARD might be 
most effective.   
Reduce the occurrence of nocebo effects in patients who transition to a biosimilar 
Since non-informed transitioning to biosimilars is not acceptable in many countries45, 
the only way to reduce nocebo effects is by optimising the way in which the transition is 
communicated. In our second transition project (chapter 8), we therefore used a structured 
communication strategy, which included several information techniques that had previously 
been described in narrative reviews as being effective in reducing nocebo effects:11,46
• Positive framing: emphasise the desired therapeutic effects of the drug and the benefits 
that come along with it. Since a previous blinded trial had demonstrated that biosimilar 
etanercept (SB4) is associated with less injection site reactions than originator etanercept47 
the reason of the transition could be phrased as “Biosimilar etanercept has the same price 
as originator etanercept, but has higher discounts and is associated with less injection site 
reactions” instead of calling it a cheap version of originator etanercept. 
• Contextualised informed consent: this consists of tailoring the information about AEs 
to provide the most transparency with the least potential harm. We sent all ENB-treated 
patients simultaneously a short letter describing why and how the hospital was going to 
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transition signed by the patients’ treating rheumatologist. The letter was followed by a 
national news item on television the next day. Trained pharmacy technicians were available 
by telephone to answer questions of patients according to a “questions and answers” (Q&A) 
file. The aim of this pro-active uniform approach was to prevent negative rumours in society. 
• Healthcare providers’ education: healthcare providers should be aware that their own 
words and gestures can have a negative impact and should be educated in communication 
techniques.48 To achieve this, a 2-hour soft-skills training was provided by a communication 
officer to both rheumatology and pharmacy staff before the start of the transition project. 
In this training healthcare providers’ own believes of the transition to a biosimilar were 
discussed showing that the comfort of physicians with prescribing biosimilars varied. This 
finding was in line with surveys performed in physicians in other countries.49,50 Education 
and reassurance about biosimilars were provided. Secondly, physicians learned in role 
plays how to act if a patient has doubts about the transition to a biosimilar (i.e. do not try to 
convince a patient immediately, but take time to listen and ask questions).
• Patient education: approximately 75% of patients are unaware of or do not believe in the 
nocebo effect.51 Educating patients about the nocebo effect might avert negative outcomes.52 
During the soft-skills training healthcare providers learned in role plays how to explain the 
potential occurrence of nocebo and attributions effects to patients with subjective health 
complaints. 
Besides these information techniques, our communication strategy included a tight process 
schedule and strict protocols prepared by a multi-stakeholder steering group. Based on 
the higher acceptance and persistence rates in our second transition project (chapter 
8) compared to our first (chapter 7), I postulate that adequate communication between 
physicians and patients can reduce nocebo effects and is the determining factor of the success 
of transitioning to a biosimilar in daily practice.
Aim at optimal treatment for society by paying the lowest possible costs for bDMARDs 
High costs of bDMARDs are a threat to affordability and accessibility of these drugs. From 
socioeconomic perspective, it is therefore important to optimise the healthcare expenditure 
on bDMARDs. Costs of bDMARDs can be optimised by decreasing respectively the volume or 
the price of bDMARDs. An example of both strategies is provided below. 
- Taper bDMARD treatment to the lowest efficacious dose in patients with sustained remission.
Cost-effectiveness analyses of the DRESS study and Spacing of TNF-blocker Injections in 
Rheumatoid Arthritis Study [STRASS] have shown that disease activity guided tapering 
of adalimumab and etanercept in RA results in large cost savings and no or a small loss in 
quality of life (as reflected in Quality-Adjusted Life Years (QALYs)).53 Mean cost savings in the 
tapering arms were €12,280 (95% CI: €10,502 to €14,104) per patient per 18 months in the 
DRESS study54 and €8,440 (95% CI: €6,507 to €10,212) per patient per 18 months in the STRASS 
study55.  Thus, implementation of disease activity guided tapering of bDMARDs improves 
the cost-effectiveness of bDMARD treatment in RA. The same holds probably true for other 
inflammatory rheumatic diseases, but tapering studies in PsA and axSpA are still scarce.56
- Select bDMARDs (off-patent originator or biosimilar) with the highest discounts and 
transition treatment of patients accordingly. 
Currently, more than 40 biosimilar candidates are in development for the treatment of 
inflammatory rheumatic diseases.57 The introduction of these biosimilars enables price 
competition.58 The European Medicines Agency (EMA) does not designate biosimilars as 
interchangeable (i.e. the possibility of exchanging one drug for another drug that is expected 
to have the same clinical effect).45 This decision is rather taken at national level.59 In the 
Netherlands, the Dutch Society for Rheumatology (Nederlandse Vereniging voor Reumatologie, 
NVR), the Dutch Medicines Evaluation Board (College ter Beoordeling van Geneesmiddelen, 
CBG) and the Dutch Federation of Medical Specialists (Federatie van Medisch Specialisten, 
FMS) state that the transition between an originator and a biosimilar is permitted if patients 
are properly informed and adequate clinical monitoring is performed.60-62 This stance provides 
hospitals the opportunity to choose within each bDMARD category the bDMARD (off-patent 
originator or biosimilar) with the highest discount. Such a market strategy was performed by 
the Sint Maartenskliniek in 2016 when it transitioned from ENB to SB4.63 A working group of both 
rheumatologists and pharmacists was formed that defined for each inflammatory rheumatic 
disease which biosimilars were interchangeable with the off-patent originator. Secondly, 
pharmaceutical companies were invited to propose a partnership. This proposition included 
the combination of a multiyear price proposition and a project proposal for improvement 
of rheumatology care. Such a multiyear deal – if executed properly - has 3 advantages: a) it 
prevents the hospital from yearly spending a lot of time and effort in getting the bDMARD with 
the lowest costs, b) patients are not at risk for multiple transitioning between bDMARDs in a 
short period of time, c) co-creation of innovations means that the costs are not only lower but 
patients also benefit from the deal due to better quality of care. For all proposals the long-
term benefits/costs were calculated and the most favourable bDMARD was chosen.
Future research 
This thesis raises several interesting directions for further research: 
Examine how well a marker should be able to predict clinical response to be cost-effective 
compared to current bDMARD treatment 
If the required predictive thresholds for prediction of clinical response after starting bDMARD 
treatment are as high as for tapering bDMARD treatment (sensitivity and specificity ≥86%), 
it is questionable whether any marker will ever be able to reach these thresholds and 
correspondingly have added value for daily practice. Using Markov models based on data from 
the BIO-TOP study, predictor guided bDMARD treatment can be evaluated against current 
bDMARD treatment. For this strategy, a theoretical predictor (e.g. sensitivity 80%, specificity 
80%, costs €100 euro per test) should be used that determines the treatment decisions (i.e. 
start a bDMARD in patients with predicted good response and not start a bDMARD in patients 
with predicted bad response). 
Explore potential similarities in in-vivo clinical response within other bDMARD groups 
Although the increasing number of available bDMARDs can be grouped, within each bDMARD 
group some drugs are more equal than others.64 Recently, a second IL-6 receptor (IL-6R) 
inhibitor has been developed called sarilumab. According to the 2016 update of the EULAR 
recommendations, sarilumab and tocilizumab have overall similar efficacy and safety.65 
However, the efficacy of sarilumab after treatment with tocilizumab has not been addressed 
yet. With now two drugs within the anti IL-6R group, it can be hypothesised that the clinical 
responses to treatment with tocilizumab and sarilumab are strongly correlated with each 
other. A way to investigate this is by measuring the response to sarilumab in patients doing well 
on tocilizumab and in patients not responding (enough) to tocilizumab. Interpretation could 
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be that if the DAS28-CRP changes in both the “tocilizumab responder” group and “tocilizumab 
non-responder” group are >0.6 and significant different from zero, tocilizumab and sarilumab 
can be considered as IL-6R inhibitors with different clinical effects. It would then be rational 
to start sarilumab in patients who have failed for lack of efficacy on tocilizumab. On the 
other hand, if the DAS28-CRP changes in both groups are close to zero, with an upper limit 
of the confidence interval ≤0.6, tocilizumab and sarilumab can be considered as more or less 
interchangeable. This would mean that patients who fail on tocilizumab for lack of efficacy 
should perhaps not start sarilumab and that patients who respond to tocilizumab can switch 
to sarilumab in case of adverse events or pharmaco-economical reasons. 
Perform a N of 1 trial to investigate the effects of repeated blinded treatment cycles with 
respectively the originator and the biosimilar in patients who discontinued the biosimilar due to 
subjective health complaints 
In our practice, we discussed with some patients who discontinued a biosimilar (respectively 
CT-P13 or SB4) the possible occurrence of the nocebo effect. Most of them were interested 
in this phenomenon and were curious to know if the awareness of the transition might 
have indeed caused the complaints instead of the biosimilar itself. An ideal research design 
to investigate this would be a N of 1 trial. A patient would be treated blindly with 5 random 
ordered cycles (e.g. biosimilar-originator-biosimilar-originator-biosimilar) and the clinical 
response to each cycle would be documented. If the subjective health complaint does not 
occur again during treatment with the biosimilar, it is likely to be assigned to the nocebo 
effect in the open-label study. If the subjective health complaint occurs during treatment 
with both the originator and the biosimilar, it remains questionable if it is truly associated 
with the pharmacological effect of the drug. Since a patient knows that he/she is participating 
in a trial, he/she might be triggered to focus more on physical symptoms and report them. 
An example of this phenomenon is the increased subjective disease activity outcomes in both 
the originator and biosimilar arm compared to baseline in the NOR-SWITCH trial.8 And finally, 
if the subjective health complaint occurs only during the biosimilar cycles, it seems to be 
related to the biosimilar itself. We proposed this trial design to a few patients and they would 
be willing to participate. In theory, they agree with permitted non-information. Of note, the 
blinding of patients is hard to perform for subcutaneous bDMARDs, since the devices differ 
per brand. For this trial, effort should be invested in producing uniform devices containing 
respectively the originator and biosimilar drug. 
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Hoofdstuk 1: inleiding
Ontstekingsreuma is een verzamelnaam voor reumatische aandoeningen die gekenmerkt 
worden door langdurige gewrichtsontstekingen. Ongeveer 420.000 mensen in Nederland 
hebben een vorm van ontstekingsreuma. De meest voorkomende vormen zijn: reumatoïde 
artritis (RA), artritis psoriatica (PsA) en axiale spondyloartritis (axSpA).  
De behandeling van ontstekingsreuma, met name van RA, bestaat uit: 1) zo vroeg 
mogelijk starten van behandeling (“hit early”), 2) het combineren van reumaremmers 
(disease-modifying anti-rheumatic drugs, DMARDs) (“hit hard”), 3) frequent meten van de 
ziekteactiviteit, het opstellen van een behandeldoel en de behandeling aanpassen totdat het 
doel bereikt is (“treat-to-target”). 
Sinds eind jaren ’90 zijn de behandelmogelijkheden voor ontstekingsreuma toegenomen 
dankzij de komst van biologische DMARDs (biologicals). Dit zijn medicijnen waarvan de 
werkzame stof vervaardigd is door of afkomstig is van een levend organisme. Biologicals 
remmen de werking van ontstekingseiwitten (zoals tumor necrosis factor-alfa (TNFα), 
interleukine 6 (IL-6)) en afweercellen (zoals B- en T-cellen) in het lichaam. Behandeling 
met biologicals wordt gestart als traditionele reumaremmers (zoals methotrexaat) of 
ontstekingsremmers (zoals naproxen) niet voldoende effectief zijn. De meest voorgeschreven 
biologicals voor de behandeling van ontstekingsreuma behoren tot de groep van TNFα-
remmers. Voorbeelden hiervan zijn adalimumab, certolizumab pegol, etanercept, golimumab 
en infliximab. Daarnaast zijn er ook biologicals geregistreerd die andere aangrijpingspunten 
hebben zoals abatacept (CTLA4-Ig fusie eiwit), anakinra (IL-1 remmer), rituximab (anti-CD20 
monoklonaal antilichaam) en tocilizumab (anti-IL-6 receptor antilichaam).
Ondanks de toegenomen behandelmogelijkheden is de behandeling van ontstekingsreuma 
een uitdaging. Twee belangrijke uitdagingen worden hieronder toegelicht. 
Ten eerste kan het effect van biologicals op de ziekteactiviteit van een individuele patiënt 
(nog) niet worden voorspeld. Hoewel biologicals op groepsniveau even werkzaam zijn, 
verschilt het effect tussen patiënten. Bij sommige patiënten is de ene biological effectief en 
bij andere patiënten een andere biological. In de dagelijkse praktijk worden dus verschillende 
biologicals achter elkaar uitgeprobeerd totdat een biological is gevonden die goed werkt in 
een individuele patiënt (“trial-and-error”). Omdat de effectiviteit van biologicals pas na enkele 
maanden te beoordelen is, zullen slecht reagerende patiënten gedurende deze periode een 
hoge ziekteactiviteit hebben. Dit is nadelig, aangezien het pijn, beperkingen in het dagelijks 
leven en beschadiging van de gewrichten kan veroorzaken. Ter overbrugging worden slecht 
reagerende patiënten behandeld met snelwerkende prednisonachtige medicijnen. 
Het kunnen voorspellen van de effectiviteit van biologicals in individuele patiënten zou een 
vooruitgang in de behandeling van ontstekingsreuma betekenen. Dankzij de voorspelling 
zou meteen gestart kunnen worden met de biological met de grootste kans op goede respons 
waardoor snel een lage ziekteactiviteit wordt bereikt. Om het effect van biologicals vooraf 
te kunnen bepalen, dienen voorspellende biomarkers te worden gevonden. Biomarkers zijn 
indicatoren van een patiënt die objectief gemeten kunnen worden, zoals  leeftijd,  geslacht, 
uitslagen van bloedtesten en van beeldvormend onderzoek. 
Ten tweede zijn biologicals dure medicijnen, omdat het ontwikkelingsproces van een biological 
complex is. Mede door het toenemend gebruik van dure medicijnen stijgen de kosten van de 
gezondheidszorg. 
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De totale kosten van biologicals worden bepaald door de hoeveelheden biologicals die worden 
voorgeschreven en de prijs. Het voorschrijfvolume van biologicals kan onder andere worden 
verlaagd door het toepassen van dosisoptimalisatie. Dit houdt in dat in patiënten met een 
stabiele lage ziekteactiviteit de dosis van een biological in stapjes wordt verlaagd of de tijd 
tussen de injecties in stapjes wordt verlengd tot stop. Wetenschappelijk onderzoek heeft 
laten zien dat het op geleide van de ziekteactiviteit afbouwen van de dosering van biologicals 
leidt tot het maximale effect met zo min mogelijk bijwerkingen en kosten. Op basis van deze 
resultaten is dosisoptimalisatie opgenomen in de biological-richtlijn van de European League 
Against Rheumatism (EULAR) en van de Nederlandse Vereniging voor Reumatologie (NVR).
Voor de prijzen van biologicals geldt dat er grote onderlinge verschillen zijn. Daarnaast is in 
de afgelopen jaren het patent van een aantal biologicals verlopen. Dit betekent dat andere 
farmaceutische bedrijven medicijnen met dezelfde werkzame stof op de markt mogen 
brengen. Deze medicijnen worden biosimilars genoemd. Voor biosimilars geldt dat de 
kwaliteit, effectiviteit en veiligheid in hoge mate vergelijkbaar is met die van de biological 
(de “originator”) en dat ze zijn goedgekeurd door het Europees Geneesmiddelen Agentschap 
(EMA). Door deze gelijkwaardigheid ontstaat er meestal prijscompetitie tussen de originator 
en de biosimilar, en tussen biosimilars onderling.  
In dit proefschrift hebben we aan de hand van 3 thema’s onderzocht of de behandeling van 
ontstekingsreuma met biologicals kan worden geoptimaliseerd. Deze thema’s zijn: voorspellen 
van therapierespons (predicting), afbouwen van de dosis van biologicals (tapering) en het 
overstappen van een originator naar een biosimilar (transitioning). 
Hoofdstuk 2: literatuurstudie naar voorspellers van respons na afbouwen biologicals in 
RA
Een nadeel van afbouwen van biologicals is de mogelijkheid dat de ziekteactiviteit tijdelijk 
opvlamt. Daarnaast zou het bij patiënten die uiteindelijk blijken te kunnen stoppen met 
biologicals voordelig zijn als er niet eerst een tijdrovend afbouwprogramma doorlopen 
hoeft te worden. Verschillende afbouwstudies hebben daarom de voorspellende waarde 
van biomarkers voor succesvol afbouwen en succesvol stoppen van een biological in RA 
onderzocht. Aangezien de resultaten van deze studies nog niet waren samengevat, hebben 
we in hoofdstuk 2 een systematische literatuurstudie uitgevoerd. Onze zoekstrategie leverde 
3.029 artikelen op, waarvan 16 artikelen voldeden aan onze inclusiecriteria. In totaal waren 17 
biomarkers onderzocht in 2 of meer studies voor succesvol afbouwen en 33 biomarkers voor 
succesvol stoppen. Vervolgens hebben we de voorspellende waarde van deze biomarkers in 
kaart gebracht. Een biomarker werd  gekenmerkt als “mogelijke voorspeller” als de associatie 
tussen de biomarker en succesvol afbouwen of stoppen redelijk sterk (odds ratio of hazard ratio 
>2.0 of <0.5) of statistisch significant was. Biomarkers die een “mogelijke voorspeller” waren 
in ≥75% van de studies waarin ze waren onderzocht werden gedefinieerd als “voorspeller”. 
Uiteindelijk hebben we 3 biomarkers geïdentificeerd als voorspeller: 1) hoge adalimumab 
dalspiegel voor succesvol afbouwen, 2) lage Sharp/van der Heijde erosie score voor succesvol 
stoppen, 3) kortere symptoomduur bij de start van de biological voor succesvol stoppen. Voor 
deze 3 biomarkers geldt dat ze slechts onderzocht waren in 2 studies. De sterkte van het bewijs 
is beperkt door de lage kwaliteit van de geïncludeerde studies en de waarschijnlijkheid van 
multiple testing (bij het doen van veel testen wordt vaker op basis van toeval een verschil 
gevonden) en reporting bias (selectieve rapportage van uitkomsten waarbij negatieve 
uitkomsten meestal worden ondergerapporteerd). 
Hoofdstuk 3: afbouwen van abatacept en tocilizumab in RA 
Wetenschappelijk onderzoek heeft aangetoond dat het afbouwen van TNFα-remmers 
uitvoerbaar, effectief en veilig is in patiënten met RA. Voor andere biologicals die worden 
gebruikt bij de behandeling van RA is dit nog niet bewezen, zoals abatacept en tocilizumab. 
In de “Study ON Abatacept and Tocilizumab Attenuation” [SONATA] hebben we de 
uitvoerbaarheid, effectiviteit en veiligheid van het afbouwen van abatacept en tocilizumab 
in RA patiënten onderzocht. 
RA patiënten met een stabiele lage ziekteactiviteit die zijn behandeld met abatacept of 
tocilizumab in de Sint Maartenskliniek werden geïncludeerd. Vervolgens hebben we een 
onderverdeling gemaakt in patiënten die abatacept hadden afgebouwd (n=13), patiënten 
die abatacept niet hadden afgebouwd (n=15), patiënten die tocilizumab hadden afgebouwd 
(n=64) en patiënten die tocilizumab niet hadden afgebouwd (n=27). Na 12 maanden waren 
3 van de 11 (27%, 95% betrouwbaarheidsinterval (BI): 6% tot 61%) abatacept behandelde 
patiënten en 20 van de 48 (42%, 95% BI: 28% tot 57%) tocilizumab behandelde patiënten 
succesvol afgebouwd. De gemiddelde verandering in ziekteactiviteit bij 6 en 12 maanden 
was niet significant en relevant verschillend tussen de groepen en de veiligheid was ook 
vergelijkbaar. 
Hoofdstuk 4: voorspellende waarde calprotectine voor respons op TNFα-remmers in RA
In dit hoofdstuk hebben we de voorspellende waarde van calprotectine (S100A8/A9) voor 
individuele respons na het respectievelijk starten en afbouwen van behandeling met TNFα-
remmers onderzocht. Calprotectine is een calcium- en zinkbindend ontstekingsremmend 
eiwit dat wordt afgegeven door ontstekingscellen.  Voor dit onderzoek hebben we klinische 
gegevens uit 2 longitudinale RA studies gebruikt: de “Biologic Individual Optimized Treatment 
Outcome Prediction” [BIO-TOP] studie en de “Dose REduction Strategies of Subcutaneous TNF 
inhibitors” [DRESS] studie.
In bloed dat was afgenomen bij patiënten voorafgaand aan het starten of afbouwen van 
adalimumab of etanercept hebben we vervolgens calprotectine gemeten. Uit onze resultaten 
blijkt dat calprotectine matige voorspellende waarde heeft voor respons na het starten van 
een TNFα-remmer (area under the receiver operating characteristic curve (AUC) voor EULAR 
goede respons van 0.61 (95% BI: 0.50 tot 0.71)). Echter calprotectine heeft geen toegevoegde 
waarde ten opzichte van factoren die al in de dagelijkse praktijk worden gebruikt, zoals de 
ziekteactiviteitsscore (DAS28). In patiënten met een lage ziekteactiviteit, is calprotectine niet 
voorspellend voor de respons na het afbouwen van een TNFα-remmer. 
Hoofdstuk 5: overeenkomsten in respons en cytokine productie tussen adalimumab en 
golimumab
Uit een eerder onderzoek blijkt dat de respons op behandeling met golimumab veel lager is in 
RA patiënten die vooraf zijn behandeld met adalimumab dan in RA patiënten die vooraf zijn 
behandeld met etanercept. Om het mechanisme achter deze lagere respons op golimumab 
na adalimumab falen te kunnen verklaren, hebben we de ex-vivo effecten van adalimumab, 
etanercept en golimumab op de productie van ontstekingsbevorderende eiwitten (cytokines) 
onderzocht in de BIO-TOP studie. Dit houdt in dat we binnen 24 uur na bloedafname de 3 
verschillende TNFα-remmers toegevoegd hebben aan de perifere mononucleaire cellen in het 
bloed en vervolgens hebben we de veranderingen in de cytokineconcentratie van IL-1β, IL-6 en 
TNFα  gemeten. De absolute veranderingen in IL-1β, IL-6 en TNFα na remming door golimumab 
en adalimumab waren allen significant gecorreleerd (rs 0.52-0.99, p<0.001). Deze correlaties 
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waren veel lager of niet significant tussen etanercept en golimumab en tussen etanercept 
en adalimumab. De sterke overeenkomst tussen de ex-vivo geremde cytokine productie 
door golimumab en adalimumab zou de lagere respons op golimumab na adalimumab falen 
kunnen verklaren. Dit suggereert dat patiënten die slecht reageren op adalimumab beter niet 
kunnen worden omgezet naar golimumab en andersom.  
Hoofdstuk 6: voorspellende waarde ex-vivo cytokine productie voor respons op 
biologicals in RA
In dit hoofdstuk hebben we onderzocht of ex-vivo geremde cytokine productie de effectiviteit 
van biologicals in RA patiënten kan voorspellen. 
Van 2014 tot en met 2017 werden in de Sint Maartenskliniek RA patiënten >18 jaar die starten 
met een biological gevraagd voor deelname aan de BIO-TOP studie. Deelname hield in dat er 
voorafgaand aan de start van de biological (het baselinemoment) bloed werd afgenomen en 
dat de respons op de biological na 3 en 6 maanden werd gemeten. 
In totaal is er 307 keer bloed afgenomen (abatacept n=21, adalimumab n=56, etanercept n=112, 
rituximab n=86 en tocilizumab n=32). In 120 van de 307 (39%) gevallen behaalde de patiënt 
een EULAR goede respons na 6 maanden. Een aantal baselinekenmerken waren voorspellend 
voor therapierespons, namelijk DAS28 voor alle biologicals, reumafactor voor rituximab 
en anti-CCP voor abatacept. Deze bevindingen komen overeen met die uit de literatuur. In 
de ex-vivo analyse bleken slechts 4 van de 64 (6%) testen enige voorspellende waarde (AUC 
betrouwbaarheidsinterval bevat geen 0.50) te hebben. Dit is een laag percentage, omdat de 
kans op een positieve test door toeval 1 op 20 (5%) is. Daarnaast hadden de 4 testen geen 
toegevoegde voorspellende waarde ten opzichte van factoren die al in de dagelijkse praktijk 
worden gemeten, zoals de DAS28. Kortom, onze zelf ontworpen ex-vivo geremde cytokine 
test is niet zinvol om te gebruiken voor het voorspellen van de respons op behandeling met 
biologicals in RA. 
Hoofdstuk 7: BIO-SWITCH studie, van originator infliximab naar biosimilar infliximab 
De Federatie Medisch Specialisten (FMS), het College ter Beoordeling van Geneesmiddelen 
(CBG) en de Nederlandse Vereniging voor Reumatologie (NVR) hebben ieder een standpunt 
ingenomen over het gebruik van biosimilars. Deze standpunten komen grotendeels overeen 
en stellen dat: 
1) nieuwe patiënten met een biosimilar kunnen worden behandeld; het uitgangspunt is om 
het goedkoopste product (originator of biosimilar) voor te schrijven.
2) eenmalige uitwisseling tussen biologische geneesmiddelen (onafhankelijk of het hier 
originator of biosimilar betreft) mogelijk is, mits de patiënt hierover goed is geïnformeerd 
en er adequate klinische monitoring plaatsvindt.
3) ongecontroleerde en herhaalde uitwisseling tussen biologische geneesmiddelen vermeden 
moet worden.
4) wanneer met een biologisch geneesmiddel wordt behandeld, in het patiëntendossier op 
detailniveau (product en batch) informatie moet worden vastgelegd zodat traceerbaarheid 
van het product geborgd is. 
In juli 2015 stapten 4 afdelingen Reumatologie (Sint Maartenskliniek Nijmegen, 
Maartenskliniek Woerden, Radboud Universitair Medisch Centrum Nijmegen en Rijnstate 
Arnhem) over van behandeling met originator infliximab (REM) naar biosimilar infliximab (CT-
P13). 
In totaal gingen 196 van de 222 (88%) REM-behandelde patiënten akkoord met de overstap 
naar CT-P13 waarvan 192 patiënten mee wilden doen aan de “Biosimilar of Infliximab Options, 
Strenghts and Weaknesses of Infliximab Treatment Change” [BIO-SWITCH] studie. 
De resultaten van deze studie laten zien dat de meerderheid van de patiënten met 
ontstekingsreuma wil en kan overstappen van REM naar CT-P13 zonder veranderingen in 
effectiviteit, infliximab dal spiegels, anti-infliximab antilichamen en veiligheid. Echter een 
interessante bevinding is dat een kwart van de patiënten met CT-P13 stopte tijdens de 6 
maanden follow-up. De voornaamste redenen om met CT-P13 te stoppen waren: een toename 
in het aantal pijnlijke gewrichten, een toename in de ervaren ziekteactiviteit en het optreden 
van subjectieve gezondheidsklachten. Subjectief betekent dat de gezondheidsklachten niet 
objectief kunnen worden gemeten, maar wel ervaren worden door de patiënt zelf. Enkele 
voorbeelden hiervan zijn vermoeidheid, artralgie en hoofdpijn. 
Opvallend is dat er in geblindeerd onderzoek waarbij de ene helft van de patiënten overstapte 
van REM naar CT-P13 en de andere helft doorging met REM geen verschil werd gevonden in 
het aantal patiënten dat met REM of CT-P13 stopte. In andere woorden: als patiënten niet 
weten of ze behandeld worden met REM of CT-P13 dan is het aantal patiënten dat met het 
medicijn stopt gelijk, maar zodra patiënten weten dat ze overstappen op CT-P13 stoppen er 
veel patiënten mee. 
De kennis bij patiënten over het overstappen op een biosimilar kan leiden tot negatieve 
verwachtingen over de behandeling met de biosimilar. Deze negatieve verwachtingen kunnen 
vervolgens leiden tot subjectieve gezondheidsklachten (nocebo effect) of tot het toewijzen 
van klachten aan de biosimilar terwijl ze daar niet door veroorzaakt worden (incorrecte 
causale attributie). Vermeldenswaardig hierbij is dat het nocebo effect het tegenovergestelde 
is van het algemeen bekende placebo effect. 
Hoofdstuk 8: BIO-SPAN studie, van originator etanercept naar biosimilar etanercept 
Uit wetenschappelijk onderzoek blijkt dat de kans op het optreden van nocebo effecten kan 
worden verkleind door het vergroten van de kennis over biosimilars bij zorgverleners en 
het verschaffen van eenduidige communicatie aan patiënten. Om dit te doel te bereiken, 
hebben we een gestructureerde communicatiestrategie ontwikkeld. Deze strategie hebben 
we vervolgens toegepast tijdens de overstap van originator etanercept (ENB) naar biosimilar 
etanercept (SB4) in de Sint Maartenskliniek in juni 2016. 
In totaal gingen 635 van de 642 (99%) ENB-behandelde patiënten akkoord met de overstap 
naar SB4 waarvan 625 patiënten mee wilden doen aan de “Study on Persistence and role 
of Attribution and Nocebo” [BIO-SPAN]. De resultaten van deze overstapgroep hebben 
we vervolgens vergeleken met die van een historische controlegroep bestaande uit 
patiënten die in juni 2014 behandeld werden met ENB. Na 6 maanden follow-up was 10% 
in de overstapgroep met SB4 gestopt en was 8% in de controlegroep met ENB gestopt. De 
overstapgroep werd gekenmerkt door een significant hoger relatief risico op het stoppen 
met etanercept (gecorrigeerde hazard ratio 1.57, 95% BI 1.05 tot 2.36) en kleinere afnames 
in de ziekteactiviteitsscore DAS28 (gecorrigeerd verschil 0.15 (95% BI 0.05 tot 0.25)) en het 
acutefase-eiwit CRP (gecorrigeerd verschil 1.8 (95% BI 0.3 tot 3.2)). Deze kleine verschillen ten 
opzichte van de controlegroep kunnen echter als niet klinisch relevant worden beschouwd. 
Daarnaast kunnen ze worden verklaard door kalendertijd bias. Waarschijnlijk werd er in 2016 
meer volgens het “treat-to-target” principe behandeld dan in 2014 waardoor patiënten sneller 
van behandeling veranderden als het behandeldoel niet werd bereikt en dankzij de strakkere 
behandeling ook een lagere ziekteactiviteit hadden. 
Het overstappercentage (99%) en het continueringspercentage (90% na 6 maanden) van 
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SB4 in deze studie zijn beiden hoger dan die van CT-P13 in de BIO-SWITCH studie. Hoewel het 
biosimilars zijn van 2 verschillende originators (ENB versus REM), vermoeden we dat de betere 
percentages het gevolg zijn van het gebruik van de communicatiestrategie. Deze strategie 
kan de verwachtingen van patiënten over de overstap naar de biosimilar positief hebben 
beïnvloed waardoor minder nocebo effecten optraden en daardoor minder patiënten stopten 
met SB4. Ook de opgedane ervaring bij reumatologen kan hebben gezorgd voor het uitstralen 
van meer vertrouwen in de overstap richting patiënten. Ten slotte zijn beide percentages 
vergelijkbaar met het verplicht overstappen van ENB naar SB4 in Denemarken. Aangezien 
verplicht overstappen op een biosimilar als onacceptabel wordt beschouwd in veel landen 
(waaronder Nederland), lijkt het gebruik van een communicatiestrategie bij het niet verplicht 
overstappen op een biosimilar een voorwaarde voor het bereiken van een zo hoog mogelijk 
overstap- en continueringspercentage.  
Hoofstuk 9: discussie
In het laatste hoofdstuk hebben we de belangrijkste bevindingen van dit proefschrift 
bediscussieerd in de context van recent gepubliceerd onderzoek. Ook hebben we een aantal 
implicaties voor de klinische praktijk gegeven en hebben we suggesties voor toekomstig 
onderzoek gedaan. 
De belangrijkste  conclusies uit dit proefschrift zijn: 
- Tot op heden zijn er geen relevante biomarkers geïdentificeerd die kunnen voorspellen 
welke RA patiënt met stabiele lage ziekteactiviteit kan afbouwen of stoppen met een 
biological en welke niet. (Hoofdstuk 2)
- Het afbouwen van de dosis van abatacept of tocilizumab bij RA patiënten met stabiele lage 
ziekteactiviteit is uitvoerbaar, effectief en veilig. (Hoofdstuk 3)
- Zowel calprotectine als ex-vivo geremde cytokine productie zijn geen relevante biomarker 
voor het voorspellen van de individuele respons van RA patiënten op de behandeling met 
een biological. (Hoofdstuk 4, 5, 6) 
- Het staken van een biosimilar door subjectieve gezondheidsklachten, nadat is overgestapt 
op een biosimilar, kan worden veroorzaakt door nocebo en/of incorrecte causale attributie 
effecten.  (Hoofdstuk 7)
- Het toepassen van een gestructureerde communicatiestrategie bij het overstappen van 
een originator naar een biosimilar kan het overstap- en continueringspercentage van een 
biosimilar verbeteren. (Hoofdstuk 8)
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Lieke Tweehuysen werd op 29 september 1988 geboren te 
Nijmegen. In 2006 behaalde ze haar VWO diploma op de 
Koninklijke Scholengemeenschap (K.S.G.) te Apeldoorn, 
waarna ze in datzelfde jaar begon met de studie 
Geneeskunde aan de Radboud Universiteit Nijmegen. 
Eind 2012 behaalde zij haar artsexamen.
Na haar afstuderen begon ze als arts-assistent niet in 
opleiding op de klinische afdeling reumatologie van de 
Sint Maartenskliniek in Nijmegen. Een jaar later startte 
ze met een promotietraject waarbij het optimaliseren 
van de behandeling met biologicals van patiënten met 
ontstekingsreuma het centrale thema was. Dit traject 
werd begeleid door Prof. dr. F.H.J. van den Hoogen, dr. A.A. 
den Broeder en Prof. dr. L.A.B. Joosten. 
De resultaten hiervan zijn beschreven in dit proefschrift en gepresenteerd tijdens verschil-
lende (inter)nationale conferenties.
Naast haar onderzoekswerkzaamheden heeft ze verscheidene klinische en organisatorische 
taken in de Sint Maartenskliniek verricht. En in 2017 heeft ze twee maanden stage gelopen op 
de afdeling reumatologie in het King’s College Hospital te Londen. 
Per 1 februari 2018 is ze begonnen met haar vooropleiding interne geneeskunde in het 
Rijnstate ziekenhuis te Arnhem (opleider dr. L.J.M. Reichert) in het kader van de opleiding tot 
reumatoloog (opleider dr. A.E. van Ede).
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Dankwoord
Toen ik in 2013 de mogelijkheid kreeg om te starten met een promotietraject vroeg ik mezelf 
twee dingen af: Vind ik dit leuk? En kan ik dit? Aangezien ik het in de Sint Maartenskliniek goed 
naar mijn zin had, besloot ik de uitdaging aan te gaan. Inmiddels kan ik beide antwoorden met 
“Ja” beantwoorden. Natuurlijk waren er de opstartproblemen in het begin en de stressvolle 
deadlines in het midden, maar aan het einde is dit het allemaal waard geweest. 
Belangrijk om hierbij te vermelden is dat ik het niet in m’n eentje voor elkaar heb gekregen. Dit 
proefschrift was er niet geweest zonder de steun van heel veel mensen en ik maak graag van 
de gelegenheid gebruik om hen te bedanken. 
Allereerst wil ik mijn copromotor dr. A.A. den Broeder enorm bedanken. 
Beste Alfons, jouw onuitputtelijke inhoudelijke kennis en goede begeleiding hebben dit 
proefschrift gemaakt tot wat het is. Je leerde me om kritisch na te denken en stimuleerde me 
om datgene te onderzoeken wat ik interessant vind. De introductie van de biosimilars in de Sint 
Maartenskliniek betekende dan ook de ideale kans voor mij om klinische cohortonderzoeken 
op te zetten en uit te voeren. Ik ben erg dankbaar dat ik dit heb mogen doen. Daarnaast heb 
je me herhaaldelijk wijs gemaakt dat werklast niet hetzelfde is als werkdruk. Dankzij het 
onthouden van deze zin kreeg ik het voor elkaar om bij een toenemende werklast steeds 
minder werkdruk te ervaren. Mijn laatste half jaar was zelfs de meest relaxte periode van het 
gehele traject. 
Ook wil ik mijn beide promotoren, prof. dr. F.H.J. van den Hoogen en prof. dr. L.A.B. Joosten 
bedanken voor hun fijne begeleiding. 
Beste Frank, dank voor je enthousiasme, positieve houding en vertrouwen in een goede 
afloop van de onderzoeken in dit proefschrift. Wanneer we elkaar vluchtig tegen kwamen op 
de gang, riep je steevast “Keep on smiling”. En als ik je hulp ergens bij nodig had, dan was je 
altijd beschikbaar. Zo zal ik ons dagje uit naar Zeeland voor een praatje van 20 minuten op een 
congres nooit vergeten. 
Beste Leo, het gezamenlijke idee van de BIO-TOP studie is de basis geweest voor mijn 
promotietraject. Ook tijdens de uitvoering van deze studie verliep de samenwerking met de 
afdeling Interne Geneeskunde van het Radboudumc altijd goed. Daarnaast heb ik dankzij 
jouw geduldige uitleg en mooie tekeningen van cytokines en cellen wat opgestoken van de 
immunologie, dank hiervoor. 
Geen van mijn onderzoeken was mogelijk geweest zonder de deelname van patiënten. Graag 
wil ik daarom alle proefpersonen bedanken voor hun bereidwillige deelname en vertrouwen. 
Verder gaat achter alle onderzoeken uit dit proefschrift een grote hoeveelheid werk schuil wat 
mij niet was gelukt zonder de hulp van anderen. 
Mihai, in het begin ben je nauw betrokken geweest bij het opzetten van de BIO-TOP studie 
en nadat dit eenmaal liep heb je feedback gegeven op de artikelen die daaruit voortkwamen. 
Dank hiervoor.  
Kiki, Heidi en Helga, zonder jullie steun was het nooit gelukt om zoveel ex-vivo bepalingen 
uit te voeren. Ook al stond de bode nogal eens onaangekondigd op de stoep, jullie probeerden 
altijd tijd te vinden om het materiaal in te zetten. 
Joke, ik heb veel plezier gehad tijdens onze overleggen over de cognities en verwachtingen van 
patiënten en artsen over de overstap naar biosimilars. Het is allemaal niet zo simpel.   
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Els, naast de directe bijdrage aan hoofdstuk 2 en hoofdstuk 8 heb je me tijdens de 
teamoverleggen bijgebracht waar je als onderzoeker allemaal aan moet denken. Dank 
hiervoor. 
Bart, bedankt dat je me hebt betrokken bij de overstapprojecten naar een biosimilar in de 
kliniek. Ik vond het interessant om bij de besprekingen aanwezig te zijn en leuk om samen 
met jou presentaties te geven aan onze collega’s.  
Victor, we hebben twee keer mogen helpen om de logistiek voor de overstap naar een biosimilar 
te regelen. Hoewel de deadlines onhaalbaar leken en het stressvolle weken waren, lukte het 
ons toch om die te halen. Bedankt voor de fijne samenwerking. 
Isabelle, Margo en Cor, bedankt voor het meedenken tijdens het opzetten van alle klinische 
cohortonderzoeken. Jullie wisten altijd iets te noemen waar ik zelf nog niet aan had gedacht. 
Miranda, hoewel ik steeds weer met een nieuw onderzoek aan kwam zetten, bleef je altijd 
enthousiast. Dank hiervoor.  
Leo, bedankt voor het creëren van genoeg ruimte in de vriezers voor alle afgenomen samples 
uit de onderzoeken en het bewaren van het overzicht hierop. 
dr. Alphons J.L. de Jong en dr. Willemijn H. van der Laan, dank voor de hartelijke ontvangst op 
de afdeling reumatologie van respectievelijk het Rijnstate Arnhem en de Maartenskliniek 
Woerden en de fijne samenwerking tijdens de BIO-SWITCH studie. 
Iris, tijdens mijn seniorcoschap reumatologie in het Rijnstate was jij degene die me enthousiast 
aanraadde om te solliciteren op de vacature van zaalarts in de Sint Maartenskliniek. Dank 
voor dit perfecte advies!
Aatke, Dieneke, Peter, Thomas, Rogier, dank voor jullie inhoudelijke feedback als co-auteurs 
van artikelen uit dit proefschrift. 
Steven, dank voor je hulp bij het uitvoeren van de statistische analyses in hoofdstuk 8. 
Nathan, bedankt voor je hulp bij het analyseren van de data uit hoofdstuk 4 en het voor mij 
invallen tijdens posterpresentaties op congressen. 
Fenna, Evelien, Britt, Kimberly, Maike, Sophie, Stijn en Jessica, dank voor het invullen en 
invoeren van duizenden case report forms (CRF’s). 
I would like to thank dr. James Galloway for the opportunity to perform an observership at the 
rheumatology department of King’s College Hospital in London. I really appreciate the time 
and effort you took to teach me a lot about the healthcare in England and research in general. 
Katie Bechman, I really enjoyed working together and I’m happy that it resulted in a scientific 
paper. Let me know when you will visit the Netherlands, I would be delighted to show you 
around. 
De afgelopen vijf jaar heb ik met veel plezier gewerkt in de Sint Maartenskliniek. 
Graag wil ik alle reumatologen, physician assistants, arts-assistenten, reumaverpleeg-
kundigen, doktersassistenten en secretaresses van de afdeling reumatologie bedanken 
voor hun interesse in en medewerking aan mijn onderzoeken en de prettige samenwerking 
in de kliniek. Ook heb ik genoten van onze gezellige lunchpauzes, de praatjes bij het 
koffiezetapparaat en de borrels in café Jos. Verder bedank ik alle apothekers(assistenten) 
en laboranten voor de fijne samenwerking tijdens de uitvoering van de onderzoeken en alle 
reumaonderzoekers voor de gezellige tijd op de schrijfdagen en de congressen. 
In het bijzonder wil ik mijn (ex)-kamergenoten bedanken. 
Noortje en Nienke, jullie zijn mijn voorbeelden. Omdat jullie een paar jaar voorlopen op mij, 
kon ik bij jullie afkijken hoe het promoveren in zijn werk ging. Ook sloot ik me graag aan bij 
het gezamenlijk thee halen, ijsjes eten en kletsen over van alles en nog wat.  Net als jullie start 
ook ik nu met de opleiding tot reumatoloog. En we werken zelfs weer allemaal in hetzelfde 
ziekenhuis (Rijnstate Arnhem), gezellig!   
Chantal, tijdens onze promotietrajecten hebben we nauw samengewerkt en onze 
hoogtepunten en tegenslagen gedeeld. Wat bijzonder en leuk vind ik het daarom dat we op 
dezelfde dag promoveren. We maken er een mooi feest van! 
Lieke, hoewel je geen arts-onderzoeker bent ben ik blij dat je op de onderzoekerskamer zat. 
We hadden een mooi evenwicht tussen werken en kletsen waardoor de dagen omvlogen en 
we vervolgens gezellig samen naar huis konden fietsen. Ik vind het leuk dat je mijn paranimf 
wilt zijn en wens je alle goeds toe met de opleiding tot physician assistant!
Diane en Michelle, jullie begonnen met promoveren toen ik bijna klaar was. Ik vind het 
bijzonder dat ik toen aan de andere kant stond en jullie af en toe tips kon geven. Veel plezier en 
succes met jullie onderzoeken!
Dit proefschrift had er niet gelegen als ik naast mijn werk niet zoveel fijne vrienden zou hebben 
die voor afleiding zorgen. 
Alexandra T, Jelina, Alexandra B, Mirjam, Ilse, onze vriendschap is ontstaan tijdens de studie 
Geneeskunde en inmiddels is ieder zijn eigen weg ingeslagen. Ik geniet van onze etentjes 
samen waarin we nooit raken uitgekletst. Ik hoop dat we dit nog jaren volhouden.    
Alexandra T, bedankt voor alle support de afgelopen jaren en wat fijn dat je mijn paranimf wilt 
zijn!
Lylian, ik vind het bijzonder dat we al zo lang vriendinnen zijn. Hoewel we elkaar inmiddels 
minder vaak zien door de afstand voelt het als vanouds wanneer we samen afspreken. 
Peter & Floor, Mark, Ward & Anniek, Thomas & Sanne, Duby & Viola, Martijn & Marlijn, Emile 
& Kim, Piet & Ellen, Jossje & Lard, Maarke & Floris, Roddy & Marleen, dank voor de gezellige 
weekendjes en het samen vieren van elkaars mijlpalen. 
Ook wil ik mijn ooms, tantes, neven en nichten bedanken voor de gezellige familiemomenten 
en de belangstelling voor mijn werk.
Frank & Helma, Rutger & Hanneke, Victor & Jessica, Olivier & Lonnie, dank dat jullie mijn 
gezellige schoonfamilie zijn. Het is altijd een plezierige drukte tijdens de sinterklaasvieringen 
en gourmet-avonden in Prinsenbeek. Ook de skivakantietripjes naar de caravan in Riezlern 
bevallen me goed, nu alleen het skiën zelf nog. 
Papa & mama, hartelijk dank voor de mogelijkheden en het vertrouwen die jullie mij gegeven 
hebben om te kunnen doen waar ik gelukkig van word. Jullie luisterend oor en wijze raad zijn 
enorm belangrijk voor mij geweest en zullen dat altijd blijven. 
Mama, ik vind het heel speciaal dat je de voorkant van mijn proefschrift hebt getekend. 
Niet alleen is het heel knap dat je zo goed kan tekenen, de tekening is ook geinspireerd op 
een poster die veel voor mij betekent. Op mijn 12de jaar mocht ik van jullie mijn slaapkamer 
opnieuw inrichten. Ik koos een poster van een landschap met een houten bootje. Ik vond de 
natuur mooi, maar het had ook toen al een diepere betekenis voor mij namelijk; door jezelf een 
doel te stellen en er vol voor te gaan kun je bereiken wat je wilt. Jouw tekening op de voorkant 
van mijn proefschrift maakt het geslaagde promotietraject voor mij dan ook helemaal af.     
Niels, als mijn “grote” broertje neem je voor mij een bijzondere plek in. We denken over veel 
dingen hetzelfde en ik geniet van het delen van onze gezamenlijke interesses (heerlijk dineren, 
lekker borrelen en sport kijken). Ik zou je voor geen goud willen missen.   
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Lieve Christiaan, jij bent mijn grootste steun. Want wat is het fijn als je vriend ook aan het 
promoveren is op een medisch onderwerp. Je begrijpt precies wat onderzoek doen inhoudt en 
bent altijd beschikbaar om kritisch mee te denken. Maar nog veel belangrijker voor mij is dat 
je me eraan herinnert om tijd vrij te maken om te ontspannen en om leuke dingen te doen. Of 
we nu samen niets doen thuis op de bank of samen naar de andere kant van de wereld reizen, 
ik ben gelukkig met jou!
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